WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS 12th Annual Conference Guide 1st-2nd October 2012 www.sachsforum.com INVESTOR FORUM INVESTOR

Hilton Zurich Airport Hotel, Switzerland Hotel, Hilton Zurich Airport BIOTECH IN IN BIOTECH M U R O F R O T S E V N I E P O R U E N I H C E T O I B WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS next u General Information The registration be open from 8am on October 1st and from 8.15am on October 2nd desk will Please collect a copy of the agenda for although you are welcome to join the event at any time. information room allocation on timing and for each session. which is available to Networking at the Forum is facilitated by our online 1-2-1 meeting system, all participants. A & B rooms. A Networking Lunch will be set up in the Zurich A & B rooms and the presentation the rooms throughout Coffee stations up in the Zurich will be set event. Sachs Associates are delighted to welcome you to the 12th Annual Biotech in Europe Investor Annual Associates to welcome you to the 12th are delighted Sachs the forum again once provides access to an Following the success of previous years, Forum. small-capexciting cross-section of venture-funded and and companies with leading investors pharmas. This Forum is highly transactional and is comprised of a series of panels and presentations each one providing an expert pharmaceutical and biotech companies, from leading investment, industry. Biotech outlook on growth and investment activity in Europe’s the Private The programme highlights the current issues surrounding the evolving M&A market, Plus, Capital major trends in Partnering. environment and a special session on Venture Equity & programme features more than 70 company presentations from a range of publicly this year’s listed and private life science companies looking to raise finance and/or find partners. Sachs Associates are delighted to welcome you to the: are delighted to welcome you to Sachs Associates Annual 12th in Europe Biotech Forum Investor 1st-2nd October 2012 Switzerland Hotel, Airport Hilton Zurich Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request will endeavour to send you the requested We to [email protected] after the conference. presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides thatconference. are shown during the Welcome WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back For regular updates, sponsorship, presenting and attending opportunities presenting and attending opportunities sponsorship, For regular updates, regarding anyand further information future events please contact of our Zoe Harris on [email protected] 13th Annual Forum Investor Biotech in Europe 30th September – 1st October 2013 • Zurich • Switzerland Annual Forum Cancer Bio Partnering Collaboration Promoting Public & Private Sector, & Investment in Drug Development 21st – 22nd May 2013 • Boston • USA Back for its sixth year, this exclusive and highly this exclusive transactional partnering event is a must for Back for year, its sixth engage with leading investors and forge new companies wishing to meet with their peers, partnerships. the forum will provide an excellent platform to gain event, Building on the success of this year’s Networking at the in the Biotech and Pharma industry. insight into partnering and investment trends which is available to all participants. Forum is facilitated by our online 1-2-1 meeting system, The conference will feature up to 8 presentations by large to mid size pharmaceutical companies looking for strategic alliances/partners. leading global investors and Do not miss out on this great opportunity to meet emerging companies, Big Pharma representatives! 6th Annual CEO Forum Life Science European & Investing For Partnering 5th – 6th March 2013 • Zurich • Switzerland Events Diary Events WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS www.nycomed.com www.amgen.co.uk www.astellas.eu www.biogenidec.co.uk www.helsinn.com www.ipsen.com www.jnj.com www.menarini-biotech.com www.merck.com www.merckserono.co.uk/en/index.html www.norgine.com www.novartisoncology.com www.novartisvaccines.com www.pierre-fabre.com www.roche.com www.sanofi.com Pharma Licensing Groups Licensing Pharma

at the Forum Groups Pharma Licensing represented represented WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers , Maxwell Biotech Managing Director, Eliseev, Alexey Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the His career includes over 17 years of experience in industryacademia, Massachusetts Technology. Institute of and venture capital. Eliseev has been working in the Dr. United States and Europe Following since three 1992. years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, (later Therascope company the co-founded he 1999 In 2000. in tenure awarded was he where 1995 in Buffaloat University Alantos Pharmaceuticals) with a number of prominent founders including French Nobel company used a Laureatenovel Jean-Marie technology developed in Lehn. several academic The labs, including group Alantos Eliseev’s in Buffalo. division. US its of President and Alantos of Officer Technology Chief became later and 2000 in company the joined He Amgen in 2007 for $300 million. was acquired by AC including entrepreneur, and scientist a as companies biotech several starting in involved was Alexey years recent the Over Immune (Switzerland) and Boston BioCom Alexey (US). has been working with the Russian-based numerous Maxwell managed Biotech Venture has and Fund the of activity international for responsible is He 2009. since Director Managing its as Fund deals with portfolio companies in the US and Europe. Oncology Executive Director Business Development & Licensing, Novartis Altmeyer, Anne Anne is a Vice President in Business Development and responsibilities Licensing are to in in-license or acquire the Oncology assets Oncology that can further Business strengthen the Novartis Unit ongoing Oncology several manages portfolio. also In She at opportunities. oncology for transactions negotiates Novartis, and evaluates, USA. identifies, she role, Her this alliances. Anne has over 15 years of experience in the working in positions of increasing responsibilities in ManagementgroupOncologyof Project the joined Anne Licensing. and Development Business and Development, Research, Novartis in 2004 as There a she Project led Leader. numerous multidisciplinary through Project Teams the generation and worked Anne Novartis, joining Before market. the on and development in compounds various for strategies of implementation forVisiting Research Scientist 2 years. for close to 4 years and as a as a Project Manager at Merck & Co. Anne received her Ph.D. in Molecular from . She University, then performed a postdoctoral fellowship at New York University School of Medicine, USA, and subsequently University became Medical College, New a USA. York, In Research addition Associate to her at scientific training, Anne Cornell also received a Master in Business USA. Administration and a Master in Public Health from the University of Medicine and Dentistry of New Jersey/Rutgers, BioVoition AG CEO, BioVoition Caduff, Andreas Dr Andreas was born in 1971 and is a Swiss citizen. He industry. In held his various previous positions position in he the was pharmaceutical serving and as medical CTO device of Solianis glucose Monitoring AG, a monitoring. company At focusing Solianis, on he noninvasive orchestrated the overall technologystudy strategies, regulatory and considerations, product external technical development, communication experimental/clinical and interaction with the industrial/scientific regulatory community, bodies as well as the He investor’s community. is an expert in physiological monitoring techniques and involved physiological/metabolic processes, combining the expertise in industrialisation various and fields commercialisation relevant of such to technologies. the development, Dr. Caduff is scientific a conferences frequent and invited meetings speaker at on physiological industrial monitoring, and mobile Healthnumerous patents and and co-authored several subjects.dozen related scientific publications in peer reviewed journals. He holds a He has innovated BSc degree in an MSc degree in Biotechnology and a Ph.D. Switzerland, Winterthur, Applied Science, in Chemistry from the University of Israel. UK and the Hebrew University of Jerusalem, Teesside, Biophysics from the University of Apposite Capital , Partner, Allan Marchington Allan is a founder and Partner at Apposite Capital a London based healthcare Allan President Vice Senior investor. an was as team management Pharmaceuticals Millennium of member a formerly was this to prior and management at Abingworth with responsibility for technology He Investments. also served as Chairman of Millennium Pharmaceuticals Allan in Europe. founder. and CEO was he where Chemistry, Discovery Cambridge of 2000 July in acquisition their following Millennium joined Allan began his career as a medicinal chemist at Pfizer Central Research. Convergence and Inc., Anaphore Inc., Ambrx Inc., Biosciences Ambit Association, BioIndustrythe of member Board a is Allan Pharmaceuticals Ltd. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Apricus Biosciences Speakers Dr Benedkt Timmerman, CEO, Genticel Timmerman, Dr Benedkt Benedikt founded Genticel (initially called BT Pharma) in 2001 and Benedikt is had currently a successful CEO career of at the NOVARTIS company. Prior (1996 to – Genticel, 2000) In and these its companies, predecessor he company held SANDOZ various (1991 management the - of positions, member and Committee including Executive 1996). European the of member Head Eu, – Seeds Novartis of of Development & Research Director Biotechnology, Sandoz Seeds Eu, Senior organisations, several of member board also is Timmerman Dr team. Acquisition and Licensing Technology Novartis corporate ‘Cancer the of Club Industrials the Representativeof Biotech Associationand Biotech French a BioMedicalAlliance, including Pole GSO’ in France. Benedikt is of Belgian nationality, holds a PhD in France (1990-1991). Molecular Fontainebleau, (1986) and an MBA from INSEAD, Genetics from the University of Ghent, BioQuarter Bill Blair, Bill joined BioQuarter as the Head of Business Creation in April 2011. He is responsible for managing the companies launch from of new the BioQuarter portfolio, as well as leading a team businesses based of on world-leading medical research from the College University of professionals of Veterinary Medicine Edinburgh’s and in the development of further new Medicine and NHS Lothian. Prior to joining Edinburgh Mr BioQuarter, Blair was Investment Director at Scottish Widows Investment Partnership (SWIP) for eight years where he established and led its venture capital investment programme before setting up his own venture Mr Blair also Advisers. previously capital headed strategicHVS up pharmaceutical consultancy company business, research in worked he investment, into moving Before Middleton. Greig and Securities Fleming International, Nomura stockbrokers for various commercial functions in the pharmaceutical industry for seven years. Administration from Edinburgh University. He holds a BSc (Hons) in Biological Sciences and an MSc in Business Bassam Damaj, CEO & President, Bassam Damaj, Chairman as served Damaj Dr. 2009. December since director a and Officer Executive Chief President, the been has Bassam of the Board of Directors from October 2010 April to He 2012. has served as a member of our ad hoc Finance Committee since 2010. He is Scientific the Chief co-founder and Officer of Executive Celltek Chief Biotechnologythe as and served and served Inc. as a Bio-Quant, of director co-founder from a 1997 is He until 2000. Healthcare. He R&D is of founder also the Officer and a director of Bio-Quant since its inception in June He 2000. has also served as theGroup Leader for the Office of Intelligence New Target and a Group Leader for immunological and inflammatory diseaseTanabe programs Research at Laboratories, U.S.A., Inc., as a senior scientist and member of the senior staff board also He of (NIH). Health of the Institutes National the drug and discovery Inc. Pfizer department Inc., Genentech at scientist at visiting a as and Inc., Pharmacopeia served as an Damaj independent holds director a fordegree Ph.D. Dr. Inc. CreAgri, in Immunology/Microbiology from Laval in molecular oncologyUniversity and completed a postdoctoral fellowship from McGill University. Gilde Healthcare Partners Gilde Healthcare Partner, Arthur Franken, Arthur joined Gilde in 2001. He led the investments in Moximed Conatus and MTM Pharmaceuticals, FlowCardia Laboratories (acquired (acquired by by Roche). C. He R. has Bard), Medicine (IPO on NASDAQ) BG and Pieris. uniQure, been Agendia, Ablynx on Euronext), (IPO involved including in numerous investments and divestments He represents Gilde on He the servedboard of Moximed and as Symphogen. a board member for FlowCardia (until its trade sale to MTM Bard), R. C. Laboratories (until its trade sale to Roche) and observed on the boards Agendia of AMT and (until its IPO on Euronext). Prior to joining Gilde he gained experience in cardiovascular research at the Leiden/Amsterdam Center for Drug Research He TNO. holds and a masters degree in Biopharmaceutical the He Sciences Netherlands. is from a Leiden Dutch University, national. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Athera AB Biotechnologies Athera Clinical medicine, drug hunting, translational medicine, product development, registration, finance & Speakers Carlos Buesa, CEO, Oryzon Carlos earned his PhD in from the University of Barcelona in Spain. He has produced more was than a thirty member papersof the and cellular patents signaling internationally, research team in the Pharmacy Faculty at held the an University EU of post-doctoral Barcelona, fellowship in the Faculty of Medicine at the University of Ghent in Belgium, and later became Senior Investigator with the Flemish Institute of Biotechnology (VIB), also in Belgium. In 2000, he founded Oryzon, one of the strongest-growing biotech companies in Spain, and since 2001 he has served as Chief Executive Officer and Chairman of the Board of Directors. the taken has He Pharma. Oncnosis and Pharma Neurotech like companies biotech other of board the on sits he addition, In at the IESE Business School. executive education programme (PADE) Currently he is President of the Association of Catalan Biotechnology Companies CataloniaBio, and he is a that member model development of regional new a the Catalunya, de BioRegió of Committee Executive the of and ASEBIO of body governing has been set up with the aim of improving people’s quality of life through better coordination of the biotechnology activity being carried out in Catalonia. CEO, Carina Schmidt, a Karolinska Development portfolio company. AB (publ), Biotechnologies Athera Carina is Chief Executive Officer, Ms Schmidt has experience from nearly 30 years in mainly industry, in business development, international marketing and product management within the Life Science area. Former management consultant, interim CEO and business advisor to (now Biosciences Biotech/Amersham Pharmacia with worked has she 2000 to 1985 years During start-ups. biotech several 2006. year in Scandinavia Partners BioBusiness co-founded and 2000 year in AB Bioscience Grasp founded HealthCare), GE AB Board (publ) Director and in Member Genovis of Lecturer the in AB Investment RegionCommitte in Mitt. Innovationsbron at Umeå University and Umeå Biotech Incubator. “Entrepreneurship in Biotechnology” Cerecor, Inc. Cerecor, M. Paterson, Co-Founder & CEO, Blake registration, development, product medicine, translational hunting, drug lead to ability with Entrepreneur / Physician-Executive finance & commercialization operations.Successful company Device organizations. large and small builderwithin operations affiliate and research clinical global management, portfolio / planning experience with licensing, in marketing, strategic able to and Proven develop therapeuticsfundraiser, and communicatetech transfer. vision throughout the organization and America; trilingual. And South North EU, in in exploiting biomedical business opportunities Successful in the marketplace. Specialties: commercialization operations in therapeutics and medical portfolio management, global clinical research devices. and affiliate operations within small Product and large organizations. Board Certified licensing, marketing, strategic planning Anesthesiology (ABA). in / Dr. de Dr. Sousa earned his M.D. degree from Lisbon University, Portugal in 1983 and USA in 2000. his University, Executive M.B.A. from New York Takeda Pharmaceuticals International GmbH Takeda VP Corporate Licensing, Carlos de Sousa, He was Vice Carlos Vice Head previously President is President, of of Commercial Corporate Licensing Takeda. Licensing at in 2011. Takeda which was acquired by at Nycomed, he where Italy, in SpA Pharmaceuticals Newron at Officer Business Chief was Sousa de Dr. Takeda-Nycomed, joining to Prior activities. acquisitions & mergers and out-licensing, and in- its including strategy, growth company’s the for responsible was de Sousa was BeforeGlobal Dr. Head Newron, of Business Development and Licensing at Schwarz AG Pharma in Germany also was he latter the At Switzerland. in based AG, Pharma Novartis at Negotiations Global of Head as served that to prior and European Business Head for the Respiratory and Dermatology Franchise. de Dr. Sousa started subsequently, his career and, Director in Medical the International pharmaceutical appointed initially industry was with he where Pfizer in USA, 1989, asYork, Medical Director New in in Portugal. Corporation HePfizer then the joined America. Affairs for LatinDirector of Corporate Licensing and Development and Director of Medical and Regulatory WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers CEO, Pantec Biosolutions CEO, Christof Boehler, moved Böhler Christof Dr. systems, release drug bio-polymeric with dealing Zurich ETH at chemistry in PhD his finishing After to the United States for a Postdoc at the Salk and Scripps Research USA) Institutes carryingin La Jolla (CA, out bio-medical basic research. From there he started to work as the head of development for a start up biotech company he moved into product management of Realizing the need to in develop his commercial know-how, now been commercialized. Zurich, whose process has CH). Buchs, Aldrich company, AG (a Sigma research chemicals and biologicals at Fluka Chemie at the FH Liechtenstein “International Management” During his Fluka time he completed a postgraduate executive degree in and UBC Vancouver (Canada). His further career involved Business Development Manager Europe and Business Manager for Maybridge, a Drug Discovery service company, and finally Marketing Director “Drug DiscoveryMaybridge (Fisher Scientific). Chemicals” for Acros/ CEO, Immune Design Corp. Carlos Paya, CEO, President served previously as He Officer. Executive Chief and President as 2011 May in Corp. Design Immune joined Carlos teams development and research, clinical, marketing, commercial, company’s biotechnology the led Corporationand Elan of from 2008 to Paya Before 2011. was joining at Dr. Elan, Eli Lilly & Company Vice as Lilly President, Research Laboratories where he led various therapeutic areas encompassing discovery, clinical development, and franchise. the Prior to and this, Endocrine Dr. Paya was Professor of Medicine, Immunology, and He received Investigation Minnesota. his Program MD atand PhD the degreesMayo Pathology, from Clinic the in University Rochester, and Vice Dean of the Clinical France. Paris, postdoctoral training atof Madrid and underwent the Institute Pasteur, Takeda Pharmaceuticals International GmbH Takeda VP Corporate Licensing, Carole Nuechterlein, Carole Nuechterlein has headed the Roche Venture Fund since pharmaceutical/biotech 2001. industry as Prior an attorney for ten to She years. joined Roche from SangStat her in Fremont California where current position, she worked in the she was General Counsel. Carole began her career working at Skadden Arps in background Slate her to Due Meagher deals. licensing & and collaborations research Flom M&A, on in focusing California the Alto, Palo M&A in Syntex/Roche group. From there, she worked at Therapeutic Human Polyclonals. Carole led the negotiation team for the Roche acquisitions of GlycArt and M&A, and Nereus. Technology Idaho Envoy, Conatus, Ambrx, Ambit, Alios, She currently servesAileron, as a board observer at Fund Venture More information the Roche on of Michigan. University and a JD from University Valparaiso She has a BA from can be found at www.venturefund.roche.com. Chirs Britten, Independent Consultant Chris has gained huge experience and contacts a PhD in biochemistry and an MBA. Chris has a scientific background, divestments and strategic alliances with licences, in the Life Sciences market having negotiated a variety of acquisitions, partners around the world. from molecular diagnostics to Current activities include advising clients across the spectrum of the Life Science sector, generics to specialty pharmaceuticals and OTC products. biotechnology, Merck Serono Merck Head of Oncology, Catherine Pickering, clinical and preclinical of Licesning field. licensing oncology the in focussed professionals BD of team a Leading Specialties: stage products within biotechnology companies. and pharmaceutical Transfer within Technology UK Oncology Research Institution for four years. Responsible for protecting and exploition the IP. Institution’s More recently Oncology business development role within company. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u TiGenix 1 billion. At €1 Sanofi-Aventisbillion. he also held positions such as Marketing and Sales Speakers After completing his post-doctoral research Edwin in Moses Germany, began a commercial career with successful periods Enzymatix Amersham spent firstand International, From at as Raggio-Italgene. 1993-2001, CEO and later he as Chairman, in (LSE) flotation a in cumulating rounds venture of series a through (OAI) Asymmetry Oxford of growth the for responsible was million. £316 for 2000 in Biosystems Evotec to company the of sale a byfollowed was This million. £120 of value a at 1998 OAI During grew this period, from four people Over to the over Edwin past 250. has eight played years, an important role at Board level (primarily as Chairman) in over 15 European life science During companies. this time he has been involved in a number of afinancing series rounds, of M&A transactions and He four has IPOs. been Ablynx Chairman and since of 2004, in 2006 he extended his role as Chairman to include that of Chief Executive Officer. CEO, Ablynx CEO, Edwin Moses, Eduardo Bravo, Managing Director & CEO, Bravo, Eduardo senior several includes career professional His industry. bio-pharmaceutical the in experience years 20 than more has Eduardo 2000 than more of charge in was he where America, Latin for President Vice including Sanofi-Aventis, at positions management employees and oversaw sales of more than Manager for Europe and General Manager for Belgium. He also worked for 7 years in SmithKline Beecham in sales positions Bravo is co- Mr. AdministrationMBA (INSEAD). and an Bravo holds a degree in Business Mr. nationallyboth and internationally. TiGenix. He is an executive Board member of YPO. and member of Therapies (AAT) Advanced Alliance for chair of the General Partner, SR One General Partner, Harland, Deborah operational, extensive One SR to brings She office. investment European firm’s the establish to 2005 in One SR joined Deborah and affairs medical development, clinical in held roles numerous through gained experience licensing and development drug business development during her more than 20 year tenure in Deborah the is pharmaceutical currently industry. a member of the Board of Directors of Therapeutics Bicycle Therapeutics Syntaxin AG, Mission Limited, Protaffin and Limited, Limited, f-star She GmbH. was previously a member of the Board of Directors Addex of Pharmaceuticals SIX (IPO, Swiss Exchange, and 2007) Brussels Euronext (IPO, Ablynx of Boards the observeron an and Orexo) to (sold Limited Pharmakodex and 2007) from Pharmacology in PhD her Bath, of University the from Pharmacology in (Hons.) BSc. her received Deborah Pharma. 7TM and her MBA from Henley Management College. the , NovImmune SA NovImmune Head of Corporate and Business Development, Slack, David 2012. in NovImmune joined and experience, development business and management senior of years 20 nearly brings David David has a track record of innovation in business fundraising development, and in senior management positions at public and private biotech as well as large His pharmaceutical deal-making companies. experience encompasses nearly $1 billion spin-outs and financings. in corporate partnerships, Prior to joining NovImmune, David co-founded and served as Chairman, President and CEO of Kinagen, an innovative next generation Kinagen, kinase to Prior drug discovery 2011. in and sold development was Under company. and David’s leadership, diseases, Kinagen ocular advanced and fibrotic programs and inflammatory, cancer, targeting collaborations established major several for responsible was he where Pharmaceuticals, Isis at Development Business of President Vice as served David partnerships and for the GeneTrove functional genomics division. From was he where the Pharmaceuticals, Aventis “buy and Rorer Rhône-Poulenc as positions development side” business senior servedin David corporate partnering perspective, Force. Task Genomics the to representative business the as served and partnerships, strategic major multiple for responsible of range a services to consulting provided has and companies emerging for financing securing in roles key played has David biotech and medical device companies as well as investor groups. pharma, WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Francis Marsland, Head of EU Corporate Development, Biogen Idec Marsland, Francis Francis is the Site Leader of Biogen Idec’s International HQ in European Zug, CorporateAs Switzerland. VP, Development, advises Francis opportunities. M&A and development business European transacting forand responsible sourcing is Francis on Biogen Idec’s European Corporate Strategy, Corporate Communications, Investor Chief International Counsel. Relations, Francis was previously Biogen Idec’s and Government Affairs. Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was at Novartis for over 20 over for Novartis at was Pombo-Villar Dr OBT, joining to Prior Biotherapeutics. Oxford for Officer Operations Chief is Esteban of Head was he recently Most managingalliances. and creating of aspects all on focused he which of years 12 last the years, proof-of-concept to up alliances for responsible (NIBR), Research Biomedical for Institute Novartis the at Management Alliance in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in At 1988. Sandoz he worked on drug discovery projects as well as leading collaborative Dr Pombo-Villar is a Fellow of the Royal Society of Chemistry. projects investigating the potential of emerging technologies. Oxford BioTherapeutics AG BioTherapeutics Oxford Chief Operating Officer, Villar, Esteban Pombo CEO, AM-Pharma B.V. CEO, den Berg, Erik van therapeutics phosphatase alkaline human novel of development the in engaged company, biopharmaceutical a is AM-Pharma for unmet needs in severe inflammatory The diseases. lead Company’s programs for this therapeutic are in Acute Kidney Injury and Inflammatory Bowel Disease. positive Strong, results from Phase II clinical studies using native bovine alkaline phosphatase demonstrated the efficacy of this treatment in patients Acute with Kidney Injury and Moderate-to-Severe Ulcerative Colitis (a type of Inflammatory Bowel thereby providing proof-of-concept for phosphatase. the development of recombinant human alkaline Disease), proprietary AM-Pharma’s human form of this enzyme has been optimized for treating inflammatory conditions and is being produced by cGMP manufacture for and clinical trial supply preclinical and commercialization. AM-Pharma discovered that a key function of alkaline phosphatase is to protect organs against damage. While inflammationalkaline andphosphatase tissue is found in many cells of the human it body, is present proprietary therapeutics Acute The are KidneyatCompany’s disease modifying Injurydiseases including and Ulcerative Colitis. reduced levels in certain medicines. “first-in-class” therapies and have the potential to be development II Phase to through therapeutics phosphatase alkaline human its advance to is strategy business Company’s The currently is AM-Pharma commercialization. and development clinical further for partners seeking before Injury, Kidney Acute in seeking strategic partners for the further development of its therapeutic in AM-Pharma Ulcerative Founded Colitis. in 2001, international of syndicate strong a by backed is Company The Netherlands. the Bunnik, in based is thatcompany private a is investors and has raised over €55 million equity to date. Delenex Therapeutics Delenex CEO, Eric de La Fortelle, Eric is CEO of Delenex Therapeutics AG, a Zurich-based biotechnology company focused on biologic medicines delivered locally for chronic diseases, and administered systemically generating clinical efficacy data in patient inflammatory studies in psoriasis, bowel three disease areas: for and acute systemic acute diseases. The company is It also uses its proprietaryinflammation. PENTRA® currently platform to generate a full pipeline of highly stable smallantibodies that focused on but superior tissue penetration properties and have comparable affinity and other drug-like properties to existing antibodies, enhancing safety for thus patients. rapid clearance, worldwide a headed he there, years six During Roche. for Technologies, and Research External Head, Global was Eric Formerly, group with a global mandate to find establish partners, contracts and manage alliances with companies offering innovative development and life cycle. technologies for every stage of product discovery, of structures 3D of (determination design drug structure-based of field the in contributions with training, by scientist a is Eric protein targets by X-ray crystallography). He has extensive experience of negotiating Pharma/Biotech alliances (both from the Biotech and the Pharma He side). was trained as an engineer and Physicist at Ecole Centrale holds de in and a Paris, Biophysics an Ph.D. from Paris XI University, MBA from INSEAD. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Pierre Fabre Pierre Takeda Research Investment Research Takeda Speakers Graeme Martin, President & CEO, Martin, Graeme Inc the (TVI), Graeme corporatePharmaceutical Ventures, is Company, venture President arm Takeda and of CEO Takeda of Martin has overseen investment of $49mm into 18 early Dr and mid-stage biotechnology in 2003, Takeda Since joining Ltd. companies, the result of which has been several strategic relationships R&D with Takeda operations. During more than 30 years R&D management in multinational Pharmaceutical and Biotech companies in Europe pursued and scientific enquiry with resulting a in passion, the IND submissions for three novel drugUSA, candidates one under of which, Dr Martin has peer- 85 than more of author the is He migraine. of treatment acute the for worldwide marketed is Zomig®, name brand the reviewed publications and book obtaining chapters, his Bachelor of Science degree in Pharmacology from the University of UK. London, UK and his doctorate College, from University Bath, ISA Therapeutics BV Therapeutics CEO, ISA Plattenburg, Gerard Gerard holds a degree as a chemist/molecular biologist from the managingUniversity director of He ISA of is Pharmaceuticals responsible B.V. for the Leiden, overall The management and strategic Netherlands. direction of ISA He several is for worked Gerard currently industry. biotech the in experience managerial senior years 20 than more has He Pharmaceuticals. biotech companies such as Pharming and Genpharm (Medarex) prior to founding Prosensa (a Fierce 15 Biotech company), which he grew into a generally recognized RNA modulation clinical stage company. VP, Head Alliance Management Sanofi R&D & Contracting, Head VP, Grams, Frank Alliance Head Management R&D In &this Contracting. Frank functionjoined heSanofi is in leading September VP, 2011 as ManagementAlliance organization up to POC. the early stage technology contracting activities and the R&D Before coming to Sanofi he has been working for Roche as Executive Roche Director, been Partneringinstrumental Asia, andin assetting suchup has the Roche Pharma Partnering officeAustralia. in the region presence from China to instrengthening Roche’s Shanghai starting in 2008. The office has been Prior to taking up this post, Frank was Global Head, Drug Delivery Partnering, responsible for both the strategic cycle management activities related and to drug delivery Frank life- partnering. was a Alliance Global Director from managing 2002, transactions 100 than more in involved been has He Biotie. and Syrrx SGX, Evotec, Chugai, as such alliances research pivotal including product and technology deals, in- and out-licensing opportunities and also an acquisition. He is also one of the initiators of the Greater Plan Competition SEED (www.seedcompetition.com). China Life Sciences Business worked previously having 2001, July Surveillancein Opportunity of Head as team Partnering Pharma Roche the joined Frank in various research functions in Roche and at Mannheim GmbH. Boehringer Frank has a degree in chemistry from the University of Heidelberg and received his with Ph.D. summa cum laude from the Technical University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Germany). Martinsried, EVP, Global Head Business Development – Market Intelligence, EVP, Desdouits, Frederic Frederic is head of Pierre Fabre Group Business Development, Frederic was a Fabre, Managing Partner York a atconsulting Acquisition and Bionest transaction Partners, firm based in Paris and New and Market Intelligence. Prior to join Pierre specialized in healthcare and biotechnology; and the founder Managing Partner of Bionest Frederic was a partner in charge specialized in value strategyBefore Bionest, and fund raising forPartners emerging bio-companies. Finance, a boutique of Pharmaceutical and Biotechnology sectors at Exane BNP-Paribas, an investment Before company. heading for finance, Frederic work in research for GlaxoWellcome in France (now GSK), as a consultant MS for a obtained Hoechst (Palaiseau), Polytechnique Ecole in from graduated is Frederic the Sanofi). USA (now France in and Rhône-Poulenc at student as a PhD a PhD in in pharmacology, did Neurosciences, a post-doc at the Rockefeller University and in is York New a (Certified CEFA Analyst). European Financial WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u , Inc. Pharmaceuticals, Astex Speakers MorphoSys AG MorphoSys Team, Member of Senior Management Heinz Schwer, Heinz is Senior Director of MorphoSys and currently establishing the corporatecompany’s venture activities. He joined the company in 2010 after he has sold Sloning Biotechnology to MorphoSys. Heinz Schwer co-founded Sloning in 2000 and managed the company as Managing Director from 2005 until 2010. In the years Operating Officerbefore, andhe Head of R&D. Heinzheld Schwer spentthe several years aspositions postdoc atas the HarvardChief Institute of Medicine and the Dana-Farber-Cancer Institute in Boston. In this time, he has received numerous awards, including a fellowship for his research in the field of leukemia disease and the biogenesis of blood platelets. He obtained his Ph.D. inmember founding clinicala also chemistryis He UK. in College Management Henley from MBA an holds and Regensburg of University the from Bioscience. Eucodis of member board advisory an and Biology Synthetic of Association International the of President Vice and Harry Welton, VP & CFO, Cytos Biotechnology Welton, Harry Harry has more than 15 years of international senior executive experience, eleven of which as CFO in biotech companies. he successfully restructured Recently, He joined Cytos Vice President in June and 2010 Chief as Financial Executive Officer. Cytos and its convertible bonds and raised more than CHF 33 million in equity and debt from an international syndicate of investors and through a rights offering. Prior to joining he Cytos was Biotechnology, CFO at Nitec AG Pharma in Reinach which merged with the US based Horizon in Pharma order Inc. to go public at the US stock market From in 2001 2011. he to was 2009, AG CFO where Arpida athe raised more than CHF 250 million in private equity and public monies including the Initial Public Offering at the SIX Swiss Exchange in Prior he 2005. to Arpida, was joining a Director following at Warburg in various York UBS New senior positions and administration business and economics in degree a finance, and banking in Harrydegree a holds Group. UBS the within York. New an MBA (Hons.) from Columbia University, President & Director, Jhoti, Harren Harren has served as Astex Pharmaceuticals™ president and member of the Board of Directors since July 2011. He co- founded Astex Therapeutics in 1999 and was chief scientific officer until November 2007 when executive. heJhoti Dr. waswas appointedawarded chief the Prous Institute-Overton and Meyer Award for New Technologies by in the Drug European Discovery Federation for Medicinal Chemistry in 2012 and was also named byfor He 2007. has “ChemistryWorld Entrepreneur published of Year” widely the the including in leading journals Royal such as Society of Chemistry as and Science and has also been featured TIME in magazine after being named by World the Economic Forum Technology a Pioneer Jhoti in served2005. Dr. as a non-executive director of Iconix Inc. Before starting up Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at in GlaxoWellcome the Prior United to Kingdom Glaxo, (1991-1999). Jhoti was a post-doctoral Dr. scientist He at received Oxford a University. BSc (Hons) in Biochemistry in 1985 and a PhD in Protein Crystallography from the University of London in 1989. CEVEC Pharmaceuticals Director Marketing & Business Development, GmbH Tintrup, Harmut positions various held He Germany. University, Frankfurt from 1998 in Ph.D. his received and training by biochemist is Harmut GmbH, Pharmaceuticals Artemis at Scientist Research a as starting /Sales, Marketing and R&D in responsibility increasing of and later at Exelixis Inc., South San Francisco, USA. Hartmut joined the US subsidiary of AG) in Cologne 2004 to support amaxa US and global AG sales in various functions (now like export industrial and sales, tactical marketing. Lonza After joining CEVEC in his 2010, main focus are now the european and ROW business development activities and CEVEC’s overall marketing strategy. Hans T. Schambye, CEO, Galecto Biotech Schambye, T. Hans Gastrotech of CEO Hans the as T. Schambye and 2009 to is 2006 from ReceptIcon a of Officer Executive seasoned Chief the biotech as served Schambye entrepreneur Dr. with Previously, extensive experience in drug discovery and development. Pharma A/S from 2004 to 2006. Before joining Schambye companies, Gastrotech, Dr. biotech was several Director co-founded has of Schambye Biology and PharmacologyDr. and company. biotech US a Maxygen, at Management Portfolio of Head including ProFound Pharma A/S, a Danish biotech company, which was acquired by Maxygen Schambye had in a successful 2000. research career Prior at Stanford to University and this Copenhagen University Dr. within the field of receptor Schambye from Copenhagen Sciences PhD in Medical holds an MD from Odense University and a University. Dr. biology. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers PledPharma AB CEO, PledPharma Jacques Nasstrom, Jacques has a basic training as Pharmacist with PhD in Pharmacology from Uppsala Sweden University, and degree a from Business Stockholm School of Economics. He has 25 years of experience from the pharmaceutical and biotechnology industries, including a position as Investment Manager at Karolinska Investment management positions Fund, within Stockholm drug discovery Sweden, at Astra and and AstraZeneca, Södertälje, Sweden various and most recently as Director of Research & Sweden Jacques Development Since from Uppsala, is 2010, at2006-2010. AB, CEO Q-Med of PledPharma which is a Swedish based specialty pharma company that for develops prevention a PledOx®, of new the medicine, severe side effects that patients develop as a consequence of chemotherapy treatment of cancer. CEO, ProFibrix BV CEO, Jan K Öhrström, Dr Öhrström has 20+ years biotech industry experience from companies in EU and Jan is CEO and President of ProFibrix BV. Development within seniority increasing of positions various held and 1990 in A/S Nordisk Novo at career his started He US. the and Business/Marketing in Denmark and the US. Dr Öhrström joined the Senior at Management Team ZymoGenetics Inc in Seattle in and 2000, was part that of took the Team the Management company public (Nasdaq:ZGEN) in Dr 2002. Öhrström During his development was and tenure responsible atforbusiness infrastructure. ZymoGenetics establishing the company’s Inc, the company submitted its first BLA (RecoThrom©) that was approved in 2008. Dr Öhrström joined ProFibrix in 2008, incorporated the and company in in 2011 the he He US, was is promoted an to MD CEO. from University of Copenhagen and completed 6 years of clinical practice prior to joining the pharmaceutical industry. Jakob assumed his role as CEO of ViroGates in April 2011. Jakob was previously CCO & CFO of Egalet Ltd. a Danish based biotech based Danish A/S a ViroGates CEO, Knudsen, Jakob Ltd. Egalet of CFO & CCO previously was Jakob 2011. April in ViroGates of CEO as role his assumed Jakob and Financing, and IP including operations commercial all oversaw Jakob products. pain of development on focusing company was responsible for entering into multiple commercial collaborations (licensing Prior and to feasibility this stage agreements). Jakob was heading the Corporate Business Development function at ALK-Abelló A/S, a Danish biopharmaceutical company. Jakob was responsible licensing forALK’s and M&A Beforedeals. this Jakob held positions within sales and marketing with UK. Jakob is a lawyer by training and he also holds an MBA from Imperial College, the company. NOXXON Pharma AG Pharma CEO, NOXXON Iain Buchanan, Iain was appointed CEO of NOXXON in September 2010 having worked closely with the board of directors since 2007 and as a non-executive member of the supervisory board since 2009. He brings to the company over 30 years of commercial experience in the pharmaceutical and biotech industries. Iain joined NOXXON from CEO since Novexel the in Company’s formation in Paris 2004 until where its he sale to AstraZeneca acted in 2009. as (Europe) Prior Pharmaceuticals Vertex to include Novexel, These Iain held companies. various across a responsibility increasing of Cilag variety positions management at of 2004, to 1994 from Europe in presence Vertex a building for responsible was he Director, Managing as where, Limited internationally business licensee managedthe he where Switzerland) Zug, in based Johnson and Johnson of division (a A.G. in activities commercial oversaw he where 1987 to 1981 from Switzerland Geneva, in S.A. Biogen at and 1994 to 1987 from Iain began his career in Product Management at in 1978. Merck Sharp & Dohme (UK) Limited Europe. of Director non-Executive a is and Scotland Andrews, St of University the from Physiology in Science of Bachelor a holds Iain Synairgen plc based in Southampton UK. Boehringer Ingelheim Venture Fund Venture Boehringer Ingelheim Director, Wicke, Ilka discovery drug new in specializing laboratory research interdisciplinary an of head as 1996 in Ingelheim Boehringer joined Ilka approaches. She later joined the Corporate Licensing Division of Boehringer Ingelheim where she over negotiation and the management licensing transactions. of global gained extensive experience in the evaluation, the last 10 years Subsequently Ilka joined the Corporate Licensing group as head of the business advisory teams for urology oncology, and opportunities licensing clinical and pre-clinical of evaluation and identification the for responsible was she where metabolism as well as agreements. structuring licensing global of and variety a of negotiating conclusion and negotiation the technology for responsible was and she where Licensing licensing Corporate agreements. She later joined the transaction group of Ilka has a PhD in organic chemistry from Goethe Wolfgang the University Johann Following in her Frankfurt. graduation she spent a year as a postdoctoral fellow at the Sloan Kettering investigating Cancer retroviral Center gene York in therapyNew approaches to stimulate antitumour responses. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Telormedix S.A. Telormedix Speakers Johanna Holldack, CEO, Johanna Holldack, Johanna has worked in the where pharmaceutical she industryhas held key positions in both start- for more than 20 years, up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma. pediatrician. Certified Board a is and Germany Gottingen, in Georg-August-University from degree medical a has Holldack Dr. In addition, she has held positions as an assistant professor at the University of Essen, research Krebshilfe and a research associate at Harvard Medical School. fellow for the Deutsche CEO, PolyTherics CEO, John Burt, John joined PolyTherics in November 2010 and which he led as with Professor Steve Bloom (Imperial College), Thiakis, Prior to joining PolyTherics he co-founded Company. brings broad business and corporate development experience Wyeth in 2008. CEO through a major financing round in 2006 and ultimately to a very to successful sale to the John was a board member of a Sterix, joint Imperial College – University of Bath spin-out company which was acquired by Ipsen in 2004, and has been an active advisor to early-stage biotech and life sciences development and finance issues. companies on strategy, business ImmunoVaccine Technologies ImmunoVaccine CEO, Trizzino, John biotechnology traded publicly for initiatives strategic advancing experience of years 25 than more with executive senior a is John Novavax at President Vice Senior the was he Immunovaccine, joining to Prior market. vaccine the within primarily companies, Inc., where he provided strategic direction and successfully negotiated profitablejoint venture and licensing agreements, including a $179M BARDA contract. Prior to joining Trizzino Novavax, held Mr. senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his successful of effortsseries marketing a commercial executing leading and atvaccines Henryin career extensive Inc. Schein master’s his received and University Island Long graduateof a is Trizzino Mr. agreements. distribution and commercialization Stern School of Business. Leonard N. University’s York degree in business administration from New Jeremy Warren, CEO, NanoSight Warren, Jeremy From a degree in Chemical Engineering from the University of Birmingham, UK, Jeremy worked production where for he Unilever qualified asin achemical chartered He engineer. then set up a successful chemicals manufacturing business in Belgium, before completing an MBA at INSEAD in France. After a period in strategy consultancy with began a Booz.Allen, Warren series of CEO roles in SMEs centered on developing technology Warren joined businesses. NanoSight in 2005 as CEO and was directly involved in development of the company’s multiparameter characterization last two technology. During years emphasis the has been on biological nanoparticles, specifically exosomes, with particular interest in the use of NanoSight as a platform for and diagnostic their detection application to address a range of unmet need in oncology. Head of Life Sciences Advisory Initiative, Deloitte Advisory Initiative, Head of Life Sciences Jason Rushton, focusJason leads the life science of Deloitte Corporate Finance in Switzerland. pharmaceutical advised management consulting and venture capital. in the pharmaceutical sector spanning R&D, He has 20 years of experience he where Group Consulting PA to moved then and Lilly Eli with discovery drug in career his began Jason /biotech clients commercial in due technical, diligence and Forfinancial 10 transactions. years Jason was a venture capital investor with direct involvement in completing over 30 private life science transactions latterly with the venture capital fund of Nestle. Jason has been a board member of a number of biotech companies and has firsthand experience of business development and licensing. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Alta Partners Speakers Partner, Venture Katya Smirnyagina, Katya Alta joined in 2002 and focuses on European investment She opportunities. currently Alta represents on the board of Ablynx. investment in Alta’s She also led Therapeutics and Kiadis Pharma. directors of Cerenis Prior to joining Alta, she worked in business development and finance at Genset, a French genomics-based biotechnology where she negotiated a number company, of licensing agreements and strategicPrior Katya to partnerships. was Genset, a from 1997 to 2000. a global management-consulting firm, manager with the Mitchell Madison Group, in Cellular Wisconsin-Madison and and received Molecular her BiologyBachelor She from obtained the a University Ph.D. of of Science in Biochemistry with high honors from Moscow University in Katya Russia. completed her scientific training as a post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of She Medicine. has co-authored a number of scientific papers. APIM Therapeutics AS Therapeutics APIM CEO, Alevizoloulos, Konstantinos Konstantinos Alevizoloulos, the current Chief therapeutic novel of commercialization Executive and development the Officerin experience corporate ofof years 12 APIMthan more Therapeuticswith enterpreneur AS, is a biomedical executive and and diagnostic leads in the biomedical sector. He is also Asia. a Europe and consultancy with affiliate offices in the US, partner of Ventac Partners SA, an international life science Before joining APIM Therapeutics, Kostas held various executive positions including: CSO of Gerolymatos International SA (GR), CEO of Medexis SA (GR), Head of Preclinical R & D of Biovista Inc. (US) and Head of R Alevizopoulos & D consults of for Apotech several SA (CH). biotech Dr. companies, Academic Institutes and government associations; he is also a co- Alevizopoulos received his founder Biology AG of degree (Switzerland) Zestagen from and Casigen Pharma Dr. (Hong Kong). the University of Athens, Greece and his Ph.D. in Molecular Biology from the University of Lausanne, Switzerland. He has also conducted post-doctoral studies in the Swiss Institute of Experimental Cancer Research (Switzerland) and the Schering Patent European in trained is Alevizopoulos Dr. research. oncology pre-clinical in specializing (USA) Institute Research Plough France). Law (Robert Schuman , CEO, Hermo Pharma Oy Ltd CEO, Juhani Lahdenperä, since February 2010. Juhani as served Ltd. as the Chief Executive Officer of Hermo Pharma Lahdenperä holds Mr. a degree in biochemistry from the University of Oulu. Before joining Hermo Lahdenperä Pharma Mr. served as a Chief Executive Officer in Plex-Press a Ltd., gene expression that analysis he technology co-founded company, he Thus, has in 5+ 2006. years of CEO he experience VC held from backed managerial Previously, organizations. positions journals high-profile in published been has work this of Some Inc.). Elmer, (Perkin Inc. Wallac and Helsinki of University the at such as Nature. CEO and Co-Founder, Covagen CEO and Co-Founder, Julian Bertschinger-Ehrler, Julian is co-founder and CEO of Covagen. After his studies in molecular biology Bertschinger joined the group and Dario of Neri Prof. at the Institute of biochemistry Pharmaceutical Sciences ETH Zurich as student. a Ph.D. at ETH Zurich, Julian There he co-invented Covalent DNA Display After technology. obtaining his Ph.D. in May 2005, he continued Covalent DNA developing Display as a postdoctoral fellow in Prof. Dario group. Neri’s In June 2006, Julian Bertschinger was selected from more than 100 applicants as one of the Leaders winners Venture Prize of founded the This by the Gebert Rüf Stiftung. enabled him to join a training program Boston area (USA) with a course in entrepreneurship at in the Babson College. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers BioVersys AG BioVersys CSO and Co-Founder, Tigges, Marcel performed and Munich Ludwig-Maximilians-University from M.Sc a holds He AG. BioVersys of co-founder and CSO is Marcel his PhD studies at ETH Zurich in the group company of performing Prof. research Martin and development Fussenegger. In in 2009, the he field of co-founded antimicrobial the resistance. Since BioVersys then, heAG, the is a implementation responsible for of synthetic biology derived assay modules into BioVersys`TRIC technology molecules towards entering clinical phases. development of BioVersys`LEAD platform and the current Chief Medical Officer, PharmaNeuroBoost Chief Medical Officer, Ludo Haazen, Ludo is Chief Medical Officer (PNB) since 2008. at PharmaNeuroBoost 1995, since differentAffairsin positions activities Medical and Development Research, Clinical Global directing been has He mostly in CNS. As Ludo such, directed the Global Development of Durogesic® in chronic pain at was JNJ, involved in the development of Therapy Advanced in having ChondroCelect® TiGenix approved as the first and assisted antidepressants at Roche and JNJ, in Europe. Medicinal Product (ATMP) Depression Major in plans development clinical III to I Phase the directing and designing in instrumental been has Ludo PNB, At He also is a registered Qualified Person for Pharmacovigilance. and Schizophrenia. With an international background in clinical medicine and economics, Lukas joined the Wellington Life Science investment team in 2007. Prior to joining Wellington, Lukas had worked for organ six and years cell as transplantation a at surgeon the and department researcher of specializing surgery in at to 2002, the Lukas was Universities a of post-doctoral scientist Heidelberg at and Harvard University Freiburg. in From Boston, where 2000 he conducted of research immunology in the and fields protective genes. In 2003/2004 Lukas completed a fellowship in University of Minnesota in participatingclinical Minneapolis, in NIH multicenter Lukas trials. studied islet Medical Sciences in Berlin transplantation and at the He holds a summa cum laude doctorate in Medicine from Town. the Humboldt CapeUniversity Berlin and a Global OneMBA Rotterdam. degree from RSM Erasmus University, Therapeutics Heptares Chief Executive Officer, Weir, Malcolm Biomolecular the of Head was He London. College, Imperial from biophysics and biochemistry in PhD and BSc a has Malcolm Structure Department and then the Molecular Sciences engaged in target validation Division and lead During discovery. this time of he led the application GlaxoWellcome of structural biology and with modelling responsibility for to drug resulting discovery, in 300 the advancement of clinical candidates people to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 100-person 2000, company. Inpharmatica growing was it sold from to the Galapagos spin-out NV stagein 2006. to He a joined MRC Technology in establish 2006 Heptares in Therapeutics order to Ltd in same the at JulyBoards Advisory Biology Chemical and Chemistry 2007, the on is as and 1997 in London co-Founder College, Imperial at Biochemistry and CEO. Malcolm was elected Visiting Professor of He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011. university. Wellington Partners Wellington Principal, Lukas Guenther, Health & Biotech Equity Analyst, Equity Development Analyst, Health & Biotech Equity Castellón, Lorenza Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe Prior Australia. and to joining Equity Development in January 2005 she held similar roles at leading international distributing and writing of means by companies and investors together brings Development Equity organisations. investment detailed We research. provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate Over metrics. the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of Please experience. visit for www.equitydevelopment.co.uk more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international organisations. investment WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in product pharmaceutical development research and marketing and areas, with in special many expertise in the areas of biotechnologies, strategic alliances, and Hosang Before was Venture Partner theranostics/diagnostics. a joining at BioMedPartners MPM where in Dr. Capital, 2004, he was co-responsible for their Pharma European the in positions managementdeal senior several held flow,he and years, 20 nearly servedfor where, onBasel, in Roche theat was he boardsPreviously, of several European portfolio companies. R&D organization, Vice including President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Roche Genetics Executive Committee. and a member of the Chief Integrated Medicine, Scientific Officer of Genetics and He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduateHosang training at Stanford Dr. University dieseases. vascular in Seattle in Washington of University the at subsequently and neurobiology in School Medical served on the Board of Directors and the Board of of Trustees the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its from Treasurer 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and ViaCell), with merger its (until Kourion Omrix, of boards the on was he Earlier Board). the of AnergisChairman interim (as SA He has published and more Neuraxo. Avontec than 30 articles and in is peer coinventor reviewed on journals, Atugen, IDEA, several patents. BioMedPartners AG BioMedPartners General Partner, Markus Hosang, EpiTherapeutics ApS EpiTherapeutics CEO, Martin Bonde, Martin is a serial entrepreneur, founded Osteometer Biotech) and Biosensor, Torsana managed Inc., CelTor several A/S, Combio A/S, NatImmune companies in Denmark and the US (Aros Pharma ApS, Martin fronted several successful exits over the last decade (NatImmune A/S out-licensing deals, A/S to Celtor Inc) as well as significant to Biosensor IPC, Combio A/S to Arpida AG, Torsana He is engaged as board member in Orphazyme ApS (www.orphazyme.com) (Chairman) and Danish Association of Biotech (Chairman). Companies (www.danskbiotek.dk) Novartis Venture Funds Venture Novartis Partner, Markus Goebel, Venture Fund Markus Novartis Markus is Goebel Managing started Director, his career in the Health Care Industry in 1990. An MD by training and amongstcertified, in others, hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an MD and a PhD from the Ludwig University Maximilian’s in Munich FoldRx, and an Sirtris, MBA from from Henleyothers Management amongst College. Markus exited, having companies, portfolio Fund Venture Novartis several of boards the on serves EraGen and Intellikine. CBO, DCPrime CBO, Zwaal, Marcel After receiving his MSc in Finance and EMFC degree from VU University in Amsterdam, Marcel Zwaal (1967) has started his business career at Philips Subsequently Electronics. he has gained over 10 years of experience in international finance His experience in the field of vaccines and both in a multinational setting and as an independent consultant. and controlling, in positions management senior several held has he where 2006 in Crucell biotech Dutch joining when started biotechnology recombinant He Business adeno has Development vaccine been and responsible Corporatefor Finance. managing Crucell’s development portfolio and he has concluded several collaborative financing and corporateacquisition of Crucell restructuringby Johnson deals.& Zwaal AfterJohnson, has Mr. decided to the join start-up company DCPrime as Chief Business professionalizing strategy, company the developing further for responsible been has he role this In 2012. 1st, Jan per Officer the organisation Outside as of well his work as he rolling is out the a partnering sport enthusiast and and funding approach. an avid rower and road racing cyclist. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u €24.6m) & Speakers Phase4 Ventures Limited Ventures Phase4 Partner, Siddiqi, Naveed Naveed is a Partner of Phase4 Ventures with over 11 years experience of investing in healthcare and Asia. Naveed companies worked in for US, Nomura Europe and was actively involved with many of Nomura Phase4 private Venture’s investments including Pharmion and Paratek. He has taken Board observer roles healthcare Nomura’s on investment business, he spent the 5 years advising Boards management teams and of companies on buy-outs, cross several companies. Naveed Prior Group. EFG and Nomura to at whilst sectors other and joining biotechnology in offerings company public and private M&A, border He is also National Health Service as a London doctor. and worked in the UK’s Hospital, holds a degree in Medicine from Guy’s qualified as a chartered accountant whilst at KPMG and holds a Diploma in Company from the Institute of Directors. Direction Mike is CEO and founder of Crescendo Biologics, an innovative transgenic antibody fragment company based in Cambridge, Cambridge, in fragmentcompanybased antibody innovativetransgenic an Biologics, Crescendo founderof and CEO is Mike UK. He has 25 years’ biotech and pharmaceutical industry experience Biotech in the 1980s. Wellcome in starting with therapeutic areas, biologic and NCE drug discovery across most managing and building R&D, GlaxoSmithKline in years 10 over for positions leadership held Mike role, current his to Previous global Discovery organisations that made a major impact in targets, technology and pipeline antibody lead established projects. discoveryGSK’s capability In which generated a pipeline of Mike in-house several particular, monoclonal antibodies, of which are in clinical development. Mike holds a degree a in PhD Virology Naturalin from and Molecular Sciences Imperial from College, Cambridge University, Biotechnology Yeast National Institute for Medical Research and Virologyin at the MRC’s undertook postdoctoral research in which funds Developmental Pathway He Funding is Scheme, currently a panel atmember of Leicester the Biocentre. MRC’s and a Fellow of the Society of Biology. translational studies through preclinical and early clinical development, Global Head Research & Technology Partnering, Roche Partnering, Technology Global Head Research & Matthias Steger, Matthias is Global Head Research & Technology Partnering at Roche; Switzerland. the University of St Gallen, and an MBA from he UK, University of Sussex, holds a PhD in Medicinal Chemistry from the Prior to joining Roche in his current role, Dr Steger was a Pharma/Biotech analyst at Basel, the Actelion, by acquired subsequently investment was which company biotech a bank Axovan, atKepler Equities Technologies Chemical of Head was and Chemistry.. Medicinal in Head Laboratory as 1999 in Roche at industry pharmaceutical the in career his began He Switzerland. Biologics Crescendo CEO, Romanos, Mike secured strategic investment from Trans Nova (€20.9m). Trans secured strategic from investment Prior to Affitech AS, he was DirectorTechnology of at Axaron Bioscience AG, Heidelberg, Germany during the Company’s start-up phase. During a portion of this period was an expatriate Therapeutics at Inc., Hayward, the LYNX parent company, massive parallel cloning & sequencing technologies. contributing to the process development of LYNX California, Opsona Therapeutics Ltd Therapeutics Opsona CEO, Welschof, Martin novel on focused Dublin in company development drug immunology leading a Ltd, Therapeutics Opsona of CEO the is Martin diseases. human major of range wide a with associated system immune innate the of targets key to approachestherapeutic Before Opsona he was the MD & Co-founder of Affitech A/S, a biopharmaceutical companydevelopment focusedof onhuman theantibodies, listed discoveryon the & Nasdaq OMX Copenhagen stock exchange. Affitech AS was transformed through a reverse merger in 2009 with Pharmexa A/S, listed on the Copenhagen stock exchange. In 2010 he was a resource in key implementing a strategic partnership with the Russian Pharmaceutical IBC Generium (worth up to WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u . Speakers EVA the Basel Life Sciences Start-up agency EVA CEO, Peter E. Burckhardt, Peter plays an important role in supporting innovation in Northwestern His Switzerland. main focus is life sciences start-ups. Peter is CEO the “EVA of Basel Life Sciences This Start-up company agency”. was founded in 1996 with the aim to support life sciences start-ups access with to coaching, a high value In network addition and he providing is seed CEO money. of the which BASEL he INCUBATOR, helped to establish 2 years The ago. BASEL is INCUBATOR a joint venture of the University of complement To Applied Sciences of the Northwestern University Switzerland of (FHNW) and the Canton Basel, of Basel-Stadt. focusing Switzerland in Club Angel’s Business only the Club, Angel Business BioValley the of president the is Peter activities, his Novartis / Ciba-Geigy joined and Basel of University the chemistryfrom in PhD a has Peter MedTech. / sciences life on entirely Throughout his professional career he had managerial positions with worldwide responsibility in 1984 as a research chemist. technical regulatorydevelopment, production manufacturing, affairs, and communication and was the CEO of the subsidiary in 2006. He joined EVA of a sector of Novartis in Germany. Chairman & CEO, Norgine Chairman & CEO, Peter Stein, Peter is the Chairman and Chief Executive and principal shareholder of Norgine, an independent specialty pharmaceutical company with operations throughout Europe. biomanufacturer contract a Corporation, Invitron of President Vice and co-founder a was Peter 1987, in Norgine joining to Prior He started his pharmaceutical career with Centocor. formed as a spin-off from the Monsanto Company. Peter holds BA and MA degrees in Chemistry from Harvardan MBA from Stanford University and University. Patrik is founder and CEO of Venture Valuation AG, Switzerland. Patrik graduated from the Business University of St. Gallen and Gallen St. of University Business the from graduated Patrik Switzerland. AG, Valuation Venture of CEO and founder is Patrik Technology, of Institute Federal Swiss the at companies”) growth high of valuation and (”Assessment thesis Ph.D his completed international several for worked and company logistic a of CFO was Patrik Valuation, Venture forming to Prior Lausanne. EPFL corporations: LeCroy (Geneva, New York), Hans Merensky Holding (South Africa) VC- and implant dental Swiss the of Swatch company holding a ineo, of foundersGroup original the of one and member board – a is Patrik (Marin). EM Microelectronic backed Thommenfirm Medical and a board member of a Ophthalmopharma, Swiss based biotech ophthalmology company. articles Patrik’s have been published in a number of scientific and journals “Chimia” “Nature including other Biotechnology”, business publications (“Starting a Business in the Life From Sciences: Idea “Building to Starting, and Biotechnology: Market” and Korea South University, National Seoul at lectured also has He Companies”). Biotechnology Understanding and Managing, was Patrik recently, More world. the around workshops Valuation numerous at presented and Austria Krems, University Danube named as one of the 20 most influential people in the Swiss Life Sciences Industry a by Swiss Bilan, Business Journal along Meier. and HenryVasella B. Daniel Bertarelli, with other noteworthy individuals such as Ernesto area equity private and VC the in companies growth high of reporting acquisition, and merger valuation, Finance, Specialties: immatics Biotechnologies Managing Director, Paul Higham, Paul was appointed as CEO of immatics in August he 2008. Previously, served as Director Commercial Development at Ark addition, In activities. development business all and strategy commercial for responsible was he where plc Group Therapeutics Finland. Therapeuticsin Ark of facilities production medicine gene-based and operations establishingthe of charge in was he Therapeutics Prior Paul in Ark to Higham 2001, joining worked as Vice International President Commercial Metabolicfor GI, and Pain marketing and at sales various held GlaxoWellcome he plc Biology, Applied in from studies his completing 1996 after 1996, to to 1985 From 2001, sales. and marketing where he covered all aspects of business development, strategic positions of increasing responsibility with Bayer AG and eventually became General Manager of Bayer Pharmaceuticals for Sweden and Denmark. Valuation Venture CEO, Patrik Frei, WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Index Ventures Index Partner, Venture Remy Luthringer, Remy joined the Index Ventures life science team as Chief Medical Officer in 2010. Afterpsychiatric spending some practice years in and clinical getting in parallel a master Pharmacology. obtained a PhD in Neurosciences and another in Clinical degree in functional explorations and computer engineering, Remy Prior to joining Index RemyVentures, was the CEO of one of the most recognized research institute in Thus neurosciences. he was involved in several European grants and research programs focusing on development and validation of biomarkers/ the reducing of purpose programsthe development with drug in implemented be can latterthese The of surrogateendpoints. attrition rate also an early and failures in the CNS space and readout of the potential of a molecule as early as Phase I/IIa. Remy is the author of aboutserved 50 publications, on advisory boards of biotech as well as pharmaceutical companies and CNS active molecules. was involved in the development of more than 150 CEO, BerGenBio CEO, Godfrey, Richard Richard is an industrial pharmacist; originally trained as his a career scientist, developed sales supply through & chain, R&D, since marketing, 1999 he has servedand CEO, NED as in Managing life Director, science He companies. has worked in UK, Reckitt Benckiser and SwissCaps. DCC, Catalant, Switzerland and USA for Eli Lilly, Germany, During his career Godfrey Mr. has led and been involved in the development and life cycle Temgesic. management Advil and of Cialis, broad Zyprexia, Cyclosporin, range Vegagel, of including Zydis, products and technologies, He has successfully grown businesses Godfrey relocated with his family to organically, In Germany2008 Mr. and Romania and USA. Switzerland, divestment transactions in UK, secured funding and executed substantial merger, Bergen Norway and in 2009 led the formation and spin out of BerGenBio from the University of Bergen. acquisition and Riccardo has a degreewith specialization in Business Economics Management. in Business He is HELSINN Chief GROUP’s Executive Officer and Entrepreneur; Managing Director and Member of HELSINN HOLDING’s Board of Switzerland Directors, and Executive Committee for HELSINN strategic GROUP’s management; Managing Director Birex Helsinn of Member Switzerland; Synthesis, Advanced ManagingHelsinn Switzerland; of Director Healthcare, Helsinn of USA. Therapeutics’ Board of Directors, Ireland; and Chairman of Helsinn Pharmaceuticals’ Board of Directors, His main role and functions are to focus on fundamental operational strategies such as high level business development, political andfinancial, regulatory publicrelationships other relations stakeholders, with institutions, pharmaceutical industry, business trend. as well as final control of Helsinn Group’s and communication internal and external to the Group, Riccardo is a Board Member of Thorne Research, USA; Member of Management Committee Industry and of Handicraft of Switzerland; Chamber Canton Ticino, Board Member of of American School Commerce, in Switzerland; and Chairman of WS Fashion Holding Switzerland. Helsinn Healthcare S.A Helsinn Healthcare CEO, Braglia, Riccardo uniQure BV uniQure CFO, Piers Morgan, Piers joined uniQure’s predecessor company AMT in Therapeutics December Arrow and SA, Pharma BioAlliance 2009 plc, Phytopharm including companies, biotechnology with CFO as experience as Chief Financial Officer. He has overEquity and Acquisitions, & Mergers in working banking, investment in experience years ten gained he years ten period, this to Prior Ltd. Accountant in London He qualified as a Chartered Corporate Finance. Capital Young Markets with Close Brothers and Ernst & with PricewaterhouseCoopers. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Speakers Bicycle Therapeutics Bicycle CEO, Rolf Guenther, Rolf has over 25 years of pharmaceutical industry experience with an extensive background in drug development, biologics and speciality Since pharmaceuticals. 2004 he has served as CEO and aCOO Affimed, monoclonalof recombinant antibody and has company, successfully developed its clinical product portfolio He in previously oncology. held the position VP of and 1996, in Research Clinical Global VP as joined he which Behring, Aventis of unit business Care Critical the of Manager General and was responsible for successful drug approvals in the US and Europe. Günther is Dr. a trained physician in critical care medicine. He received his MD and his PhD in Physical Chemistry from the He University completed of an Germany. Mainz, Executive Development Program at the Wharton University of Pennsylvania’s School of Business. CEO, 4-Antibody CEO, Robert Burns, Therapeutics Celldex and A/S Affitech at previously leader business biotech experienced an is and 4-Antibody at CEO is Robert both antibody discovery companies. and development Inc., Dr Burns joined 4-Antibody following the successful repositioning and refinancing of CopenhagenAffitech listed NASDAQ A/S (AFFY, OMX). and Prior to Oslo-located his time at Affitech, he was CEO at Celldex Therapeutics Inc. (CLDX, NASDAQ) during the critical period of Celldex’s emergence from Medarex through to its eventual reverse merger into NASDAQ-listed Immunotherapeutics. Avant where he played leadership York, Dr Burns was at the Ludwig Institute for Cancer Research in New Before his role at Celldex, at Director Commercial was he that to Prior UK. the in Piramed including companies successful several of spin-out the in roles Diagnostics. CIBA-Corning and Mass.; Cambridge AbT, previouslyand UK; Biotech, British and UK Oxfordboth Glycosciences, clotting blood haemostasis in specialising company UK stage early an Haemostatix, of Chairman non-executive also is Burns Dr next on based therapies cancer novel of developer Finnish a Oy, Therapeutics Oncos of board the serves on also and products generation oncolytic viruses. CEO, Scancell CEO, Goodfellow, Richard companies. Biotech with and Pharma Big in industry, pharmaceutical the in experience international years 30 over has Richard of post the held he Thereafter, internationally. products key other and Losec of launch the oversaw he Astra, at time his During Director of Licensing and New Business Development at where Scotia he Pharmaceuticals, was involved with the company’s flotation Stock Exchange and successfully on the London negotiated numerous deals. Paradigm of co-founder a also was Goodfellow Dr business, vaccine cancer ImmunoBody Scancell’s co-founding to addition In based functional genomics company a Cambridge was a former and Director of Enact Pharma plc. Therapeutics, Rolf has over 25 years experience in finance and lawnumber anda for capital hasraising in successful consultedbeen has manyand Germany in companiesfunding public the onof knowledge thorough financiala has andWitte legal matters. Dr. of biotech companies. CEO, PSites Pharma GmbH CEO, Witte, Rolf WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 1.1 billion in 2011. Ipsen’s ambition is ambition Ipsen’s 2011. in billion €1.1 €250 million, above 21% of Group The sales. Speakers CEO, Ennar Pharma CEO, Rudi Neirinckx, Rudi is an experienced pharmaceutical industry with executive, a record of being invention, the author of over 100 scientific clinical research, i.e. business, pharmaceutical the of aspects most in worked He patents. dozen a than more and publications in the diagnostic etc. as well After business as an development, the therapeutic licensing, side of the development, business. academic career in Nuclear Medicine and Radiology he headed up the R&D operations of Amersham International (UK) and Serono but (Geneva), also was responsible for reorganizing the M&A Department of Merck where KGaA, he made numerous based Belgium), Pharma, (AgysCompany OTC an founded He Systems. Imclone with deal a including deals, M&A and license on his invention of an effective treatment of dental sensitivity and was COO of a Generics Company (PAR Pharmaceuticals, USA), which he helped turn around. He also was CEO of atugen, a Berlin high-tech start-up, before he became a full-time consultant to Subsequently the Altana he President Pharma. has of exclusively worked on the which psoriasis is project, now AG. handled at Ennar Pharma Managing Partner, Aravis Managing Partner, Simon Nebel, Since joining Aravis in 2001, Simon Swiss first has the participated in LP, the I Energy financingAravis ofof co-founder a awas he numberrecently Most of companies. lifeportfolio Aravis scienceof number companiesa of andtransactions the M&A Limited Partnership focused on renewable energy. Simon was Aravis, a Before group joining strategist atwhere Basel he and UBS coordinatedZurich), (London, and worked on Capital. UBS for proposal business Capital Venture Biotechnology a developing included This modelling. and planning business He is currently a board member of MarinoMed, ImVision and MerLion AG Pharmaceutical as Energy well as an observer on SA the and Anaphore board a (USA), of former member of the board and of directors of Borean Leading Swiss Renewable Pharma (Denmark) and secretary board of Evolva (Switzerland). of the Simon holds a PhD in Biophysics from the Biocentre of the University of Basel (1996) and an MBA with distinction from the London Business School (2001). Director, Corporate Business Development Team, Ipsen Team, Corporate Business Development Director, Scott Cuthill, exceeding sales total with company pharmaceutical specialty-driven global a is Ipsen Roche Partnering Roche Strategic Partnering, Global Head, Holland, Sarah Sarah Holland is the Global head, projects Strategicinclude broad strategic landscapes Partnering of M&A and late forstage opportunities, transactional support for Roche all pharma M&A Partnering based initiatives transactions, to generate income through spin-outs divestments, and strategic in and partnerships, development and Basel, Switzerland. Her team’s danoprevir to rights world-wide acquired team the 2010 In needs. business key address to structures deal creative deliveryof from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche responsibilities in in business such development, as Global 2005, Head of CNS Sarah and Partnering, has led projects in has a range of disease held various including the Plexxikon deal on b-raf inhibitors. areas, Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast She and held EU various launch. commercial and strategiccancer roles over her including ten Global years Strategicthere, during Planning US Manager for early Pricing compounds, Strategist she and AstraZeneca, held Health Before local Economist. and international biotech and pharmaceutical companies. sales and marketing roles in diagnostics, first and D.Phil her and 2004, until Fellow Visiting a was she where School, Business Manchester from MBA her gained Sarah degree at Oxford University. by supported is strategy development Its diseases. debilitating targeted for solutions healthcare specialty in leader a become to Moreover, hemophilia. and Decapeptyl® / uro-oncology Somatuline®, / endocrinology Dysport®, / neurology franchises: four the Group has an active policy of partnerships. R&D is focused on innovative and differentiated technological patientdriven platforms, and toxins. In 2011, R&D expenditure totaled more than Group has total worldwide staff of close to 4,500 employees. WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers CEO, Mucosis BV CEO, Johnston, Tom In his role he of has Bachelor a and School Business Wharton global The from M.B.A. responsibility an holds Johnston for Mr. alliances. strategic other the and partnerships licensing and marketing of Mucosis’s technologies, negotiating corporate Arcadia University. Science degree in Computer Science from BioCrea GmbH BioCrea CEO, Thomas Kronbach, Thomas is CEO of BioCrea, a drug discovery company in Radebeul, Germany, concept which to is drug creating candidate. first-in-classTom established drugsBioCrea from as a Management buy-out of was CSO CSO and Therapies, of founder Biotie Tom of elbion assets and and AWD had various Asta positions Medica, at Previously, from Biotie Therapies in 2010. Goedecke. Tom has initiated, negotiated and fostered partnerships with Boehringer Ingelheim, Wyeth/Pfizer andTom and Switzerland Basle, GlaxoSmithKline. of University the at Fellow Doctoral Post a was Germany, Tubingen, of University the from Ph.D. a holds CA. The Scripps Clinic and Research Foundation in La Jolla, Associate at a Research Management Abingworth Partner, Haines, Tim Tim has more than 25 years of company, portfolio Abingworth the of Executive Chief was he international 2005, in Abingworth joining Before devices. medical in expertise management experience in the life sciences industry Tim including Astex was Therapeutics. Previously, Chief Executive significant of two divisions of the publicly-listed medical technology company, Datascope Corp. Prior to Datascope, he held a number of other Abingworth, he senior identifiesmanagement and createspositions newin businessesthe and providesUS supportand for Europe. existingAt companies withinHe portfolio. is or the has been Abingworth a board member of the Powdermed following Therapeutics, Astex (acquired portfolio companies: Therapeutics. XCounter (AIM) and Chroma KSpine, (acquired Fovea by sanofi-aventis), Stanmore Orthopedic, IMI, by Pfizer), Torreya Partners Torreya Advisor, Senior Stephanie Leouzon, a life sciences advisory boutique. Partners, Torreya Advisor at Stephanie is a Senior She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical and speciality pharmaceutical sectors. She has advised clients on a number of strategic transactions, valued healthcare clients. financing transactions to provide over $7 billion to at over $70 billion, and she has been Morgan involved JP Brothers, in Lehman at Care Health in working included experience Stephanie’s 1998, in Suisse Credit joining to Prior and Salomon Brothers (now Stephanie Citigroup). earned an degree M.B.A. from the Darden Graduate School of Business at from Mount Holyoke College in 1985. cum laude, degree, Virginia in 1989 and a B.A. the University of Novo A/S Novo Managing Investment Director, Moller, Søren Søren obtained his MSc degree from University the Technical of Denmark in 1993 and his PhD degree in molecular biology in 1997 University from of Technical the Denmark for a project on In molecular addition microbiology. to his Søren PhD, has fellow atacademic training as postdoctoral Stanford of Medicine. University School Prior to joining Novo microRNA of development for Seeds, responsible was he where A/S Exiqon at R&D Søren of President Vice and CSO was Søren Novozymes, served as global manager of Bioinformatics based products and for life science Genomics research, pharma services atand diagnostics. In 2007 Novozymes. Exiqon completed an Before IPO on NASDAQ Søren OMX Copenhagen raising 400 mio DKK to develop and Previously, commercialize life science and diagnostic products. Identificationworked in cancer drug development as head of Lead at BioImage and as research scientist at Novo Nordisk. Søren Denmark). in Industries Biotechnology of Association (the Biotech Danish of member board been has Søren 2008, Since a Swedish based biotech company. AB, serves on the board of directors of Denator WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Willem obtained an MSc degree in biomedical and sciences an from Executive Utrecht MBA University, degree from NIMBAS / Bradford He University. began his professional career in clinical research at GSK and joined Genzyme in 1994 European sales in clinical, & marketing From positions. various 2004 to 2006 he was globally responsible for marketing of the genetic disease business unit in Genzyme’s worldwide headquarters in Cambridge, MA and in Genzyme Netherlands 2006 organization he in moved Naarden. In back 2009 Willem to joined the lead to-BBB the team as their CEO to break-through help brain deliveryAdvisoryWillem is member platformof Boards the of for the patientsLeiden with develop CNS diseases. their life science start-up management and Rabobank Leiden. VenGen BioScience Park, Torreya Partners Torreya Principal, Wilder Filford, Wilder is the founding partner of Partners Torreya Europe, the London branch of Partners, Torreya an international advisory firm assisting LifeScience companies with M&A, licensing, alliances, financings andDr. Fulford otherhas transactions. had a long career advising healthcare companies of all kinds around After the completing globe. his PhD in molecular biology at the Rockefeller University in 1986, he worked for a few years as a venture capitalist, before embarking on He M&A a has advisor. career run healthcare as M&A an or coverage groups in New York and London at Salomon Brothers, Merrill Lynch, Bank of America and (most recently) Deutsche Bank. He has participated in close to 100 financing andwith an M&Aaggregate value transactions in excess Partners of has Torreya $100 a billion. full team in and London, about a dozen mandates in execution. to-bbb CEO, Weperen, Willem van WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 4-Antibody www.4-antibody.com PROFILE COMPANY company4-Antibody is a biopharmaceutical with a powerful fully-human antibody drug-discovery technology The Company is making this technology available it to to pharmaceutical partners and is also using platform. generate a proprietary pipeline of antibody therapeutic initially drugs in in the immune check point target area commercially-experienced leadership located in Basel, 4-Antibody is a private company with strong, oncology. Germany Switzerland and Jena, MANAGEMENT CEO PhD, Robert F Burns, CTO PhD, Marc van Dijk, Head R&D Germany PhD, Luis Martin-Parras, CFO Andreas Richter, EMAIL [email protected] TELEPHONE +41 61 633 22 60 ADDRESS Hochbergerstrasse 60c Basel CH4057 CONTACT PhD Robert F Burns, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u – 0% (9%) (4%) 30% 30% 25% 31% 33% (10%) (69%) (17%) – 0.8 4.9 0.8 12.8 12.0 33.8 28.9 92.6 (21.0) (20.2) (23.3) 1.0 4.7 0.8 (0.4) (7.3) 16.6 15.6 30.6 25.9 (14.4) (13.6) H1 2012 H1 2011 % change 76.5(1) R&D income Grants R&D G&A (1) Including €2.7 million in restricted cash PROFILE COMPANY a novel Ablynx is a biopharmaceutical company engaged in the discovery of Nanobodies®, and development for a range of serious human class of therapeutic antibody fragments, proteins based on single-domain the Company has Today, oncology and pulmonary disease. haematology, including inflammation, diseases, Ablynx has approximately 25 programmes and seven Nanobodies at in the pipeline clinical development stage. including ongoing research collaborations partnerships with major pharmaceutical companies, and significant More Belgium. The Company is headquartered in Ghent, Merck Serono and Novartis. Boehringer Ingelheim, information can be found on www.ablynx.com. MANAGEMENT Chairman and Chief Executive Officer Edwin Moses, Chief Medical Officer Josi Holz, Chief Business Officer Allan, Eva-Lotta Chief Scientific Officer Andreas Menrad, Chief Financial Officer Wim Ottevaere, Ablynx www.ablynx.com FINANCIAL SUMMARY (€ million) Revenues

Operating expenses

Other operating income/(expense) Finance income (net) Net result Net cash burn Operating result Cash at June 30 YEAR FOUNDED 2001 EMAIL [email protected] [email protected] FAX +32 (0)9 262 00 01 TELEPHONE +32 (0)9 262 00 00 ADDRESS Ablynx nv 21 Technologiepark 9052 Zwijnaarde Belgium CONTACT Edwin Moses Chairman and Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Trial ver 500,000 patients in North America and millions worldwide use iv-5FU. ver 500,000 patients in North Breast cancer is the second leading cause of cancer related death among women, according to the National Breast cancer is the second leading cause of cancer related death among women, while NCI estimated that 207,090 women were diagnosed cancer, with breast In 2010, Cancer Institute. 39,840 women likely died from the disease. Adherex is a biopharmaceutical company focused on cancer therapeutics, which is publicly traded in both the companyAdherex is a biopharmaceutical focused on cancer therapeutics, ADHXF). OTC: United States and Canada (TSX:AHX, The Company believes eniluracil might enhance Adherex has principally focused on eniluracil. its resources reduce the occurrence of a disabling side effect and expand the therapeutic of 5-FU, spectrum of activity known as hand footto be given syndrome and allow 5-FU orally. the eniluracil / 5-fluorouracil the principal inventor of Spector, Thomas The new clinical plan is led by Dr. Laboratories 20 years ago. Wellcome cancer treatment while working at Burroughs Phase 2 clinical trial for Metastatic Breast Cancer compares the oral regiment of Eniluracil + The Company’s 5-Fluorouracil (5 FU) and Leucovorin versus Capecitabine (Xeloda®). The comparative study intends to enroll 140 patients at approximately 20 clinical sites in the United States and 2012 the August 10, As of Russia with enrollment anticipated in the fourth to be completed quarter of 2012. It plans to enroll 80 patients arm and 60 in the eniluracil/5-FU/leucovorin Company had enrolled 134 patients. in the capecitabine arm. The secondary endpoints include the overall The primary endpoint of the trial is progression-free survival. duration of response, disease control rate, antitumor response rate, toxicity (including hand-foot syndrome), Patients (30 mg) receiving eniluracil (40 mg)/5-FU (30 mg/m2) /leucovorin and time-to-treatment response. Patients receiving capecitabine are treated are treated once per week for weeks per month. three consecutive with 1000 mg/m2 every 12 hours for 14 days every three weeks. Adherex www.adherex.com FINANCIAL SUMMARY million Cash @ 06/30/12 – $3.6 The Companyanticipate doesn’t the need fordata further funding until becomes available from the enrolling Phase II trial next year. PROFILE COMPANY Business Summary • • • Clinical • • • Market Target • O •  MANAGEMENT Chief Executive Officer Rostislav Raykov, Chief Financial Officer Andrade, Robert Chief Scientific Officer Thomas Spector, Dr EMAIL [email protected] [email protected] [email protected] FAX (919) 890-0490 TELEPHONE (919) 636-4530 Rostislav Raykov, (919) 636.5144 Andrade Robert (919) 636.5013 ADDRESS Alexander Drive TW 68 PO Box 13628 Park, Triangle Research NC 27709 CONTACTS Rostislav Raykov Chief Executive Officer Andrade Robert Chief Financial Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u B.V. AM-Pharma www.am-pharma.com FINANCIAL SUMMARY round of EUR 29.2 million in September 2011. Raised a series D financing PROFILE COMPANY companyAM–Pharma is a biopharmaceutical human alkaline phosphatase developing novel recombinant Acute Kidney Injury (AKI) and Ulcerative Colitis (UC). including therapeutics for inflammatory diseases, MANAGEMENT CEO MBA, MSc, Erik van den Berg, VP Clinical Development MD, Arend, Jacques VP Preclinical Development BSc, Steve Connor, VP Finance Verwayen, Peter VP Research PhD, Andrea van Elsas,

EMAIL [email protected] YEAR FOUNDED 2001 FAX +31-30-2289220 ADDRESS AM-Pharma B.V. TELEPHONE +31-30-2289222 CONTACT Erik van den Berg Chief Executive Officer Rumpsterweg 6 AK Bunnik 3981 The Netherlands WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 20+ years global clinical development and management experience CEO • LS Pharma International, CEO • Hesperion, Clinical Director • Hoffmann-La Roche, patents experience and start-up immunology, 20+ years biology, CSO/COO Anergis, • CSO • Dictagène, Assist Professor University Lausanne • 20+ years medical practice and research in immunology and allergy Allergy/Immunology and Chief Prof. Assoc. • • Lausanne University Hospital (CHUV) Anergis • President & founder of MSc MBA Insead, • Business and Finance consultant AG • Director Finance Kuros Biosurgery VI Partners • Investment and finance manager, management pharma business and commercial 20+ years biotech, Managing Director • IDEFI Gestion, GM & CEO • Stallergenes, Head Pharma Division • Eli Lilly France, SA Anergis www.anergis.ch FINANCIAL SUMMARY CHF 18M round March 2011. PROFILE COMPANY biopharmaceutical companyANERGIS SA is a Swiss-based specializing in the discovery and development Allergy is the “desensitization”) products. or “SIT” immunotherapyof novel ultra-fast specific (also known as growingmost prevalent and the fastest million with over 300 world chronic condition in the industrialized SIT remains underused due to its long duration Current (3-5 years of treatment) and safety people affected. can achieve induction which SIT treatmentsANERGIS develops ultra-fast and safe for allergic patients, risks. know-how and the exclusive ANERGIS possesses a unique of tolerance to the allergen in few injections only. rights to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Hospitalier Universitaire (EPFL) and the Centre Technology of the Federal Institute Switzerland (UNIL), Lausanne, ANERGIS COPs are long peptides they present the advantage of being recognized Because (CHUV). Vaudois and processed by mechanisms as the originalof the immune system using similar the antigen presenting cells combined with the fact that the COPs reproduce – in separate molecules – the full This feature, allergen. and that overlapping sequences guarantee thatlinear epitopes are all sequence of the allergen, ANERGIS has studied proprietary COPs In the past years, ensures the high immunogenicity of the COPs. present, These studies have confirmed the targeting bee venom and birch pollen allergies both in animals and in humans. excellent safety (no immediate allergic and expected immunogenicity (production of specific antibodies reaction) ANERGIS COPs. and cytokines against the original allergen) of MANAGEMENT CEO Vincent Charlon, CSO Christophe Reymond, Medical Expert François Spertini, Finance Director Zoltan Czigler, Business Development Jean-Paul Rohmer, YEAR FOUNDED 2001 EMAIL [email protected] FAX +41 21 651 9221 TELEPHONE +41 21 651 9220 ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland CONTACTS Vincent Charlon PhD, CEO Zoltan Czigler MBA, Finance Director WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AS Therapeutics APIM www.apimtherapeutics.com FINANCIAL SUMMARY Capital Financed. Venture AS • Ro Invest • Norsk Innovasjonskapital Venture • Sarsia Seed • Birk Current investors include: PROFILE COMPANY AS is a Norwegian biotech company develop and commercialize novel anti-cancer set to Therapeutics APIM therapies potentiating chemotherapy-induced cells. responses in cancer protein called Proliferating cell “hub” offer a unique physiological interventionWe point targeting a cellular cell cycle control and apoptosis, repair, regulator PCNA acts a master of replication, Antigen (PCNA). Nuclear ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells. features a novel PCNA-interacting Stress Switch current preclinical lead, the company’s ATX-101, with several cellular defense interferes being incorporated in peptide sequence, This motif, APIM. Motif termed to chemotherapysystems dealing with stress resulting in both hypersensitivity and direct induction of apoptosis in selected cancer cells. including single has shown potent preclinical efficacy activity and potentiationagent of the ATX-101 Overall, vorinostat, dasatinib, decitabine, cytarabine, bleomycin, melphalan, action of >15 clinical drugs in vitro (cisplatin, and solid tumor indications. in animal models of blood cancer bortezomib and others) as well as proof-of-efficacy is being developed as a novel candidate drug for various oncology indications. ATX-101 Currently, MANAGEMENT Chief Executive Officer Alevizopoulos Ph.D., Kostas Chief Scientific Officer Marit Otterlei Ph.D., YEAR FOUNDED Founded in 2009 as a spin out from the Norwegian University in Technology of Science and Norway. (NTNU), Trondheim EMAIL [email protected] [email protected] TELEPHONE +41 78 752 7002 ADDRESS AS Therapeutics APIM AS Transfer Tech c/o NTNU Sem Sælandsvei 14 3etg Kjemiblokk 1, Trondheim N-7491 Norway CONTACT Alevizopoulos PhD Kostas Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u APRI 22M* 16M* ~$5M 19.6M* $5.26** ~320k** $10.2M* ~$105M**

Inc. Biosciences, Apricus www.apricusbio.com FINANCIAL SUMMARY NASDAQ: Shares Out: Fully-diluted Shs: Float: Cash position Share-price Marketcap Daily volume Ave. 2010 Revenues 2011 **As of June 24, 2011, *As of March 31, PROFILE COMPANY Apricus Bio (Nasdaq:APRI) is a pharmaceutical company that and markets innovative develops treatments The Company has high-demand therapeutic classes. that help large patient populationsnumerous, across With four approved strong pipeline of multiple late-stage products and has developed a product opportunities. Apricus Bio generates and growth revenues from and Europe (France), commercial operations in both the U.S. its pipeline products and NexACT® in certain territories, sales of its commercial products and by out-licensing, technology. and commercialize new products through strategic develop, growth strategy is to acquire, Apricus Bio’s companies pharmaceutical large multiple with partnerships commercial Companycurrentlyhas The partnerships. and co-promotes multiple Chilcott and Bracco, Warner Sandoz, Takeda, Abbot Laboratories, including Novartis, products in France. CA and is publicly traded on the NASDAQ under the ticker Apricus Biosciences is headquartered in San Diego, APRI. symbol MANAGEMENT President and Chief Executive Officer Chairman, Dr Bassam Damaj, Vice President and Chief Financial Officer Senior Steve Martin, Vice Corporate Development and Investor Relations Edward Cox, General Counsel and Secretary Vice President, Executive Randy Berholtz, YEAR FOUNDED 1987 EMAIL [email protected] [email protected] FAX (858) 866-0482 TELEPHONE (858) 222-8041 ADDRESS Suite 103 6330 Nancy Ridge Dr., CA 92121 San Diego, U.S.A. CONTACTS Dr Bassam Damaj CEO President & Chairman, Ed Cox VP Corporate & IR Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u $121 M in unrestricted cash, cash equivalents and marketable (current & non-current) securities $121 M in unrestricted cash, as of 6/30/12 2012 DACOGEN® royalty revenue Up to $70.0 M in projected milestones plus future royalty revenues Significant potential product Inc. Pharmaceuticals, Astex www.astx.com FINANCIAL SUMMARY •  •  • PROFILE COMPANY dedicatedAstex Pharmaceuticals is to the discovery of novel small molecule therapeutics and development The Company a proprietary is developing therapies pipeline of novel and is creating with a focus on oncology. Astex Pharmaceuticals developed de-risked products for pharmaceutical companies. partnership with leading Dacogen® (decitabine) for significant royalties on global sales. Injection and receives please visit http://www.astx.com. Inc., Astex Pharmaceuticals, For more information about MANAGEMENT Officers Chairman & CEO MBA, PhD, Manuso, James S.J. PhD, President and Director , MBA, Chief Medical Officer MSc, MD, Azab, Mohammad Chief Business Officer MBA, DPhil, Martin Buckland, CFO & Corporate Secretary CPA, Michael Molkentin, Senior Management Corporate Communications and Marketing Vice President, Senior Enns, Timothy Intellectual Property Vice President, Senior PhD, EPA, Leaper, Lyn Business Development Vice President, Senior MBA, PhD, Michael McCullar, Medicinal Chemistry Vice President, Senior PhD, David Rees, Biology Vice President, PhD, Senior Thompson, Neil YEAR FOUNDED 1991 EMAIL [email protected] FAX +1 925.560.0101 US: +44 (0) 1223 226201 UK: TELEPHONE +1 925.560.0100 US: +44 (0) 1223 226200 UK: ADDRESS Office US Corporate Suite 200 4140 Dublin Blvd., CA 94568 Dublin, European Office 436 Cambridge Science Park UK CB4 0QA, Cambridge, CONTACTS PhD Harren Jhoti, President & Director Enns Timothy – Vice President Senior Corporate Communications & Marketing WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AB Biotechnologies Athera www.athera.se FINANCIAL SUMMARY Baltic Sea Foundation and KCIF Co- AB (publ), including Karolinska Development Current shareholders, have invested nearly €17 m in the company. AB, investment Fund Athera is currentlyI clinical trial of PC-mAb. with investors to raise €10 m to fund the Phase in discussion Current shareholders have programAthera plans to partner the with pharma partners at of Phase I trial. the end 1/3rd of the current financing need. committed to invest up to PROFILE COMPANY PC-mAb is a fullywhich neutralizes a key human monoclonal antibody driver of vascular inflammation, indicated and will be for secondaryphosphorylcholine to improve outcome after acute prevention (“PC”), levels of antibodies to phosphorylcholine Low endogenous have (“anti-PC”) coronary been syndrome (“ACS”). linked to a higher incidence of secondary events as well as a markedly increased mortality after the coronary This program is in IND-enablingstudies and the IND is expected in 2013. event. Athera has developed a proprietary enhance clinical success by properly selecting the target population, To companion diagnostic patients CVDefine® kit to identify with low anti-PC levels in need of receiving PC-mAb The kit is CE-approved. therapy. Athera is a biopharmaceutical company focused on developing targeted anti-inflammatory bio-therapeutics The Company and companion diagnostics for and treatment the prevention of cardiovascular disease (“CVD”). harnessing breakthrough innovations made at Karolinska the world-renowned initiated its current program, supported by an approved PC-mAb, The company currentlyproprietary has a pre-IND program, Institute. proprietary companion diagnostic kit. MANAGEMENT Athera is managed by from the pharmaceutical and diagnostics a team of senior professionals industries in has nearly Schmidt 30 years Ms. Carina Schmidt. is led byThe core team CEO, a semi-virtual organization. international marketing and product mainly in business development and management, industrial experience, During 15 years she has worked with Pharmacia Biotech/Amersham management within the biotech area. Later she founded Grasp Bioscience and co-founded Partners BioBusiness Biosciences (now GE HealthCare). interim CEO and business advisor to several where positions included management consultant, Scandinavia, biotech start-ups. which includes Professors Peter Libby, Athera, Advisory Board was formed in a new Scientific In Nov 2011, and Ulf de Faire. Wallentin Lars Maarten Simoons, YEAR FOUNDED 2002 EMAIL [email protected] [email protected] TELEPHONE +46 8 508 847 44 Carina Schmidt +46 76 1938 190 ADDRESS Fogdevreten 2A 17165 SOLNA SWEDEN CONTACT Carina Schmidt Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 9.4 Year 0.70 671

33.2 6.5% 2011 145.8 10.2% 7.1 649 76.2 19.8 0.53 2012 9.3% 13.9% 1. Half-Year Bachem www.bachem.com FINANCIAL SUMMARY

Sales (in MCHF) Number of employees (in full-time equivalents) PROFILE COMPANY public biochemicals company providing full service to the pharma technology-based, Bachem is an independent, of peptides and in the process development and the manufacturing Bachem is specialized and biotech industry. as well as innovative biochemicals for ingredientscomplex organic molecules as active pharmaceutical (APIs), Bachem and affiliates in Europe and the US, Switzerland, With headquarters in Bubendorf, research purposes. in the field of peptides. works on a global scale and holds a leading position MANAGEMENT of Directors Board Honorary Chairman Peter Grogg, Dr h.c. Chairman Dr Kuno Sommer, Secretary Thomas Burckhardt, Dr Nicole Grogg Hötzer Dr Jürgen Brokatzky-Geiger Prof Dr Hans Hengartner Dr Rolf Nyfeler Executive Commitee Corporate CEO Thomas Früh, Dr CFO Stephan Schindler, CTO Dr Daniel Erne, CMO Dr José de Chastonay, EBIT in % of sales Net income (in MCHF) EBITDA (in MCHF) Earnings per share (EPS – in CHF) Net income in % of sales YEAR FOUNDED 1971 EMAIL [email protected] FAX +41 61 935 2325 TELEPHONE +41 61 935 2323 ADDRESS Hauptstrasse 144 4416 Bubendorf Switzerland CONTACTS Dr José de Chastonay Chief Marketing Officer AG Bachem Holding Markus Schwaller Business Development Manager AG Bachem WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Identify novel targets missed by other methods in vivo & in vitro imaging and recovery of cells High throughput in vitro assays and screening Advanced in-vitro and in-vivo models Genetic dose response treatment/disease models – Revenue generating VC funded – A 2011 $10m – Series Fund • Sarsia Seed Fund • Investinor – Series B Q4 2012.

First in class, highly selective Axl inhibitor. Poised to enter Ph1 Q1`13. Axl inhibitor. highly selective First in class, Preclinical candidate at LO stage Axl. mAb inhibitor of discovery stage Undisclosed target, AS BerGenBio www.bergenbio.com FINANCIAL SUMMARY  Private Company: Investors: Capital plans: PROFILE COMPANY BerGenBio`s mission is to develop novel therapeutics against emerging targets for advanced cancer. The company of action that tumor microenvironment and mechanisms has a deep understanding of the result in the formation drug resistance. of cancer seeding (stem) cells and epithelial-to-mesenchymal transition (EMT), The company is built on proprietary CellSelect technology platform and validate used to identify novel drug targets and de-risk and accelerate of novel therapeutic the development candidates. companyThe is simultaneously developing candidates. BerGenBio has a pipeline of clinical and preclinical biomarker and PD assays as companion diagnostics for its pipeline of drug leads. BerGenBio has established a fully integrated & in vivo research in vitro With its headquarters in Bergen Norway, and development infrastructure and a drug discovery and clinical development team in UK. Pipeline BGB324 BGB109 BGB002 Technologies CellSelectRNAi CellSelectImaging CellSelectScreening CellSelectModeling CellSelectRegulated MANAGEMENT CSO – ([email protected]) Prof James Lorens, CTO – ([email protected]) Dr David Micklem, Dr Longen Zhou, Director of Cancer Biology

YEAR FOUNDED 2009 EMAIL [email protected] TELEPHONE +47 917 86 304 ADDRESS AS BerGenBio Jonas Lies vei 91 Bergen, 5009, Norway CONTACT Mr Richard Godfrey Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Limited Therapeutics Bicycle www.bicycletherapeutics.com FINANCIAL SUMMARY Funded by investment with four £3.95m seed blue chip investors: • SR One • SV Life Sciences Funds Venture • Novartis Ventures Atlas • PROFILE COMPANY UK Therapeutics is a biotechnology company based at Babraham the Research Campus in Cambridge, Bicycle developing a novel technology which uses biological to identify molecules which combine selection methods The technology allows the identification features weight drugs and and biopharmaceuticals. of small molecular Bicycle peptides of highly and selectivity against constrained peptides with high potency the target of interest. have properties that overcome many deficiencies of previous generations of the of peptide based drugs and Bicycle technology is based on the Bicycle libraries offer to interrogate a vast diversity with which target space. the work performed at the MRC Laboratory of Molecular Biology by in Cambridge the scientific founders of the The companyfounded was in July 2009 and received Winter. Prof Christian Heinis and Sir Gregory company, Fund who were subsequently joined by SR SVLS and Venture and Novartis Venture Atlas initial seed funding from One to complete the seed phase syndicate. MANAGEMENT CEO Dr Rolf Guenther, CSO Tite, Dr John YEAR FOUNDED 2009 EMAIL liz.hudson @bicycletherapeutics.com FAX +44 1223 832177 TELEPHONE +44 1223 497415 ADDRESS Meditrina Building Babraham Research Campus Cambridge CB22 3AT CONTACT Liz Hudson Office Manager WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GmbH BioCrea www.biocrea.com FINANCIAL SUMMARY minority stake. which has a Therapies, by initial funding Biotie Private Company, PROFILE COMPANY novel drugs forbiocrea discovers and develops the treatment of debilitating CNS diseases such as schizophrenia disease. or Huntington’s drug candidates track record in the development of CNS team has an exceptional has and The company’s and Wyeth Pfizer, partnered extensively major pharmaceutical companies such as Boehringer-Ingelheim, with Germany. biocrea is based in Radebeul, GlaxoSmithKline. MANAGEMENT Chief Executive Officer Thomas Kronbach, Dr Chief Financial Officer Viehweg, Viktor Chief Scientific Officer Dr Martin Gunthorpe, Vice President Chemistry& Development Executive Ward, Prof Simon YEAR FOUNDED 2010 FAX +49 351 4043 3216 EMAIL [email protected] [email protected] [email protected] TELEPHONE +49 351 4043 3374 Kronbach Tom +49 351 4043 3332 Viehweg Viktor +49 351 4043 3252 ADDRESS BioCrea GmbH Meissner Strasse 191 01445 Radebeul Germany CONTACTS PhD Kronbach, Tom Chief Executive Officer Viehweg Viktor Chief Financial Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG BioVersys www.bioversys.com FINANCIAL SUMMARY million (2011) CHF 2.5 Seed Round: expected for CHF 12 million end 2012 A: Series PROFILE COMPANY is a privately bio-pharmaceutical company held Swiss located Basel that in BioVersys focuses on research and which switch off within bacterial pathogens drug resistance and and compounds, development of new drugs restore the efficacy of approved antibiotics. developed a proprietary has multi-level screening technologyBioVersys to identify small chemical molecules that RegulatorInhibitory Compounds (TRICs) are Transcription These interfere with bacterial transcriptional regulators. able to switch off bacterial resistance atgenetic level and thus reactivate a ineffective antibiotics. molecules acting TRIC against gram negative and gram positive the company has identified active Currently, In collaboration with the INSERM Lille the company also follows a program directed against multi pathogens. Tuberculosis drug resistant MANAGEMENT co-founder and CEO Dr Marc Gitzinger, co-founder and CSO Tigges, Dr Marcel YEAR FOUNDED 2010 EMAIL [email protected] [email protected] [email protected] [email protected] FAX +41 61 633 22 59 TELEPHONE +41 61 633 22 50 +41 61 633 22 51 ADDRESS AG BioVersys Basel Technologiepark c/o Hochbergerstrasse 60c CH-4057 Basel Switzerland CONTACTS Tigges Dr Marcel Chief Scientific Officer Dr Marc Gitzinger Chief Executive Officer Patrick Burgermeister Advisor WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG BioVotion www.biovotion.com FINANCIAL SUMMARY regulatory further clinical testing, is currently Series B round for raising a CHF5.5M product finalization, BioVotion generation Revenue is expected within 12 to 18 months. ramp-up and initial market launch. production approval, should reach around CHF30M the first of several addressable markets, COPD market, Revenues in the European is envisaged Cash break-even for late 2015. by 2016. PROFILE COMPANY non-invasive providing solutions for continuous, device company, AG is a Swiss based medical BioVotion standalone wearable Vital Sign Monitoring (VSM) platform is a mobile, The BioVotion physiological monitoring. monitor of vital sign parameters supported by integrated It is cloud services for data exchange and analysis. wearable monitoring patient-friendly, directed towards patients featuring with chronic conditions BioVotion’s concept. to provide sensor relevant The company holds internationally know how in a number of fields, recognised embedded into technology and device development for and non-invasive physiological continuous monitoring, mHealth environments. MANAGEMENT AG is a Swiss medical device company established by leading and experienced experts in the field of BioVotion wearable monitoring. sophisticated, Chief Executive Officer PhD, Andreas Caduff, Officer Technical Chief PhD, Talary, Mark YEAR FOUNDED 2011 (taken over IP and technology from former Solianis) EMAIL [email protected] FAX +41 44 515 61 71 TELEPHONE +41 44 515 61 71 +41 79 677 41 79 ADDRESS 1 Technoparkstr. 8005 Zurich Switzerland CONTACTS PhD Andreas Caduff, Chief Executive Officer PhD Talary, Mark Officer Technical Chief WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ingelheim Boehringer www.boehringer-ingelheim-venture.com/ Financial Summary €100 Mio fund volume: Total life • Initial investment atan early stage of company’s progress in pace with the company’s • Follow-on investments lifetime • Stagedof up to €10 mio over company’s investments PROFILE COMPANY Okairos is a clinical stage vaccine company. www.okairos.it Therapeutics is engaged in the discovery and commercialization of new medicines for the treatmentAMP of severe bacterial infections predominantly by caused drug-resistant Gram-negative bacteria. www.amp-therapeutics.com VC fund backed by the French government as Initiative (ITI) is a life-sciences seed and pre-seed Transfert Inserm well as by private major international investors including several pharmaceutical groups. www.it-initiative.fr allogenic cell therapyPromethera Biosciences’ mission is to develop an approach to treat inborn metabolic liver diseases. www.promethera.com MANAGEMENT Fund Venture Ingelhiem Head of the Borhringer Vice President, Dr Michel Pairet, Senior Fund Venture Investment Manager of the Borhringer Ingelheim Director, Wicke, Dr Ilka Fund Venture Investment Manager of the Borhringer Ingelheim Director, Dr Martin Heidecker, Fund Venture Investment Manager of the Borhringer Ingelheim Director, Dr Knut Elbers, Fund Venture Investment Manager of the Borhringer Ingelheim Director, Dr Frank Kalkbrenner, YEAR FOUNDED April 2010 EMAIL Venture @boehringer-ingelheim.com TELEPHONE +49 6132 77 8740 ADDRESS Fund Venture Boehringer Ingelheim Backoffice Binger Strasse 173 55216 Ingelheim am Rhein GERMANY WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Inc. Cerecor www.cerecor.com FINANCIAL SUMMARY Pre-revenue Funding A US$ $23.4MM Series May 2012 PROFILE COMPANY and development is a Maryland-based biopharmaceutical company focused on the discovery, Cerecor Inc. primarywhose commercializationpharmaceuticals prescription of nervous human the in is activity of site system. atOur mission is to commercialize neuroscience discoveries Medical Institutes (“JHMI”) and our Johns Hopkins operational scientists and experts. founders include world class and highly biotechnology successful investors, developed under research grants made by the schizophrenia, Our current product opportunities are in cough and Company to various laboratories institutes at and research JHMI. MANAGEMENT Our management and advisory teams have and extensive pharmaceutical product development business registration, clinical development, with excellence in formulation, commercialization experience, Members of our management and advisory boards have been involved development and brand management. annual revenues) including the neuroscience blockbuster (>$1B in the development of many different drugs, Our advisory boards and management team possess over 200 Cymbalta® and Neurontin®. products Lyrica®, biotechnology and specialty pharmaceutical experience. pharmaceutical, years of academic, Co-Founder & CEO MD, Blake M Paterson, VP Drug Discovery & Development PhD, Reza Mazhari, Affairs & Quality VP Regulatory PhD, Sharon Rowland, VP Finance Karen Krumeich, VP Commercialization & Business Development John Kaiser, YEAR FOUNDED 2011 EMAIL [email protected] [email protected] FAX 410-327-4084 TELEPHONE 410-522-8707 ADDRESS 324 Suite 2400 Boston Street, MD 21224 Baltimore, CONTACTS Dr Blake Paterson Co-Founder & CEO Mr John Dierkes Advisor WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Biosciences Ceronco www.ceronco.nl FINANCIAL SUMMARY First financing round ongoing Privately funded, PROFILE COMPANY new drugs to fight cancer It is developing start-up companyCeronco Biosciences is a established recently. sphingolipid (SCS) technologybased on the short-chain discovered in a collaborative project at research the (NKI) and Erasmus MC. Netherlands Cancer Institute establishedProof of principle has been in combining the SCS-technology with doxorubicin in highly relevant and specifically in cancer cells, increase in uptake of doxorubicin, Addition of the SCS leads to animal models. At the same time no subsequently a significant reduction in tumor growth and increase in overall survival. increase in severity of expected side effectsnew side effects or were noted. clinical trial with expected start of the first into clinical trials, Ceronco is now taking this first product (CB001) early 2013. Technology A new class of A major barrier for uptake of chemotherapeutic drugs is the cellular membrane of a cancer cell. the cellular membrane and lead which insert themselves into short-chain sphingolipids (SCS) has been identified This results in increased uptake of a large variety of amphiphilic to catalysis of drug-membrane translocation. chemotherapeutic drugs. Cell Membrane Modulation SCS-technology using the is a novel and unique method to increase the Tumor efficacy of chemotherpaeutic drugs. Products liposomal doxorubicin GluCer-enhanced CB001: SCS-enhanced mitoxantrone CB002: MANAGEMENT Chief Executive Officer Jeroen Rovers, YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +31 6 52662000 ADDRESS PO Box 85696 2508CJ Den Haag The Netherlands CONTACT MD PhD Jeroen Rovers, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

GmbH Pharmaceuticals Cevec www.cevec.com FINANCIAL SUMMARY The Since 2009 CEVEC successfully markets its cell based technology for protein and antibody production. Lead investors include EUR venture capital rounds up to now. in several venture company has attracted 14 Mio. and NRW.Bank Venture Creathor PROFILE COMPANY business case: The CAP vaccine innovativeCEVEC commercializes an platform technology for production of vaccines and biopharmaceuticals the in human cell lines. as hCMV, such CAP cells hold high promise for production system for a best-in-class viral vaccines, CEVEC’s Compared to leading other cellular production systems as shown by a recent case study. Influenza and others, cycles and extreme short production (like MDCK) CAP demonstrated in view of virus yield, outstanding results CAP system is suspension based and serum free offeringbest starting the CEVEC’s minimal media consumption. Being the only remaining point for new vaccine production approaches with excellent upscaling possibilities. the company sets out to repeat growth the story of Crucell independent supplier for lines, human production cell recently acquired byfor Johnson & Johnson 2.4 Bn US$. B.V., Feasibility studies further demonstrated a versatile CAP being virus production platform with a broad RSV, Commercially include hCMV, significant targets susceptibility for various human-pathogenichuman viruses. Several lead projects have been identified Lentiviruses and others. Adenoviruses, AAV, Measles, Polio, Influenza, Manager, Vaccine Project together with its partner including the first human platform for hCMV, and planned, Germany. Hannover, be used to push the This investment will EUR venture round. CEVEC is underway to close another 7-10 Mio. manage such as hCMV within 3 years to clinical phase I/IIa results and a broad roll-out of vaccine lead projects, investors are still Venture its vaccine production technology its company in order to maximize exit value by 2015. invited to participate high return growth in an exciting low-risk and story. MANAGEMENT CEO Kintzel, Wolfgang CFO/COO Managing Director, Dr Rainer Lichtenberger, CSO Dr Gudrun Schiedner, VP Development & Services Dr Nicole Faust, America VP BD North Gary Boch, BD Europe & ROW Dir. Tintrup, Dr Hartmut YEAR FOUNDED 2001 EMAIL [email protected] FAX +49 221 460208 01 TELEPHONE +49 221 460208 00 ADDRESS 62 Gottfried-Hagen-Str. 51105 Koeln Germany CONTACT Kintzel Wolfgang Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Advisory Board AG Covagen www.covagen.com FINANCIAL SUMMARY Ventech • • Edmond de Rothschild Investment Partners Fund Venture • Novartis Investors: Management Venture • MP Healthcare • Seroba Kernel Life Sciences PROFILE COMPANY Covagen is a privately held company pioneering the commercialization of Fynomers and bispecific Fynomer- as next generationantibody fusions (FynomAbs) in inflammatory protein drugs to address unmet medical needs Fynomers are small binding proteins thatcan be engineered to bind to any antigen of diseases and cancer. Fynomers can be readily fused to therapeutic proteins Because of their excellent biophysical properties, interest. FynomAbs haveas they novel modes of action can engage such as antibodies to create bispecific FynomAbs. FynomAbs At the same time, simultaneously binding sites on the same target. with multiple antigens or multiple maintain the advantageous of antibodies such as excellent stability drug-like properties and long half-life. TNF/IL-17 inhibitor (in preclinical development) for the treatment of lead program is a bispecific Covagen’s psoriatic arthritis and rheumatoid arthritis. inflammatory diseases such as psoriasis, MANAGEMENT of Directors Board Executive Chairman Walsh, Frank Julian Bertschinger Jon Hepple, Mounia Chaoui, Nobécourt, Gilles Anja König, Franz Hefti, Ray Hill, Scientific Christoph Lengauer Christoph Heusser, Thierry Hercend, Ulrich Feige, Winter, Greg YEAR FOUNDED 2007 EMAIL [email protected] FAX +41 44 732 46 64 TELEPHONE +41 44 732 46 60 ADDRESS AG Covagen 25 Wagistrasse 8952 Schlieren, Switzerland CONTACTS Dr Julian Bertschinger Chief Executive Officer Dr Dragan Grabulovski Chief Scientific Officer Dr Fabian Buller Director Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Limited Biologics Crescendo www.crescendobiologics.com FINANCIAL SUMMARY 7.7m GBP Funding to date: • Rainbow Seed Fund Avlar BioVentures Technologies • Partners • Babraham • Sofinnova Bioscience Investors: PROFILE COMPANY Crescendo Biologics developed a novel antibody fragment has discovery platform which generates fully human VH fragments by immunisation of a transgenic mouse. strategy to utilise the platform is in the key for value areas the smallest and most robust antibody The company’s It intends to exploit its unique capabilities to create especially in topical products and bi-specifics. fragments, differentiated pipeline and through strategic medicines both through its in-house partnerships. by Dr Marianne Cambridge, The Crescendo mouse platform at was conceived the Babraham Institute, a pioneer in the field who was the first to engineer human antibodies. transgenic mice to produce Bruggemann, to similar analogous It is based on the generation of human heavy chain antibodies by transgenic mice, However in this case they are fully provide candidate-quality human and antibodies produced naturally in llamas. VH fragments smallest portions of immunoglobulin that are the retain target specificity and VH fragments directly. making them highly have properties more akin to small molecules, compared to whole antibodies, potency and, attractive therapeutic agents. The company benefits from a managementteam that is highly experienced in all aspects of antibody platforms, and the support of a syndicate of experienced life science investors led antibody discovery and development, It is based at the Babraham links with the Research Campus and maintains strong by Sofinnova Partners. Babraham in Cambridge. Institute and the antibody science community MANAGEMENT CEO Mike Romanos PhD, Chief Business Officer Matthew Roe, Head of Business Operations Amanda Bettison, Chairman Clive Dix PhD, YEAR FOUNDED 2009 EMAIL mromanos @crescendobiologics.com FAX +44 1223 497141 TELEPHONE +44 1223 497143 ADDRESS Meditrina Building 260 Babraham- Research Campus Cambridge CB22 3AT CONTACT Mike Romanos PhD Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u B.V. Biosciences Crossbeta www.crossbeta.com PROFILE COMPANY oligomer drug discovery Stabilizing targeting toxic oligomers is the basis for oligomers and Crossbeta’s Huntington Parkinson’s, Alzheimer´s, platforms accessible for which are partnering in therapeutics such as areas 2. Type and Diabetes Alzheimer program we have recently screening campaign with 100,000 completed a high throughput In our effect selection of 5 hit classes with >50% neutralizing compounds resulting in the on oligomer-induced neurotoxicity. Stable be used as reference in biomarker assays. oligomers can also MANAGEMENT Chief Executive Officer Guus Scheefhals, Chief Scientific Officer Martijn Gebbink,

YEAR FOUNDED 2005 EMAIL [email protected] FAX +31 30 253 7131 TELEPHONE +31 30 253 2668 CONTACT Guus Scheefhals, ADDRESS Padualaan 8 3584 CH Utrecht The Netherlands Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Biotechnology CYTOS www.cytos.com FINANCIAL SUMMARY CHF 36.1 mln 2012: per June 30, Cash and cash equivalents PROFILE COMPANY and commercialization development of a novel class of Cytos Biotechnology dedicated is to the discovery, medicines – called Immunodrugs™. Immunodrugs™ are therapeutic vaccines intended for use in the treatment and prevention of common chronic of people worldwide. diseases which afflict millions a novel allergen-independent Immunodrug™ with disease-modifying lead program is CYT003, The Company’s and with potential to treat a broad range of different potential in Phase II clinical development for allergic asthma, allergies. MANAGEMENT Executive Chairman Thomas Hecht, Dr EVP Product Development Dr Frank Hennecke, EVP Clinical Development Dr Philipp Müller, Chief Financial Officer MBA, Welten, Harry YEAR FOUNDED 1995 EMAIL [email protected] FAX +41 44 733 4702 Direct fax: TELEPHONE +41 44 733 4646 Direct phone: +41 79 750 1564 Mobile: ADDRESS AG Cytos Biotechnology 25 Wagistrasse CH-8952 Schlieren CONTACT MBA Welten, Harry Chief Financial Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u DC Prime www.dcprime.nl PROFILE COMPANY The company’s companyDCPrime is a Dutch biotech which has developed a novel approach to cancer vaccines. unique platform technology consists of sustainable cells (DCOne™) and a proprietary dendritic progenitor and to createmethod to expand these functional mature (DC). dendritic cells are used as standardized, in some indications loaded with cancer antigens for treatment, targeted These cells, The immune system in a specific manner. therapeutic products that can stimulate the patient’s off-the-shelf, platform power of DC-based vaccines with the advantages combines the of allogeneic stimulation of the immune logistics and the simple of off-the-shelf products. system, MANAGEMENT CSO/CEO Ada Kruisbeek, Dr CBO Mr Marcel Zwaal, COO Wetering, Dr Sandra van YEAR FOUNDED 2007 EMAIL [email protected] [email protected] TELEPHONE +31 71 332 2626 Marcel Zwaal +31 6 11757250 M: ADDRESS Galileiweg 8 2333 BD Leiden The Netherlands CONTACT Marcel Zwaal Chief Business Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

(i) topical administration in severe chronic conditions, and (i) topical administration in severe chronic conditions, (ii) systemic administration in acute diseases. antibody-containing ointment for topical administration in plaque psoriasis 1. fistulas (entry indication for IBD) antibody-containing gel for topical administration in Crohn’s 2. Disease (entry indication for acute inflammation) intravenous administration for Behçet’s 3. Proof of mechanism in psoriasis patients (safety and exploratory efficacy) a. Systemic safety in healthy volunteers b. AG Therapeutics Delenex www.delenex.com FINANCIAL SUMMARY closed MayA (CHF 30.2 Mio) 2011. Series PROFILE COMPANY AG is a Swiss biotech company therapeutic developing antibodies for Therapeutics Delenex highly are tissue-penetrant. PENTRA® antibodies, Its proprietarycompound class, GI and dermatology, and within this in three specific areas: The company is focused in immuno-inflammation, acute inflammation. Three PoC clinical projects are currently active clinical trials have already met their endpoints Two MANAGEMENT Chief Executive Officer Eric de La Fortelle, Chief Medical Officer Thomas Jung, Chief Scientific Officer Kretzschmar, Titus Chief Financial Officer Jakob Schlapbach, YEAR FOUNDED 2009 EMAIL [email protected] FAX +41 44 730 51 81 TELEPHONE +41 44 730 51 80 Barbara Stiefel +41 44 730 51 80 ADDRESS 27 Wagistrasse CH-8952 Schlieren Switzerland CONTACT Barbara Stiefel Office Management WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Lothar Wieczorek has been at the forefront European of the development of medical devices and products in the US and Lothar Business where he has held senior positions in R&D, Pharmaceutical and Diagnostics industries throughout his 30-year career, Affairs. Strategic Planning and Medical Development, Chief Executive Officer Ph.D. Therianos, Stavros Stavros is Therianos is one of the principal founders of Diagnoplex and has been with the company since 2005. Stavros Prior to the a consummate entrepreneur who brings his talent and passion to Diagnoplex business activities. science and USA. he was an assistant professor at the University of Rochester Medical Center, founding of Diagnoplex, SA Diagnoplex www.diagnoplex.com FINANCIAL SUMMARY “A” CHF 15 million in series PROFILE COMPANY are a dedicated and multi-disciplinaryWe team united in bringing innovation true to personalized cancer care. we develop blood-based cancer workflow and state-of-the-artUsing our unique molecular biostatistical tools, increasinglyThis is an area of initial focus Our is on systematic screening for colorectal cancer. diagnostic tests. and one that an estimated represents need as a result of an ageingurgent and unmet medical population, market opportunity of $3.5 billion. and non-invasive blood test developed for is a convenient the systematic Colox, Diagnoplex lead product, The gene signature underlying Colox detects early and screening of colorectal cancer (Colorectal cancer). advanced disease stages and reliability. with outstanding results Scientific Focus Preclinical Therapeutics, RNA Cancer, MANAGEMENT Ph.D., Executive Chairman Wieczorek, Lothar YEAR FOUNDED 2005 EMAIL [email protected] FAX +41 21 989 2001 TELEPHONE +41 21 989 2000 ADDRESS 4 Vuillette Chemin de la CH-1000 Lausanne 25 Switzerland CONTACT Therianos (speaker) Stavros Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u S.L. Biotech, Digna www.dignabiotech.com FINANCIAL SUMMARY Capital raised to date in excess of 30 M€. Currently raising an additional 20 M€ interested in PROFILE COMPANY with offices in Madrid DIGNA Biotech is a private biotechnology companyin Pamplona (Spain), headquartered The firm currently has It was founded in 2004 as a spin-off University of Navarra. of the and Pennsylvania (USA). Inflammatory/Autoimmune, a pipeline of 9 products at different stages of development in 3 therapeutic areas: Cardiovascular and Liver diseases. Digna Biotech is seeking private out a new biotech company funding to spin to conduct Phase IIb and Phase III a cytokine inhibitor for the treatment of patients with Systemic Sclerosis trials of its more advanced candidate, Phase IIa and open-label I, has already completed Phase The product (Disitertide) and Localized Scleroderma. Orphan drug extension (OLE) clinical trials under a topical formulation in patients with systemic sclerosis. designation bygranted both FDA and EMA has been in the two indications. MANAGEMENT – ([email protected]) CEO. PhD, MD, Pablo Ortiz, YEAR FOUNDED 2004 EMAIL [email protected] [email protected] [email protected] FAX +34 94 818 0500 TELEPHONE +34 94 828 7600 ADDRESS 22 Office 2 Pio XII, Avda CP 31008 Pamplona. Navarra Spain CONTACTS Ana Martinez Assistant Juan Ruiz Chief Operating and Officer Chief Medical Officer Terron Fernando Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GmbH eADMET www.eadmet.com FINANCIAL SUMMARY The company was founded rights to all as exclusive (as well in 2010 and received GO-Bio phase II funding eADMET received In 2011, developments funded by GO-Bio phase I) that supports the company until Q1 / 2013. Gründerfonds and Bayern Kapital that and brought the total funding of dilutive additional funding from High-Tech non-dilutive capital€ 1.45 million. to PROFILE COMPANY eADMET GmbH is a technology-driven company with a strong focus on the informatics solutions and consultancy QSAR & QSPR modeling, properties prediction, ADMETox in particular services in the life science area, strong partnerships and employs Germany, eADMET is located in Munich, interpretation and data integration. eADMET is a leader in providing chemical software platforms with chemoinformatic service providers worldwide. and web applications for the biotechnology and pharmaceutical industries and creates leading edge cross- platform solutions to power modern collaborative chemoinformatics. MANAGEMENT CEO Abdelaziz, Ahmed CEO Teetz, Wolfram CSO Tetko, Igor YEAR FOUNDED 2010 EMAIL [email protected] FAX +49 89 3187 4584 Fax: TELEPHONE +49 89 3187 2954 Office: +49 157 7688 7277 Mob: ADDRESS Ingolstädter Landstraße 1, Building 60W D-85764 Munich-Neuherberg, Germany CONTACT Abdelaziz Ahmed Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Pharma Ennar FINANCIAL SUMMARY a Basel based venture capital company and by The company is financially supported by an investment by EVA- the private founder. funds of the PROFILE COMPANY Ennar Pharma was founded in July topical treatment 2010 to develop a better and safer for mild-to-moderate The company is have been granted in Europe and the USA. protecting the technology, Patents, psoriasis. capital a Basel based venture company- and uses a network financially supported by an investment by EVA- of strategic of EGF and develop a suitable partners to develop the production cream-based pharmaceutical Producers for the cGMP production of high-quality EGF(epidermal growth factor) and for a stable product. cream formulation of the active ingredient have been contracted and a Proof-of-Concept trial is running at the which is carried out with mild-to-moderate psoriasis The trial, Dermatology Clinic of the University of Zurich. aims to establish the validity of the mode-of-action proposed for the EGF-based topical formulationand patients, Q1 2013. Results of the trial are expected in test an optimised formulation for and safety. clinical efficacy MANAGEMENT Chief Executive Officer Dr Rudi D Neirinckx, Board Member Dr Peter Burckhardt, YEAR FOUNDED 2010 EMAIL [email protected] FAX 061 283 8486 TELEPHONE 061 283 8485 ADDRESS Hochbergerstrasse 60c CH-4057 Basel Switzerland CONTACTS Dr Rudi D Neirinckx Chief Executive Officer Dr Peter Burckhardt, Board Member WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Enterome www.enterome.com FINANCIAL SUMMARY A round €7m Seventure Lundbeckfond Omnes Shire PROFILE COMPANY diseases. Enabling Diagnostic Solutions for gut microbiota-related dedicated of to the development Paris-based Enterome is a privately owned stratified medicine company, innovative diagnostic progress products based on recent in metagenomics of the human intestinal microbiota. encoding 150-fold more genes than the gut microbiota, Our intestine harbors an incredible number of bacteria, with a large diversity between Each individual has his own personal and unique microbiota, our own genome. and recent studies in health and diseases is undisputed, The contribution of the gut microbiota individuals. demonstrated major alterations composition in patients of the gut microbiota with metabolic and inflammatory bowel diseases translate them into diagnostic tools objective is to identify biomarkers in metagenomic signatures, Enterome’s clinical outcomes. and validate them vs. in 2014 the most advanced to be marketed Current portfolio comprises four diagnostic products, MANAGEMENT CEO Pierre Belichard, COO Marie-Laure Bouttier, CTO James Clark, CBO Rodolphe Clerval, CMO Pierre Rimbaud, YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +33 17 577 2786 Pierre Belichard Chief Executive Officer +33 68 153 9633 ADDRESS Enterome Ledru-Rollin Avenue 94-96 75011 Paris - France CONTACT Pierre Belichard Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u ApS EpiTherapeutics www.epitherapeutics.dk FINANCIAL SUMMARY Venture Astellas • Ventures 5 investors • Novo Seeds • Seed CapitalRaised $ 12.2 mill from • Lundbeckfond Venture. • Merck Serono PROFILE COMPANY EpiTherapeutics novel innovative is developing the world leading research in epigenetics cancer drugs based on conducted by Kristian Helin and his group Professor at & Innovation Biotech Research Centre (BRIC) at University of Copenhagen. EpiTherapeutics’ development programs focused are on involved in the regulation of transcription in developments may Subsequent cancer – current programs and methyltransferases. target histone demethylases identify other potential clinical indications oncology. outside Abbott Laboratories. EpiTherapeutics signed a drug discovery collaboration with In December 2010, EpiTherapeutics in Copenhagen. employs 25 FTE and is headquartered MANAGEMENT Chief Executive Officer BComm, PhD, Martin Bonde, YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +45 2025 3560 ADDRESS Ole Maaloesvej 3 2200 Koebenhavn N Denmark CONTACT BComm PhD, Martin Bonde, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Biotech Galecto www.galecto.com PROFILE COMPANY focusednovel drugs for on developing the treatment of fibrosis, Galecto Biotech is a newly founded company, a group of proteins target galectins, products The company’s inflammation serious human diseases. and other galectin inhibitors may high potency open new Galecto Biotech’s that play in many important roles disorders. The company led by is top-level scientists and biotech executives. treatmentfor possibilities many patients. in close proximity to the founders’ research groups. Valley Galecto Biotech is located in Medicon MANAGEMENT CEO MD PhD, Hans Schambye, CSO FRCP, Ph.D., M.A., B.Sc., Sethi, Tariq Prof Med Chem Head, PhD, Prof Ulf Nilsson, Immunology & Biology Head, MD PhD, Prof Hakon Leffler, YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +45 26 37 37 26 ADDRESS 3 Vej Ole Maaloes DK-2200 Copenhagen Denmark CONTACT PhD MD Hans Schambye, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Genticel www.genticel.com FINANCIAL SUMMARY and A- VC-backed Seed-, in private, of which EUR 8 Mio in subsidies and revenues), Raised EUR 27.5 Mio, B-rounds. Key investors: Investment Partners • Edmond de Rothschild • IdInvest (Kurma Biofund) • CDC Entreprises (Innobio) AMUNDI Private Equity • PROFILE COMPANY Genticel is a biotechnology company focused on developing multivalent vaccines against Human Papillomavirus which are the known cause for several cancers including cervix carcinoma. (HPV) infections, has Adenylate protein vector (CyaA), Cyclase the recombinant proprietary vector technology platform, Genticel’s the potential to be used for applications a broad range of vaccine as it allows the insertion of large antigens by This vector is the only system that naturally targets specific antigens directly to recombinant DNA technology. response. leading to a potent and long lasting cellular immune and into the cytosol of antigen-presenting cells, lead investigational product has been successfully tested in combination with an Genticel’s ProCervix, first in class HPV16/18 vaccine for the It is a proprietary, established adjuvant in a clinical phase I study. women who i.e. treatment cytology of already infected women with normal or low-grade precancerous lesions, ProCervix is designed to eliminate HPV16 and/ have not yet developed high-grade cervical lesions or cancer. The Phase Ib trial (n=47) displayed no dose or 18 infected cells and to provide protection against re-infection. two intradermal injections 6 weeks apartThe have generally been well limiting toxicity and no patient drop-out. Adverse Effects were reported. No treatment-related Serious tolerated with transient vaccine-related reactions. ProCervix a substantial proportion of induced a dose-dependent immune response as well as viral clearance in IND filing for phase II is scheduled for H1/2013. patients as compared to placebo. candidate multivalent HPV vaccine a preclinical stage, is complementing Genticel´s HPV pipeline, Heptarvix, on an adapted It is based which is designed to provide protection against up to seven oncogenic HPV types. proprietary CyaA vector (Vaxiclase). Genticel intends raising additional capital to conduct a PoC Phase 2 trial with ProCervix and advance Heptarvix up to end of preclinical development. MANAGEMENT The management team has jointly 60 years of experience in Pharma & Life Science Industry: Founder and CEO PhD, MBA, Timmerman, Dr Benedikt CSO PharmD, PhD, Dr Marie-Christine Bissery, CFO Ing., MBA, Mr Martin Koch, YEAR FOUNDED 2001 EMAIL [email protected] FAX +33 (0)5 61 28 70 69 TELEPHONE +33 (0)5 61 28 70 60 ADDRESS GENTICEL Curie 516 Rue Pierre et Marie 31670 Labege FRANCE CONTACT Timmerman Benedikt Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Total = 455 Total Switzerland = 277 Ireland = 141 USA = 37 Helsinn www.helsinn.com FINANCIAL SUMMARY 243.9M CHF 300.2M – EUR Turnover: Net Total 2011 Helsinn Group’s CHF 436.1M – EUR 359.2M Assets: Total 2011 Helsinn Group’s CHF 298.5M in last 5 years: R&D Investments Helsinn Group’s Staff: Helsinn Group’s PROFILE COMPANY and operating Switzerland, Helsinn is a privatelygroup owned pharmaceutical with headquarters in Lugano, business model is focused on the licensing of Helsinn’s subsidiaries in Ireland and the United States. Helsinn Group medical devices and nutritional supplement products in therapeutic niche areas. pharmaceuticals, the performance completes their development through in-licenses early-to-late stage entities, new chemical and files and and Control (CMC) development, Manufacturing, of pre-clinical /clinical studies and Chemistry, marketing products are out-licensed to its network of local Helsinn’s attains their market approvals worldwide. selected for Helsinn assists their deep in-market knowledge and know-how whom and commercial partners, including commercial, and supports by and scientific management providing a full range of product services, ingredients The active pharmaceutical and the finished and medical marketing advice. legal, regulatory financial, and environmental standards at Helsinn’s safety, quality, products are manufactured according to the highest worldwide to its customers. GMP facilities in Switzerland and Ireland and supplied Further information on Helsinn Group is available at www.helsinn.com. MANAGEMENT Founder & Chairman Dr Gabriele Braglia, Board Member & US Chairman Helsinn Group CEO, Dr Riccardo Braglia, Board Member & US Board Member Group Chief Financial Officer, Dr Luigi Caletti, Group General Manager & Chief Operating & US Board Member Officer Dr Giorgio Calderari, Head of Corporate Business Development Senior Director, Dr Roberto De Ponti, Chief Commercial Officer Andrea Meoli, Dr Chief Scientific Officer Dr Sergio Cantoreggi, Affairs Corporate Legal General Counsel, Senior Director, Dr Matteo Missaglia, Technical Head of Corporate Senior Director, Dr Daniele Bonadeo, Advanced Synthesis Helsinn Chemical Business, Local General Manager, Dr Paolo Guainazzi, Inc. Therapeutics (U.S.), Helsinn Local President & CEO & Board Member US Pharma Business, William Mann, Dr Ireland Helsinn Birex Pharmaceuticals, Pharma Business, Dr Padraig Somers, Local General Manager, YEAR FOUNDED 1976 EMAIL [email protected] [email protected] FAX +41 91 993 21 22 TELEPHONE +41 91 985 21 21 Roberto De Ponti +41 91 985 21 21 Direct line: ADDRESS Helsinn Healthcare SA Via Pian Scairolo, 6912 Lugano-Pazzallo Switzerland CONTACT Roberto De Ponti Head of Corporate Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd Therapeutics Heptares www.heptares.com FINANCIAL SUMMARY Venture Fund and Novartis MVM Life Science Partners, Ventures, date$40M venture finance to from Clarus Ventures. Takeda PROFILE COMPANY a superfamily of Heptares createsmedicines targeting previously new undruggable or challenging GPCRs, design approach are pioneering a structure-based drug to GPCRs, We receptors linked to many diseases. and fragment-based leveraging structure determination, proprietary technologies for protein stabilisation, Our objective is to build a broad Takeda. MedImmune and AstraZeneca, Our partners include Shire, discovery. disease, Alzheimer’s including pipeline of novel medicines to transform the treatment of serious diseases, migraine diabetes. and addiction, chronic insomnia, depression, schizophrenia, disease, Parkinson’s disease Alzheimer’s Our in-house pipeline is led by M1 programme our selective muscarinic for cognition in Our adenosine which is in preclinical development and slated for Phase 1 studies in 2013. and Schizophrenia, Further discovery is also in development for neurological disorders. licensed to Shire, A2a antagonist candidate, driven by our proprietary first-ever Family B crystalT2DM, programmes include oral GLP-1 agonists for and CGRP antagonists for prophylaxis and treatment of migraine. structure, opening up new The Heptares technology platform a unique GPCR capability represents in the industry today, Heptares possibilities for therapeutics both small molecule and antibody across the GPCR target universe. which are typically highly unstable when removed from is the first and only company transforming GPCRs, StaRs® enable GPCR structures in their natural into stabilised receptors or StaRs®. cellular membranes, thereby barrier to structure- overcoming a major historical pharmacological conformations to be determined, provides superior which invented Biophysical Mapping™, Heptares has also based GPCR drug discovery. and has engineered new fragment-based silico technologies and in elucidation of GPCR-ligand interactions, coupled with These technology breakthroughs, specifically tailored to GPCR lead discovery and optimisation. form the nucleus of a powerful and fully-integrated drug deep expertise in GPCR chemistry and biology, discovery platform. please visit www.heptares.com learn more about and technology the Heptares pipeline platform, To MANAGEMENT Co-Founder and CEO Weir, Dr Malcolm Co-Founder and CSO Dr Fiona Marshall, CBO Dr Barry Kenny, President Dan Grau, Head of Chemistry Dr Miles Congreve, CMO and Head of Development Dr David McGibney, YEAR FOUNDED 2007 EMAIL [email protected] FAX +44 (0)1707 35840 TELEPHONE +44 (0)1707 358 629 (dl) +44 (0)7968947268 (m) ADDRESS Therapeutics Ltd Heptares BioPark Broadwater Road Garden City Welwyn AL7 3AX Hertfordshire CONTACT Weir Malcolm Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Advisory Board Ltd Pharma Hermo www.hermopharma.com FINANCIAL SUMMARY Not publicly available. PROFILE COMPANY Hermo Pharma Ltd is a clinical stage biopharmaceutical cutting- company discovering and developing edge therapeutic and approaches products for currently untreatable medical needs in the field of neurology. The company outsources the majority of operational R&D Finland. headquarter is located in Helsinki, Company’s while controlling the key technology and strategic assets partnerships. tasks to external vendors, These concepts are being R&D programs are based on scientifically innovative concepts. The company’s developed by the company trials and after that and clinical Phase II proof-of-principal through preclinical Hermo Currently Hermo worldwide. trials and market its products Pharma will seek partnerships to support Phase III product development focus treatments is on novel disease-modifying for amblyopia in adults and Pharma’s disease. Parkinson’s The project is currently seems very in Phase IIa clinical trials and the results promising. Adults. Amblyopia in Company latest is expecting to out-license this product in early 2014. Company is currently with the support finalizing the pre-clinical proof-of-concepts studies Parkinson´s Disease. The therapy is based on the neuroprotective and restorative effects provided by of M.J.Fox Foundation financing. The clinical strategy includes of testing of intracrainial delivery platform to treat the patients. the CDNF protein. Toxicology The current data looks very promising and the company the IND enabling is expecting to proceed into phase during year 2013. MANAGEMENT CEO Juhani Lahdenperä, CSO Henri Huttunen, Head of Clinical Development Sigrid Booms, of Directors Board Jonathan Knowles, Veromaa, Timo Ari-Pekka Laitsaari, Henri Huttunen Jyrki Mattila Scientific Eero Castrén Mart Saarma Mary Baker Seppo Kaakkola Lamberto Maffei Heikki Rauvala Pekka Männistö.

YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +35 85 0366 9502 ADDRESS Hermo Pharma Ltd. Viikinkaari 4 00790 Helsinki Finland CONTACT Juhani Lahdenperä Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GmbH biotechnologies immatics www.immatics.com FINANCIAL SUMMARY A 2004/2005: € 14 mn Series € 40 mn Series B 2007: € 54 mn Series C 2010: € 4 mn non equity funding total: PROFILE COMPANY immatics is a biopharmaceutical company dedicated to the development of innovative cancer immunotherapeutics. immatics pep¬tides (TUMAPs) enables ’ proprietary the technology for the identification of tumor-associated immatics is currently developing development of novel anti-cancer vaccines formultiple cancer indications. IMA901 for the treatment II) for in Phase III and IMA910 (in Phase of renal cell carcinoma the treatment of colorectal carcinoma (CRC). for the treatment of malignant glioma (brain cancer) immatics has entered into two IMA950, For third product, The furthest advanced of Further product candidates are currently in pre-clinical development. clinical studies. which are for gastric and lung cancer. Tuebingen immatics was founded in 2000 as a spin-off Institute of Immu¬nology from the at the University of both in Germany. and in Munich, Tuebingen Hans-Georg Rammensee) and is based in (Prof. MANAGEMENT CEO Paul Higham, CBO Rainer Kramer, CSO Harpreet Singh, CMO Carsten Reinhardt, YEAR FOUNDED 2000 EMAIL [email protected] [email protected] FAX +49 7071 5397-900 TELEPHONE +49 7071 5397-0 ADDRESS immatics biotechnologies GmbH Paul-Ehrlich-Straße 15 Tuebingen 72076 Germany CONTACTS Mr Paul Higham Chief Executive Officer Mr Rainer Kramer Director & Head of Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Design Immune www.immunedesign.com FINANCIAL SUMMARY has raised $52M from venture capitalSince 2008 Immune Design funding. PROFILE COMPANY and formed in 2008 Washington Immune Design is a privately held biotechnology company in Seattle, based to develop and their technologies, leaders in the field of immunology, the world’s to bring together some of scientific founders The company’s therapeutic vaccines for the treatmentdisease. of infectious and malignant Whitehead Institute and the and the University, Rockefeller David (Past President of Caltech, Baltimore are Dr. Steven Reed (Past Co-founder and CSO Dr. Co-Recipient of the 1975 Nobel Prize in Physiology or Medicine), Larry Corey (President and and Dr. Research Institute), of Corixa and Founder/CEO of the Infectious Diseases and Laboratory Center and Professor of Medicine Director of the Fred Hutchinson Cancer Research at Medicine The Column date Design has raised approximately Immune $52 million from To Washington). the University of and Proquest. Ventures, Versant Alta Partners, Group, Immune Design leverages its unique vaccine technologies to precisely control the activation and context of The first antigen presentation by to shape dendritic cells in order the desired adaptive immune response. technology is a novel adjuvant for comprising Glucopyranosyl protein antigen (rP)-based vaccines recombinant Adjuvants can play formulated in a stable 2% oil-in-water emulsion (SE). TLR4 agonist, a synthetic A (GLA), Lipid GLA response to the target antigen. an important role in vaccine therapies by stimulating the immune system’s To date GLA-SE Steve Reed. ‘designer adjuvant’ and was developed by Immune Design co-founder Dr. is the first has been safely subjects. administered in over 300 human The Vector). (Immune Design-Lentiviral ID-LV Our second vaccine platform vector, is a novel lentivirus-based is unique in that it ID-LV David Baltimore. Dr. was developed by Design co-founder, Immune prototype of ID-LV and to produce any, of the immune system, “sentinels” the own dendritic cells (DCs), can stimulate the body’s effectively orchestrating the human multiple antigens of interest in the same product configuration, importantly, and GLA-SE vaccine technologies ID-LV Immune Design’s immune system to respond to targeted diseases. have the potential to be used both and thus, as documented in animal models, are immunologically synergistic, alone and in combination to creategeneration the next of vaccines for diseases with unmet medical need. MANAGEMENT Chief Executive Officer PhD, MD, Carlos Paya, Chief Development Officer PhD, Gombotz, Wayne Administration Finance and VP, J Paul Rickey, YEAR FOUNDED 2008 EMAIL [email protected] FAX 206-682-0648 TELEPHONE 206-826-7910 ADDRESS 700 1124 Columbia Street suite 98104 WA Seattle, CONTACT Carlos Paya Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Substantial business development experience (deals closed with Amgen, AstraZeneca, Boehringer Ingelheim, Centocor, GE Centocor, Boehringer Ingelheim, AstraZeneca, Amgen, with Substantial business development experience (deals closed Wyeth etc.). UCB-Celltech and Pfizer, Merck Serono, Johnson & Johnson, Healthcare, • Serial life sciences entrepreneur with over twenty years’ experience within the biotechnology• Serial life sciences entrepreneur with over twenty years’ industry; commercial and strategic expertise; • Scientific, Technology; Antibody founder and among the founding & CEO of Isogenica group scientists at of Cambridge • CEO of F-star, • Capital-raising expertise (more than €30m raised to date); •  Systems Targeting Immune www.its-innovation.com FINANCIAL SUMMARY SME Capital, Truffle HealthCap, Fund, Venture The Company by is supported leading investors including Novartis The Company is currently seeking and has raised £14.5m to-date. Ventures Wholesale Finance and Esperante investors to participate in a series-B financing. PROFILE COMPANY Systems is an emerging of vaccine products that leader in the development work by Targeting Immune lead product company’s The vaccines”). responses against viruses and cancers (“T-cell T-cell promoting immune vaccine which elicits potent cellular T-cell is a novel currently in clinical development, Flunisyn™, technology also supports a product portfolio The Company’s responses against multiple strains of influenza. vaccines against cancers. T-cell an attractive therapeutic hepatitis B vaccine and which includes Hepsyn-B, MANAGEMENT Chief Operating Officer PhD MBA, Kevin FitzGerald, YEAR FOUNDED 2004 EMAIL Kevin.FitzGerald @its-innovation.com Ghaz.mahdizadeh @its-innovation.com TELEPHONE +44 020 7691 4908 ADDRESS London BioScience Innovation Centre 2 Royal College Street London NW1 0NH CONTACTS Kevin FitzGerald Chief Operating Officer Ghaz Mahdizadeh EA WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Inc. Immunovaccine www.imvaccine.com FINANCIAL SUMMARY 63.5M Shares outstanding: $17.8M Recent Market Cap: $0.28 Recent share price: $0.28 – $0.60 Range: Week 52 35,500 Volume: Daily Average $6.2M (31/12/11): Cash & Other Cash Resources PROFILE COMPANY Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to platform DepoVax™ The Company’s the development of vaccines for cancer therapy and infectious diseases. is a patented lipid delivery system that system for presents antigens plus adjuvant to the immune a prolonged Immunovaccine has advanced its platform responses. period and has the potential to enhance immune technology and proprietary cancer vaccine into Phase I clinical trials and has demonstrated both safety and Immunovaccine is also capitalizing on the broad potential of its delivery platform immunogenicity potential. In addition to the vaccines through multiple development collaborations. by creating new DepoVax-based it continues to capture value from animal health vaccine applications. human health vaccine strategy, Company’s Immunovaccine has several key an agreement the animal health sector including partnerships in with Pfizer delivery technology platform to develop vaccines for livestock. which has licensed the Company’s Animal Health, MANAGEMENT CEO Trizzino, John J. Business Development VP, Vicki Morgan, CFO Kimberly Stephens, CSO Ph.D., Marc Mansour, of Directors Board Pulitzer Prize Recipient Communications Strategist, Albert Scardino, Chairman, 2010 Inductee Canadian Medical Hall of Fame MD, William Cochrane, CEO of Brigus Gold Dawe, Wade of Investments GrowthWorks Sr.VP CA, James Hall, Partners Torreya Advisor to Senior Stephanie Léouzon, Former President and CEO of Sanofi Pasteur Pisano, Wayne CEO of Oncolytics Thompson, Brad YEAR FOUNDED 2000 EMAIL [email protected] [email protected] FAX 902-492-0888 TELEPHONE 902-492-1819 ADDRESS Suite 412 1344 Summer Street, Nova Scotia Halifax, B3H 0A8 CANADA CONTACTS Trizzino John J. Chief Executive Officer Vicki Morgan Business Development VP, WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u B.V. Technologies InteRNA www.interna-technologies.com FINANCIAL SUMMARY OncologyAglaia Fund • PPM Oost • Investors: PROFILE COMPANY is a Dutch drug discovery development company and engaged of novel in the development Technologies InteRNA breakthrough cancer therapies based on the unique functions of its proprietary miRNAs. drug development programs aim at developing miRNA-based therapeutics that control genes InteRNA’s pathwaysconnected in signal transduction and biological that processes are known to play a role in cancer progression and metastasis. initiation, in a number of cancer indicationsInteRNA identified the function of multiple miRNAs through functional screens, which is the largest currently available. using its proprietary lentiviral-based miRNA expression library, additional and proprietarysequencing) databasedeep expression (generatedthrough miRNA Company’s the With in vivo models) in place to identify the downstream regulated proteins bioinformatics, technologies (like RNAseq, the Company is well equipped to move its novel drug candidates with their for each miRNA drug candidate, biomarkers quickly towards the clinic. MANAGEMENT Chief Executive Officer MBA, PhD, Schaapveld, Roel Q.J. YEAR FOUNDED December 2006 EMAIL schaapveld @interna-technologies.com FAX +31 30 253 9176 TELEPHONE +31 30 253 2386 ADDRESS Kruyt building Hugo R. Padualaan 8 3584 CH Utrecht The Netherlands CONTACT MBA PhD, J Schaapveld, Roel Q. Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Group Ipsen www.ipsen.ltd.uk COMPANY PROFILE COMPANY pharmaceutical companyIpsen is a global specialty-driven with total sales exceeding €1.1 billion in 2011. Its leader in specialty healthcare solutions for ambition is to become a targeted debilitating diseases. Ipsen’s endocrinology / Somatuline®, neurology / Dysport®, development strategy is supported by four franchises: R&D is Group has an active policy of partnerships. the Moreover, uro-oncology / Decapeptyl® and hemophilia. R&D In 2011, peptides and toxins. focused on innovative and differentiated technological patientdriven platforms, staffThe Group has total worldwide of above of Group sales. 21% than €250 million, expenditure totaled more close to 4,500 employees. FR0010259150) and ISIN code: IPN, A of Euronext Paris (stock code: shares are traded on segment Ipsen’s Ipsen has of the SBF 120 index. The Group is part (“SRD”). “Service Différé” de Règlement eligible to the which trade on the over-the- American Depositary Receipt (ADR) program, implemented a Sponsored Level I counter market in the United Statessymbol IPSEY. under the visit www.ipsen.com. For more information on Ipsen, YEAR FOUNDED 1929 EMAIL [email protected] [email protected] TELEPHONE Dr Sonia Benhamida +33 1 583 35000 Dr Scott Cuthill +44 1 753 627700 ADDRESS Dr Sonia Benhamida Ipsen 65 Quai George Gorse 92100 Boulogne Billancourt Paris France Dr Scott Cuthill Ipsen Biopharm Limited 190 Bath Road Slough Berkshire SL1 3XE CONTACTS Dr Sonia Benhamida Dr Scott Cuthill WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u BV ISA Pharmaceuticals www.isa-pharma.com FINANCIAL SUMMARY Fundraising series B. PROFILE COMPANY clinical stageISA Pharmaceuticals is a company developing novel therapeutic products for cancer and exploits its proprietary ISA SLP® technology to achieve therapeutic effects of in a number infectious diseases. a therapeutic vaccine is ISA-HPV-SLP®, advanced clinical product under development The most indications. Virus type 16 (HPV16) associated and malignant for the treatmentpatients of suffering from Human Papilloma premalignant disorders. responses when mixed or which yields superior immune ISA has further developed a unique adjuvant system conjugated to its target antigens. MANAGEMENT Managing director Gerard Platenburg, Managing director Mark Krul, CSO Cornelis Melief, CMO Edwin Klumper, YEAR FOUNDED 2004 EMAIL [email protected] FAX +31 71 33 22 311 TELEPHONE +31 71 33 22 310 ADDRESS ISA Pharmaceuticals BV Niels Bohrweg 11-13 2333 CA Leiden The Netherlands CONTACT Vogelezang Maaike Assistant Management WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

AG MorphoSys www.morphosys.com FINANCIAL SUMMARY Report for month of 2012: the first six m Eur 33.0 Group Revenues: EBIT (1.9) m Eur Eur Net (Loss)/Profit (1.0) m diluted in Eur (0.04) EPS, PROFILE COMPANY leading fully human antibody technologies. MorphoSys has developed and established of the world’s one such as from the pharmaceutical and biotechnologyNumerous partnerships with well-known companies sector, Pfizer and Roche illustrate our success. Novartis, Merck, Daiichi Sankyo, Boehringer Ingelheim, more than 400 employees at four industry-leading antibody technologies, With the help of our proprietary, The international locations worldwide are dedicated to engineering the medicines and diagnostics of tomorrow. teams collaborate closely coordinate to streamline and product research and development with all its accompanying processes. MANAGEMENT The Management Board and Supervisory Board of MorphoSys are committed to creating significant value for all through a sustainable customers and partners business strategy balancing short-term shareholders, employees, and long-term growth potential. The Board CEO Dr Simon Moroney, CDO Arndt Schottelius, Dr CFO Jens Holstein, CSO Dr Marlies Sproll, YEAR FOUNDED 1992 EMAIL [email protected] FAX 089 89927 5152 TELEPHONE 089 89927 152 ADDRESS 48 Lena-Christ-Str. 82152 Martinsried/Planegg Germany CONTACT Dr Heinz Schwer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u B.V. Mucosis www.mucosis.com FINANCIAL SUMMARY €3,000,000 (2007) A: Series €3,000,000 (2010) Inn.Credit: NOM • MedSciences Capital • N.V. Ventures • Biogeneration Current Investors: PROFILE COMPANY About Mucosis on which it Mimopath™, is a Dutch biotechnology company with a proprietary platform technology, Mucosis B.V. a vaccine to prevent lead products are FluGEM™, Mucosis’s develops mucosal vaccines with improved efficacy. a a vaccine to prevent diseases caused SynGEM™, by pneumococcal bacteria; and influenza; PneuGEM™, Mimopath™-based in the vaccines can be administered needle-free vaccine to prevent RSV viral infections. evoking a more natural immune response with a broader base of protection. nose and mouth, About Mimopath™ technology a safe bacterium commonly used in the food The Mimopath™ technology lactis, is based on Lactococcus lactis bacteria into non-living bacterium- to formulate Mucosis has developed a robust technique the L. industry. The antigen- parasitic or tumor origin. bacterial, like particles (BLPs) that from viral, can be loaded with antigens These for without the need a needle. covered BLPs form a vaccine that into the nose or mouth, can be delivered vaccines raise protective immunity by activation of both the innate and the adaptive immune system. MANAGEMENT Senior Management CEO Thomas Johnston, CSO Kees Leenhouts, CMO Roberto Grimaldi, QA-officer & Qualified Person Jolande Schoemaker, of Directors Board Chairman John Lambert, Barry Buckland Wouterse Annemieke Willem Hazenberg Otto Postma

YEAR FOUNDED 2006 EMAIL [email protected] FAX +31 (50) 8200051 ADDRESS Mucosis B.V. TELEPHONE +31 (50) 8200050 (T) +31 (6) 55320948 (M) CONTACT Johnston Tom Chief Executive Officer Zielstraweg 1 L.J. Groningen 9713 GX, The Netherlands WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 556 64% 68% 2417 3,775 1,861 Audited 18 65% 40% 1464 2,249 1,446 Audited 63% 96% -360 1008 1,610 1,368 Audited 820 507 748 62% 74% -241 Audited 472 282 510 60% 91% -228 Audited 91 2% 247 473 37% -382 As filed

81 243 291 33% -210 2005 2006 2007 2008 2009 2010 2011 As filed NanoSight www.nanosight.com FINANCIAL SUMMARY £k Total Sales Total Gross Profit Gross Margin Total Overheads Total PBT Sales Growth Rate COMPANY PROFILE COMPANY Our scientific focus unique role in potential early is developing rapidly. detection of cancer NanoSight’s is a unique methodology for detection NTA Analysis. Tracking continues to be the refinement of Nanoparticle Applied to cell-derived biological nanoparticles (exosomes and characterisation of nanoparticles in liquids. Liver and Gastric Oral, and microvesicles) it has emerging a diagnostic potential as platform for a Prostate, Our practical work Autoimmune and Renal diseases. disease, Parkinson’s Pre-eclampsia, Diabetes, cancers, is collaboration with research groups our instruments to develop rigorous protocols for using counting and Testing Materials standard American Society for Recent publication of speciation disease-specific exosomes. methodology. ASTM E2834 demonstrates our progressrefining NTA in Management CTO & Founder Dr Robert Carr, CEO Warren, Jeremy Chairman & Founder John Knowles, YEAR FOUNDED 2002 EMAIL [email protected] FAX +44 1 980 624 703 TELEPHONE +44 1 980 676 060 ADDRESS Minton Park London Road Amesbury Wiltshire SP4 7RT CONTACT Warren Jeremy Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u llc Biotechnologies Northern www.nothernbiotechnologies.com FINANCIAL SUMMARY Northern is seeking commercialization private funding. “a” Northern Biotechnologies has raised $1.5M in round anti-fungal antiviral and to continue the development of additional anti-bacterial, and investment partnerships of concept and commercialization proof partners. applications of our technology which require additional testing, PROFILE COMPANY therapeutic anti long lasting, Northern Biotechnologies is pioneering the commercialization of an innovative, Infectious disease control microbial technology that has significant applications Health Care arena. in the Human Issued Patents and proprietary and prevention can be revolutionized by integration of our cost saving technology. production IP offer a stable platform for growth and partnership into all human related applications of the A unique feature of the technology is its extended protection of 1-3 days through each application. technology. in contrast the physical method of pathogen destruction prevents formation types, of resistant strain Additionally, shows high performance anti-bacterial, Testing to existing technologies that rely on metabolic action for kill. and related nasal/ oral dosing and wound care, topical, anti-fungal and antiviral functioning in various direct, Application for antiseptic hand wash, are in process with the first New Drug We mechanisms of the technology. and are looking for drug approvals partners to pursue additional in specific markets. In addition to human Prefense hand sanitizer and wipes. Existing product branding in the Human market is Northern holds over twenty-five global patents for anti-microbial water filtration using our applications, opportunity exists Significant registrations for antimicrobial filter media. persistent also hold EPA We technology. existing product lines Other in the technology for used as a multi surface sanitizer all levels of food production. and cash flow are in place from additional internally developed technologies including high performance filtration and industrial processing. agricultural, biotech remediation and process technologies used in petroleum, medias, cleaning “green probiotic” Northern also holds nationally and professional brand lines of placed consumer our cGMP contract packaging division sells Additionally, products based on our IP and manufacturing base. Companyour proprietary management is made formulations to many national brands in a variety of markets. to steer strong growthof a diverse team with the experience and drive required and relationships with partner companies. MANAGEMENT President Aaron Powers, Vice President Dave Reusswig, Financial Consultants Associates, Katan & YEAR FOUNDED 2007 EMAIL [email protected] FAX 480-287-8984 TELEPHONE 630-400-2135 ADDRESS Ste 8-14 Ave, 3820 Ohio IL 60174 St Charles, CONTACTS Aaron Powers President Dave Reusswig Vice President WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u In 2011, received Orphan Drug designation in Europe and the USA for, and in 2012 EUR 6 million FP7 received Orphan Drug designation in Europe and the USA for, In 2011, grant from the European Commission for of NI-0501 for development HLH Pursuing additional partnerships for its next-generation antibody platform as well as development and commercialization of selected drug candidates • In 2009, received the European Biotechnica Award received the European Biotechnica • In 2009, anti-IL-17 drug candidate established Genentech/Roche partnership for NI-1401, • In 2010, •  •  • Potential to independently to the market for bring selected drugs focused applications SA NovImmune www.novimmune.com FINANCIAL SUMMARY corporate and Have from private raised 182M CHF individuals, investors including high-net worth private venture groups PROFILE COMPANY enterprise with a proprietaryNovImmune is a life science next-generation discovery antibody drug platform The Company is applying its capabilities to drug candidatesand expertise in advancing bench to bedside. from realize a vision of generating drugs thatto patients provide more robust benefit by attacking the cause rather NovImmune has established pre- a balanced pipeline of first- and best-in-class than symptoms of disease. clinical and clinical drug candidates of both clinically with a mix validated and novel targets. MANAGEMENT Chairman M.D., Eduard Holdener, Chief Executive Officer Sc.D., Jack Barbut, Chief Medical Officer M.D., Cristina de Min, Chief Scientific Officer Ph.D., Marie Kosco-Vilbois, Head of Corporate & Business Development David Slack, Affairs Director of Legal Nathalie Muller, YEAR FOUNDED 1999 EMAIL [email protected] [email protected] FAX +41 22 839 71 42 TELEPHONE +41 22 839 71 41 ADDRESS Aulx 14 Chemin des 1228 Plan-les-Ouate Geneva Switzerland CONTACTS Jack Barbut Chief Executive Officer David Slack Head of Corporate & Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AS Pharma NOXXON www.noxxon.com FINANCIAL SUMMARY closed two financing rounds and raised Since 2007 NOXXON has approximately €72m Euros from venture Edmond de DEWB, TVM Capital, major investors include Sofinnova Partners, NOXXON’s capital investors. Dow and GoodVent. IBB Beteiligungsgesellschaft, Seventure, NGN Capital, Rothschild Investment Partners, PROFILE COMPANY companyNOXXON Pharma is a biopharmaceutical of a new class of proprietary pioneering the development alternative non-immunogenic to antibodies. the chemically synthesized, therapeutics called Spiegelmers, NOXXON has a diversified portfoliostage of clinical Spiegelmer® therapeutics: is an anti-CCL2 (MCP-1) Spiegelmer® currently in a Phase IIa study in diabetics with albuminuria. NOX-E36 a process which is associated the kidneyCCL2 is involved in recruitment of immune cells to in diabetic patients, with progression of chronic kidney disease. is an anti-CXCL12 (SDF-1) Spiegelmer® that begun two Phase IIa studies in hematological has NOX-A12 via its two receptors, CXCL12 acts oncology indications (chronic lymphocyticleukemia and multiple myeloma). metastasis and resistance to chemotherapy. to mediate tumor invasion, CXCR4 and CXCR7, is an anti-hepcidin Spiegelmer® currently Phase I safety studies as well as a Phase I completing NOX-H94 Hepcidin human pharmacodynamic study to assess its ability to prevent inflammation-induced hypoferremia. is the key regulator of iron metabolism mediator and of iron restriction in anemia of chronic disease via its ferroportin. interaction with the iron export protein, which haveThe Spiegelmer platform provides the company with powerful and unique discovery capabilities, NOXXON is a Germany, Located in Berlin, generated investigation. a number of additional leads under preclinical 60 employees approx. well-financed mature biotech company a strong syndicate with of international investors, and a highly experienced management team MANAGEMENT Senior Management Chief Executive Officer Iain Buchanan, Chief Medical Officer Dr Matthias Baumann, Dr Sven Klussmann, Chief Scientific Officer Chief Business Officer PhD, Aram Mangasarian, Supervisory Board Chairman of the Supervisory Board Wenninger, Walter Dr YEAR FOUNDED 1997 EMAIL [email protected] [email protected] [email protected] [email protected] FAX +49 30 726 247 225 TELEPHONE +49 30 726 247 0 Emmanuelle Delabre +49 30 726 247 100 ADDRESS AG NOXXON Pharma Max-Dohrn-Strasse 8-10 10589 Berlin Germany CONTACTS and Media Contact General Emmanuelle Delabre Business Development PhD Aram Mangasarian, Chief Business Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Numab www.numab.com FINANCIAL SUMMARY moneyUp to CHF 5 million seed provided through industry collaboration. PROFILE COMPANY Numab company is a Swiss biotech focusing on the discovery and development of therapeutic antibodies. Numab is a young company lead by a Managementtrack record in the biotech industry with proven out of 5 (4 Management have members been long lasting employees in key at positions ESBATech). Numab applies selection system that a high-throughput the antibody discovery increases success rates The discovery by magnitudes and allows to efficiently best-in-class and/or first in class antibodies. identify engine is particularly against well suited to detect antibodies unconventional targets such as multi-spanning GPCRs or ion channels). transmembrane proteins (e.g. also applies its however, Numab is pursuing proprietary antibody programs in autoimmune diseases and pain, breakthrough technology to discover highly antibodies on behalf of its partners in the pharmaceutical potent industry. MANAGEMENT PhD, CSO & Co-CEO David Urech, CBO & Co-CEO PhD, Oliver Middendorp, Head of Pharmacology PhD, Gunde, Tea Head of Biochemistry PhD, Sebastian Meyer, Administration Head of Finance and Roland Helfenstein, YEAR FOUNDED 2011 EMAIL [email protected] FAX +41 44 533 0470 TELEPHONE +41 44 533 0471 ADDRESS AG Numab Einsiedlerstrasse 34 Wädenswil CH-8820 Switzerland CONTACT Oliver Middendorp CBO & Co-CEO WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Therapuetics Opsona www.opsona.com FINANCIAL SUMMARY Biotechnology Company 0-20 Employees Private Company Latest – B Round Round of Funding date to – $35M Total Funding PROFILE COMPANY focused on novel therapeutic approaches to Opsona is a leading immunology company, drug development including key targets of the innate immune system associated with a wide range of major human diseases, disease and Alzheimer’s diabetes, cancer, transplant rejection, autoimmune and inflammatory diseases, atherosclerosis. College in Dublin one of Trinity The company was founded in 2004 by world-renowned immunologists three at a fully lead product, Opsona’s leading academic institution with a core focus on immunology research. Ireland’s (TLR2) has demonstrated activity in Toll-like-receptor-2 human monoclonal IgG4 antibody (OPN-305) targeting a number of animal models & recently successfully was tested in a phase 1 clinical trial in healthy volunteers. clinical study to double blinded and placebo controlled The Company plans to conduct a two-part multi-centered, tolerability and efficacy of OPN 305 in renal transplant patients of Delayedat high risk Graft evaluate the safety, Function(DGF) as the first clinical target indication of OPN-305 to be initiatedfor the development in 2012. Roche Fund, Venture The Company is supported by an international venture consortium including Novartis Capital and Venture Inventages Fountain Healthcare Partners, Seroba-Kernel Life Sciences, Fund, Venture Enterprise Ireland. MANAGEMENT Executive Chairman Bernd Seizinger, CEO Welschof, Martin VP Pharmaceutical Development & Operations Mary Reilly, Director and CSO Co-Founder, Luke O’Neill, Finance Director Conor Dalton, Consultant Chief Medical Officer Dr Robert M Miller, YEAR FOUNDED 2004 EMAIL [email protected] [email protected] FAX + 353 1 677 8949 TELEPHONE +353 1 677 0223 ADDRESS Therapeutics Ltd OPSONA Ashford House Second Floor Street Tara Dublin 2 Ireland CONTACTS Welschof Martin Chief Executive Officer Loretta Greene Administrator Assistant & Executive WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u BV Therapeutics ORCA www.orca-therapeutics.com FINANCIAL SUMMARY OncologyAglaia Seed Fund BV Current investor: EURO 5 Million Financing Sought: PROFILE COMPANY (ORCA) is developing a pipeline of innovative anticancer therapies based on the Therapeutics B.V. ORCA on using its proprietary value proposition is based ORCA’s highly promising approach of oncolytic viruses. lead product ORCA-010 is a new ORCA’s Agents. technologies of Oncolytic in the field Replication Competent to ten thousand ORCA-010 has up T1 technology. proprietary oncolytic adenovirus based on the Company’s fold higher oncolytic current state potency as compared to of the art oncolytic adenoviruses in a variety of cancer cell lines and ORCA is currently ORCA-010 for developing its first study in man. MANAGEMENT PhD MBA, CEO Janneke Meulenberg, CSO PhD, Victor van Beusechem,

YEAR FOUNDED 2005 EMAIL meulenberg @orca-therapeutics.com FAX +31 204 442126 TELEPHONE +31 204 441826 Postal address: PO Box 7057 Amsterdam 1007 MB The Netherlands ADDRESS De Boelelaan 1118 Amsterdam 1081 HZ The Netherlands CONTACT PhD MBA, Janneke Meulenberg, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Carlos Buesa, Chief Executive Officer Carlos Buesa, PhD in Biochemistry and Molecular Biology at the University of Barcelona (UB) in Spain. In 2000, he founded In 2000, PhD in Biochemistry and Molecular Biology at the University of Barcelona (UB) in Spain. In Oryzon and since 2001 he has served of Directors. as Chief Executive Officer and Chairman of the Board he sits on the board of other biotech companies He has taken the executive education programme addition, VC. a specialized Seed He is also boardmember of Inveready Capital, at the IESE Business School. (PADE) ORYZON www.oryzon.com FINANCIAL SUMMARY Stage of funding Last funding (9M€) was (15 M€ in total) + 15 M€ in Competitive Grants. 5 Funding rounds from inception These funds were also matched of competitive grants with a set and long-term / null- accomplished in 2008. very soft rates public loans. Capital plans – IPO plans The Company a new round of funding (8-10M) in late will need 2012 early development of the 2013 to keep the The company to get this funding either through C series or is considering programs in full speed. to Phase I-II preIPO funding. VCs Other NAJETI as main stakeholder from 2003. VC firm The company has a French-Spanish Investors. Several Spanish family offices and private Invercat and Barcelona Empren. having minor stakes are CORSABE, minor investors are also present. PROFILE COMPANY Oryzon is a biomarker discovery company with a dual therapeutic pipeline in oncology and neurodegeneration. with a TARGETS Oryzon has a strong focus EPIGENETIC in and venture backed from 2002, Founded in 2000, Specific Demethylase-1 with Demethylases being a global leader on Lysine special emphasis in Histone Lysine viral diseases and neurodegeneration. LSD1 has been proposed as a target for oncology, a dominant IP position. ACUTE MIELOGENOUS one in Oryzon has two preclinical programs with different preclinical candidates LSD1i, Our inhibitors are highlynM) and in potent in vitro (low LEUKAEMIA and the other in Huntington disease. they are ablesparing normal to hit leukemic steam cells while vivo (<1mg/kg) and exquisitely selective, pharmaceutical There is strong interest from 2012 Harris et al.). hematotopoietic precursors (CancerCell, companies. Phase I/IIa studies are expected to start in early 2013. Our first product GynEC®-DX consists on we also develop new non invasive early diagnostics tools. In Oncology, developed jointly with GynEC®-DX, a new set of markers for triage cancer from uterine aspirates. in endometrial allows to rule out GynEC®-DX Reig Jofré Laboratories the Spanish market in 2Q-2012. has been launched on A global commercial partner is a sample of uterine aspirate. the presence of tumour in 99,6% of cases through sought. MANAGEMENT YEAR FOUNDED 2000 EMAIL [email protected] [email protected] [email protected] FAX +34 93 377 40 28 TELEPHONE +34 93 515 13 13 ADDRESS C/San Ferran 74 08940 Cornella de Llobregat SPAIN (Barcelona), CONTACTS Carlos Buesa Chief Executive Officer Torrell Emili Business Development Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd BioTherapeutics Oxford www.oxbt.co.uk FINANCIAL SUMMARY Private PROFILE COMPANY Oxford BioTherapeutics (OBT) is focused antibody-based medicines for on the development of targeted oncology. against novel integrated with diagnostics, strategy innovative is to develop antibody-based cancer drugs, OBT’s with world leaders Through its alliances targets that in its unique OGAP® proteomic database. it has discovered pipeline of into an exciting targets OBT is in an unrivalled position to convert its novel in antibody development pipeline will deliver cost-effective medicines to fulfill OBT’s first-in-class therapeutics for the treatment of cancer. the major unmet medical need of cancer patients. MANAGEMENT CEO Christian Rohlff, COO Esteban Pombo-Villar, CSO Terrett, Jon Protein Sciences Vice President, Senior Boone, Tom YEAR FOUNDED 2004 EMAIL [email protected] [email protected] FAX +44 1235 861771 TELEPHONE +44 1235 861770 (Head Office) +41 (0)61 225 4290 (Direct) ADDRESS 94a Milton Park Abingdon Oxfordshire OX14 4RY United Kingdom CONTACTS Esteban Pombo-Villar Chief Operating Officer Wootton Nicola WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CMO David Kerr, David is Professor of Cancer Medicine at the and a recent President of the European Society of Medical Oncology. CSO Thangue, Nick La His academic research is focused on the molecular Nick is Professor of Cancer Biology at the University of Oxford. mechanisms that give rise to the abnormal proliferation of tumour cells. Nick is the former CEO of Pronota (developer of diagnostics based on novel protein biomarkers) and Solexa (the pioneer of next gen sequencing). Biomarkers Cancer Oxford www.oxfordbio.com FINANCIAL SUMMARY from Quintiles $5M funding via equity investment PROFILE COMPANY Oxford (OCB) is a newly Cancer Biomarkers launched company tests that developing predict which cancer patients will respond favorably to existing and emerging drugs allowing treatment cancer to be tailored to individual patients. has a patent-protected and validated platform for out from Oxford which is a spin University, The company, discovering proteins that markers for are novel chemosensitivity specific drugs. OCB is developing its biomarkers tests both independently with pharma and biotech and in partnership companies. OCB has already implemented a strategicrelationship with Quintiles Setting the company apart from the crowd, the inertia that overcoming can Inc that provides a route for accelerating novel biomarkers into clinical trials, its model. sometimes hamper the companion biomarker business The companyQuintiles. $5 million equity investment from has secured initial funding via a former CEO of Solexa (the pioneer of next gen sequencing) and led by Nick McCooke, management team, OCB’s Professor of Cancer Medicine at the includes David Kerr, Pronota (protein biomarker diagnostic development), Thangue, and Nick La University of Oxford European Society of Medical Oncology, and a recent President of the Professor of Cancer Biology at of Oxford. the University MANAGEMENT CEO Nick McCooke,

YEAR FOUNDED 2011 EMAIL [email protected] FAX +44 1235 861771 TELEPHONE +44 1865 784000 Office: +44 7900 214268 Mobile: ADDRESS Magdalen Centre Oxford Science Park Oxford OX4 4GA Chief Medical Officer CONTACTS Nick McCooke Chief Executive Officer Thangue Prof Nick La Chief Scientific Officer Prof David Kerr, WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Biosolutions Pantec www.pantec-biosolutions.com FINANCIAL SUMMARY VC company. Pantec is funded by private investors and one The company round. in a new financing new investors alongside existing shareholders is seeking PROFILE COMPANY leading companyPantec Biosolutions is the for stable dermal delivery and controlled of large weight goal is to replace injection based Our of biologicals disease areas in selected biopharmaceuticals. (Precise The proprietary combination of P.L.E.A.S.E.® dermal deliverywith the help of a breakthrough method. safe, Laser Epidermal System) microporation technology with intradermal drug delivery allows easy to use, This rapid and painless application biopharmaceuticals. hormones and other large molecular weight of infertility platform significantly uptake in addition to reducing treatment improves precise drug duration and avoiding the This technology significant potential to unlock a high unmet need of treatments has requiring need for injections. large molecular weight biopharmaceuticals. focus is in combining laser of laser microporation with drug delivery dermatology in the and The company’s immunology space. as a new category ablative fractional laser device to “stand alone” can also be used In addition P.L.E.A.S.E.® break new ground in aesthetic dermatology. MANAGEMENT CEO Dr Boehler Christof, CTO Thomas, Mr Bragagna CBO Rohmann Sven, Dr Dr med. Clinical Director as permanent consultant Clemens Norbert, Dr. Advisor Chief Scientific N, Yogeshvar Dr Kalia YEAR FOUNDED 2005 EMAIL [email protected] FAX +423 377 78 99 TELEPHONE +423 377 78 00 ADDRESS Industriering 21 9494 Ruggell Liechtenstein CONTACTS Dr Christof Böhler Chief Business Officer DDr Sven Rohmann Chief Business Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u PharmaNeuroBoost www.pharmaneuroboost.com PROFILE COMPANY Pharmaneuroboost is a privately held R&D company dedicated develop CNS drugs with a significant added to of care products availablevalue compared to standard IP protected platform. based on a solid a fixed combinationof citalopram and low dose pipamperone in product PNB01, Current developments involve a fixed combination of risperidone and low dose pipamperone product III) and PNB02, Major Depression (phase II). in Schizophrenia (phase MANAGEMENT Chief Executive Officer Dr Erik Buntinx, Chief Development Officer den Broeck, Van Dr Remi Chief Medical Officer Dr Ludo Haazen, Chief Science Officer Prof Didier de Chaffoy de Courcelles, YEAR FOUNDED 2006 EMAIL Erik.buntinx @pharmaneuroboost.com FAX +32 11 484 923 TELEPHONE +32 11 480 750 ADDRESS Alkerstraat 30A Alken B3570 Belgium CONTACT Dr Erik Buntinx Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AB PledPharma www.pledpharma.se FINANCIAL SUMMARY on June 30 was SEK 68 608k Cash and cash equivalents PROFILE COMPANY for prevention PledOx®, specialty pharma companyPledPharma is a Swedish that develops a new medicine, Many of the severe side effects that patientsof chemotherapy develop as a consequence treatment of cancer. The current market for times the treatment be carried out as planned due to very cannot difficult side effects. the patent PledOx is a medicine within protected substance class some SEK 72 billion. supportive cancer care is Oxidative stress is a condition where an normal cells against oxidative stress. which protects the body’s PLED, are also evaluating We overabundance oxygen radicals) has been formed. of harmful oxygen molecules (free PledPharma (STO:PLED) is listed on NASDAQ OMX First opportunities with PLED substances for other diseases. Adviser. Erik Penser Bankaktiebolag is the Certified North. please visit www.pledpharma.se For more information, MANAGEMENT CEO Jacques Näsström, Clinical Project Director Marie Bengtson, CMC Sven Jacobsson, CFO Johan Stuart, Advisor Cardiology Medical Professor Per Jynge, Advisor Neurology VP IR and Med. Erik Kinnman, Manager and Dir Regulatory Proj. Malin Lundgren, YEAR FOUNDED 2006 EMAIL [email protected] FAX +46 8 663 57 25 TELEPHONE +46 8 679 72 10 ADDRESS AB PledPharma 11 C Turegatan Grev 114 46 Stockholm CONTACT Jacques Näsström Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Broadly portfolio diversified clinical and pre-clinical development • POL6326 (CXCR4 antagonist) novel mode of action) • POL7080 (Pseudomonas-selective antibiotic, • POL6014 (elastase inhibitor) CCR10) CXCR7, • GPCR platform (e.g. • Protease platform • PEMfinder® • MacroFinder® • Boehringer Ingelheim • Novartis • Stem cell transplantation (autologous and allogeneic). repair. Tissue • • Chemosensitization (CXCR4 antagonist to enhance impact of established anti-cancer therapies). 2013. • Phase II clinical trial planned to start in Q1, R&D collaborations with Pharma partners Two proprietary technology platforms Two

Ltd Polyphor www.polyphor.com FINANCIAL SUMMARY each of which contributed Polyphor inflows through operational secured cash revenues and capital increases, CHF. roughly amount of close to 200 Mio. 50% to the total PROFILE COMPANY overviewCorporate Polyphor pharmaceutical company is a Swiss research-driven developing innovative with high products therapeuticthe patient benefit to to its industry and providing high quality support partners engaged in drug discovery. proprietaryPolyphor has established two complementary technology platforms with the aim to innovative, discover and develop new medicines for medical needs. unmet MacroFinder® and PEMfinder® platforms were specifically developed for discovering potent and Polyphor’s selective modulators and other challenging of Protein-Protein Interactions targets. Products: Platforms: Partnering: Clinical Development Pipeline: POL7080 (Phase II ready) – highly potent Pseudomonas-selective antibiotic with novel mode of action. POL7080 has been shown to be highly efficacious against a broad Successfully completed Phase I clinical trial. including MDR Pseudomonas strains: panel of clinical isolates, MANAGEMENT Jean-Pierre Obrecht Ph.D., Co-founder & CEO Co-founder & CSO Daniel Obrecht Ph.D., CFO Christoph Rentsch, Head Corporate Development Altorfer Ph.D., Michael Chief Medical Officer Ph.D., Klaus Dembowsky M.D., Platform Technology Head Thommen Ph.D., Marc Head Internal Services Peter Zbinden Ph.D., Head Business Development Helmut Kessmann Ph.D., Polyphor’s competitive edge is based on its technology platforms which sustain a diversified portfolio of clinical Polyphor’s candidates in various therapeutic areas. POL6326 (Phase II) – a CXCR4 antagonist that the circulating mobilizes stem cells from the bone marrow to This effect can be exploited in several ways: blood.

YEAR FOUNDED 1996 EMAIL [email protected] [email protected] FAX +41 61 567 16 01 TELEPHONE +41 61 567 16 00 ADDRESS Hegenheimermattweg125 Allschwil CH-4123 Switzerland Head Corporate Development CONTACT Ph.D. Altorfer, Michael WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd PolyTherics www.polytherics.com PROFILE COMPANY PolyTherics company is a UK biotech providing technology enabling solutions development of better PolyTherics has offers proprietary conjugation site-specific technologies biopharmaceuticals. half-life for the creation and the efficient production of stable, of bispecific products extension of protein therapeutics, PolyTherics partners including antibody fragment-drug conjugates. conjugates, homogeneous antibody-drug Bono Bio (TheraPEG™ variants of Celtic Pharma Holdings/Pro interferon ß), include Nuron Biotech (TheraPEG™ ADC reagents). IX) and Spirogen (forVIIA and Factor the development of novel Factor MANAGEMENT Chief Executive Officer Dr John Burt, Chief Operating Officer Waterman, Dr Sally VP of Business Development Dr Georg Buchner, Chief Scientific Officer Dr Steve Brocchini, Technology Director of Science & Antony Godwin, Dr Director of Scientific Evaluation Choi, Dr Ji-Won Alliance Management Director of Dr Jeff Edwards, Finance Manager Brown, Tim YEAR FOUNDED 2002 EMAIL [email protected] FAX +44(0) 207 691 3742 TELEPHONE +44(0) 207 6913580 ADDRESS The London Bioscience Innovation Centre 2 Royal College Street Town Camden London NW1 0NH CONTACTS Dr John Burt Chief Executive Officer Waterman Dr Sally Chief Operating Officer Dr Georg Buchner VP of Business Development WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u BioMed Prima www.primabiomed.com.au PROFILE COMPANY As a leader in personalized bio- Australia. biotechnologyPrima BioMed is a global company headquartered in Prima is dedicated to leveraging its current technology to develop and expertise therapeutic products for cancer, lead product is CVac™, Prima’s innovative treatment options for patientsshareholders. and maximize value to product currentlyan autologous dendritic cell in clinical trials for cancer. ovarian MANAGEMENT Chief Executive Officer Matthew Lehman, Chief Financial Officer Ian Bangs, Chief Medical Officer Dr Neil Frazer, Officer Technical Chief Dr Sharron Gargosky, Chief Business Officer Voigt, Marc YEAR FOUNDED 2005 EMAIL Matt.lehman @primabiomed.com.au FAX 650-632-4384 TELEPHONE 650-632-4370 ADDRESS US Prima BioMed, Drive Dolphin Twin 303 Suite 600 Redwood City CA 94063 CONTACT Lehman Matthew B. Chief Operating Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u BV ProFibrix www.profibrix.com FINANCIAL SUMMARY added EUR 15Mill in MayCompleted B round and 2011. PROFILE COMPANY ProFibrix leveragesexpertise in fibrinogen technology its and market innovative to develop products for the plays Human fibrinogen a pivotal role in blood clotting and hemostasis and regenerative medicine markets. clinical and scientific experience in the field is led by ProFibrix a team with extensive commercial, tissue healing. is being studied to help stop biologic, lead the proposed name of the company’s Fibrocaps™, of hemostasis. A dry and thrombin, powder based on a mixture of fibrinogen bleeding during surgery and after trauma injury. Fibrocaps is a ready-to-use preparation to be stable designed at room temperature and applied in different Fibrocaps is currently enrolling patients into a final pivotal Phase 3 including sprays and bandages. formats, study and aiming at submitting a BLA/MAA in mid-2013. MANAGEMENT CEO Jan Öhrström, CSO Jaap Koopman. CBO Arnoud Dijkstra, VP Finance Martijn Meijer, CDO Eliane Schutte, CMO Paul Frohna, VP Preclinical Linda Zuckerman, YEAR FOUNDED 2005 EMAIL [email protected] [email protected] [email protected] FAX +31 715 181 340 TELEPHONE +31 888 669 665 ADDRESS Zernikedreef 9 Leiden 2333 CK, The Netherlands CONTACTS Jan Öhrström Chief Executive Officer Arnoud Dijkstra Chief Business Officer L Diepgrond WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Protagen www.protagen.com FINANCIAL SUMMARY (Years 2004-2010). financing totalling 15,3 Mio Euro Completed five rounds of PROFILE COMPANY provider of solutions for GROUP is a leading the pharmaceutical and biotech industries, The PROTAGEN protein characterization towards personalized medicines and GMP compliant supporting drug development services quality. of outstanding Protein and PROTAGEN AG with a clear focus on diagnostics, of PROTAGEN GROUP consists The PROTAGEN the proprietaryAG has developed PROTAGEN Services GmbH (PPS) providing GMP compliant protein analysis. UNIarray® platform to support patient stratification and the development of Companion Diagnostics (CDx) using in biostatistics combine our outstanding know-how We the diagnostic power of autoantibody signatures in blood. Our and expertise in Protein arrays and Luminex technology for the development of novel diagnostic assays. autoimmune diseases endometriosis, neurodegenerative disorders, e.g. R&D focus is on chronic diseases, Erythematosus Systemic Lupus as well as selected cancer and Multiple Sclerosis Arthritis, such as Rheumatoid Colon- and Pancreatic Cancer. Ovarian-, Breast-, Prostate-, e.g. indications, Protein Services GmbH (PPS) is a reliable partner for GMP compliant characterization of PROTAGEN PPS combines unique including stability and release testing. biotherapeutics (NBEs) and biosimilar comparability, expertise in bioinformatics for spectrometry protein mass in protein chemistry with a long track record and we provide customer support for all In addition, protein analytics available. in order to provide the best quality KFDA) for protein drugs. relevant regulatory EMA, issues to match with current regulatory requirements (FDA, MANAGEMENT CEO Dr Stefan Müllner, CSO Dr Peter Schulz-Knappe, YEAR FOUNDED 1997 EMAIL [email protected] FAX +49 231 9742 6301 TELEPHONE +49 231 9742 6300 ADDRESS Otto-Hahn-Strasse 15 D- 44227 Dortmund Germany WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

GmbH Pharma PSites www.psites.de PROFILE COMPANY the so competitive regulatory binding site, protein kinase inhibitors forPSites develops allosteric a new non-ATP allows a much higher specificity and thereforeThis less adverse side effects. called PIF pocket. MANAGEMENT Chief Executive Officer Witte, Dr Rolf Chief Scientific Officer Dr Ricardo Biondi, YEAR FOUNDED 2011 EMAIL [email protected] [email protected] ADDRESS 1 Haus Universitätskliniken, 7 Theodor-Stern-Kai 60590 Frankfurt / Main Germany CONTACTS Dr Ricardo Biondi Chief Scientific Officer Witte Dr Rolf Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GmbH RECARDIO www.pledpharma.se PROFILE COMPANY Austria based life science company founded Therapy) is an innovative RECARDIO (Regenerative CARDIOvascular After It is focusing on regenerative therapeutic modalities for the treatment of cardiovascular diseases. in 2011. it is developing multiple therapeutic leads as the future regenerative establishing in vivo, proof-of-principle the potential of improving their cardiac with medication for patients with various cardiovascular diseases, and survival. quality of life function, MANAGEMENT RECARDIO has an experienced management and reputation with longlasting and significant experience team in stem cell therapy and the biotech industry and is complemented by an exclusive and knowledgeable cardiology, Scientific & Clinical Supervisory Board and Board of Directors. YEAR FOUNDED 2011 EMAIL [email protected] FAX +43 463 210 131 TELEPHONE +43 463 210 131 ADDRESS Lakeside B07b 9020 Klagenfurt AUSTRIA CONTACT Dr Roman Schenk Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Scancell www.scancell.co.uk PROFILE COMPANY therapeuticScancell is developing novel vaccines for the treatment of cancer and based on its groundbreaking cancer vaccine SCIB1 is a DNA vaccine first Scancell’s technologyImmunoBody® and Moditope™ platforms. being developed for treatment the trials. of melanoma and is in Phase 2 clinical cancer by vaccination to a patient, a vaccine to be administered allows small non-toxic doses of Treating Effective target dendritic cells to stimulate cancer vaccines need to both parts stimulating response. an immune the helper cell system where inflammationof the cellular immune system; is stimulated the tumour site; and at kill specific to recognise and primed or CTL response where immune system cells are T-lymphocyte the cytotoxic cells. A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic pulsing Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, cells in vivo. time consuming this procedure is patient specific, However, them with tumour antigens and re-infusing them. Scancell has developed its breakthrough patent protected ImmunoBody® technology to and expensive. overcome these limitations. The Immunobody® technology can be adapted to provide the basis for treating any tumour type and may also HIV and other chronic infectious diseases. againstbe of potential utility in the development of vaccines hepatitis, Scancell has also identified and patented of modified epitopes that a series stimulate the production of killer CD4 believe thatThe Directors the Moditope™ platform could have a profound that destroy tumours without toxicity. effect on the way that developed. cancer vaccines are EMAIL [email protected] ADDRESS Scancell Ltd Dept Clinical Oncology City Hospital Hucknall Road Nottingham NG5 1PB CONTACT Dr Richard Goodfellow Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Limited Selcia www.selcia.com PROFILE COMPANY operates Massachusetts, in Hopkinton, UK and with a branch Essex, in Ongar, headquartered Selcia Ltd., Whilst Radiochemistry in 14C GMP specializes Selcia Discovery and Selcia Radiochemistry. two divisions, Discovery Selcia provides integrated molecule drug discovery small radiolabelling, and biotech to pharmaceutical Selcia medicinal chemistry Besides general and biology capabilities applicable across all target classes, clients. (1) medicinal chemistryDiscovery a particular strength in three unique and highly has synergistic technologies: (3) (2) capillary -based fragment electrophoresis and natural product screening, on complex natural products, Whilst relativelyneglected called PPIases). together Pin1, FKBPs, peptidyl-prolyl targets (cyclophilins, isomerase understanding of the involvement of PPIases in many diseases is by pharmaceutical companies in the past, natural presentlyAll PPIase inhibitors in clinical use or in development are natural products, currently emerging. product derivatives or have by structures inspired natural products. The combination of these technologies has enabled Selcia to deliver several clinical PPIase inhibitors to Mitopharm which was recently demerged into a new company, but has also generated IP for Selcia, clients, Mitopharm is in advanced license negotiations foracute and chronic a breakthrough drug in the field of Ltd. COPD, oncology, Other applications in the fields of chronic inflammatory diseases, neurodegenerative diseases. and virus infections will be developed by either via investment or via joint R&D programs Mitopharm with pharmaceutical companies. MANAGEMENT CEO Simon Saxby, COO Dr Clive Cornell, Business Development Director – Discovery Simon Bury,

YEAR FOUNDED 2001 EMAIL [email protected] [email protected] FAX +44 1277 367099 TELEPHONE +44 1277 367000 ADDRESS Selcia Limited Fyfield Business & Research Park, Fyfield Road, Essex CM5 0GS UK CONTACTS Dr Hans Fliri Chairman Simon Bury – Business Development Director Discovery Ongar, WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Therapeutics Shield www.shieldtherapeutics.com PROFILE COMPANY pharmaceutical company is an independent specialty focused on the founded in 2008, Therapeutics, Shield hospital pharmaceuticals which address mineral-derived development and commercialisation of late-stage, Shield is currently global pivotal Phase 3 studies of its lead conducting two need. areas of high unmet medical disease for treatment the of iron deficiency anaemia associated with Ulcerative Colitis and Crohn’s ST10, asset, a Phase 3 study of ST10 forand is now also commencing the treatment in patients of iron deficiency anaemia with chronic kidney disease. MANAGEMENT CEO Carl Sterritt, CFO Richard Jones,

YEAR FOUNDED 2008 EMAIL [email protected] FAX +44 (0) 870 458 6523 TELEPHONE +44 (0) 191 206 4046 Tyne Newcastle upon NE1 3DY 116 Quayside, ADDRESS Therapeutics, Shield Rotterdam House, CONTACT Richard Jones Chief Financial Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u €109.000 €10.000.000 €261.000 €100.000 €500.000 €201.000 €653.000 €800.000 €1.392.600 > €60Mill in 2015

VC firm: Institutional: Grants & loans: Investment in R&D 2010 2011 2012 (expected) Funding capital required: in humans. two most advanced products to Phase IIa p.o.c. secure the To Funding application: Expected sales: PROFILE COMPANY SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new which we are offering to partners for their drug pipeline. expanding therapeutic indications for given drugs, of which 3 cover with 18 positive hits (43%), During the last 34 months we have validated 41 new indications, clear medical need indications: Argon Pharma and Draconis Pharma. already licensed to SOM0777 for the treatment of Glioma, Phase II planned for2013. 1Q Orphan Disease. TTR-Amyloidosis. SOM0226 for the treatment of Phase II expected for 4Q 2013. in preclinical development. SOM0606 for the topical treatment of Psoriasis, 25 more repurposing programs to file the advanced company per year are running pipeline. MANAGEMENT Chief Executive Officer MBA., PhD, MD, Raúl Insa, Founder & Member of the Board PhD., Ignasi Belda, MBA., Part-time Chief Financial Officer BS, Ramon Morera, Advisor & Member of the Board PhD., Trias, Joaquim R&D Manager PhD., Núria Gavaldà, IP & Project Coordinator PhD., Núria Reig, Advisors Member of the Board of PhD., Hermann Mucke, Biotech SOM www.sombiotech.com FINANCIAL SUMMARY of Financing Sources Founders: FFFs: YEAR FOUNDED 2006 EMAIL [email protected] FAX +34 93 403 4510 TELEPHONE +34 93 402 0150 +34 69 062 3263 ADDRESS Barcelona Science Park 4 Baldiri Reixac, 08028- Barcelona Spain CONTACTS Dr Raúl Insa Chief Executive Officer Dra Nuria Gavaldá R&R Manager WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u MANAGEMENT CEO Prof Dr Peter Buckel, Head of BD and Licensing Dr Robert Phelps, CSO Dr Peter Sondermann, Medical Director Tillmanns, Sascha Suppremol www.suppremol.com PROFILE COMPANY of autoimmune diseases for the treatment therapeutics Delivering novel novel proteins to treat is developing autoimmune a privately held biopharmaceutical Company, SuppreMol, developed a novel therapeutic SuppreMol has concept for the treatment of autoimmune diseases that diseases. The Company was founded in 2002 as a spin-off from relies on naturally Fc gamma receptors (FcgRs). produced of Biochemistry. the Max Planck Institute Systemic Thrombocytopenia (ITP) and The Company SM101 for is developing the treatment of Primary Immune long lasting early onset, is designed to be a specific, SM101 Lupus Erythematosus (SLE) in Phase II clinical trials. Arthritis (RA) and Multiple Rheumatoid SLE, and well tolerated treatment for diseases such as ITP, autoimmune Sclerosis (MS). programs SuppreMol is working on antibody Further building its platform of selective immunoregulators, targeting Fc receptors and other immunomodulatory molecules for alternative treatment strategies in autoimmune conditions. YEAR FOUNDED 2002 EMAIL [email protected] FAX +49 30 90 60 68-68 TELEPHONE +49 30 90 50 68-0 ADDRESS Am Klopferspitz 19 82152 Martinsried/Munich WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Telormedix www.telomedix.com PROFILE COMPANY company is a biopharmaceutical focused immunity and the role of the innate on targeted immune Telormedix Toll-like is particularly interested in the role of Telormedix system in treating diseases and cancer. autoimmune Receptor 7 (TLR7) forthe topical treatment of cancer. is currently trial for in a Phase I/II clinical the treatment of Non- TMX-101, lead product, The Company’s is a new TMX-101 humans. in Cancer (NMIBC) and has showed a good safety profile Muscle Invasive Bladder formulation of a clinically-active and favourable small molecule compound with a known safety profile and a TMX-101 specifically for the localised treatment of Telormedix has optimized specific immunotherapeutic target. will TMX-101 medical need. the fifth most prevalent cancer and a disease of significant unmet bladder cancer, be the first targeted therapy dedicatedbladder cancer and the first to modulate to the innate immune system for this indication. is a small molecule for the topical treatment bladder cancers that of skin and TMX-202, The second product, the Company also has another TMX-20X series, Within the has already provided significant preclinical results. of concept has recently Proof for which is being developed use as a vaccine adjuvant. TMX-201, product called of a pipeline programme is part TMX-302, An additional product, been established in relevant animal models. targeting autoimmune diseases. MANAGEMENT CEO MD, Johanna Holldack, Founder/Head of Drug Development PharmD, Roberto Maj, Head of Research and Collaborations PhD, Alcide Barberis, CFO MBA, Filippo Riva, Head of Clinical Operations PharmD, Raffaella Pozzi, PhD, Project Management Director Nadia Passini, YEAR FOUNDED 2007 EMAIL [email protected] FAX +41 (0)91 610 7031 TELEPHONE +41 (0)91 610 7000 ADDRESS TELORMEDIX SA Via della Posta 10 CH-6934 Bioggio Switzerland CONTACT MD Dr Johanna Holldack, Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Corporation Terapio www.terapio.com FINANCIAL SUMMARY A $6.7M Series $1M seed capital $3.6M in federal funds Series B financing. Terapio’s in Ventures a lead or syndicate is seeking investors to participate with Santé Terapio will A lead investor, the Series Ventures, plans at least $10M in Series B financing where Santé Terapio The use of proceeds for B will be primarily Series used for drug development, participate on a pro rata basis. and regulatory required to fund the company activities to the valuation programs, preclinical and nonclinical Animal inflection point associated pivotal nonhuman primate with completing the efficacy trial under the FDA Rule. PROFILE COMPANY is a biopharmaceutical company developing clinical Terapio Ventures, Launched in 2007 and backed by Santé RLIP76 is a membrane-associated cellular applications based on the naturally-occurring RLIP76 protein. normal process of removing toxic metabolites formed by transport protein that is an integral cell’s part of the with exposure to radiation such as occurs and of elevated in cases oxidative stress, However, oxidative insults. Supplementing leading to cell death. the endogenous RLIP76 system can be overwhelmed, chemical toxins, liposomal formulation of the RLIP76 Terapio’s cellular levels of RLIP76 through exogenous administration of This mechanism protein promotes protection by stress and allows recovery relieving this cellular by tissue cells. including the treatment of the toxic of action has broad applicability additional clinical indications, to a variety of side effects of therapeutic radiation and chemotherapy in oncology patients and CNS diseases – a key part of commercial pipeline. Terapio’s has accumulated a large body of data demonstrating that the protein is Terapio For biodefense applications, effective of whole body radiation. to otherwise lethal exposures in protecting and rescuing animals exposed Acute Radiation Syndrome (ARS) as a lead the company is pursuing the prevention and treatment of Therefore, making this a highly need. unmet ARS exist today, No effective countermeasures for indication. ARS and has performed multiple 30-day survival in animal models of studies with the RLIP76 protein Terapio demonstrated that administered either before and/or after exposure to lethal doses of radiation results in greater versus 20% survivalthan 90% survival of controls. of treated animals, MANAGEMENT President and CEO PhD, Curt Bilby, co-founder and Chief Medical Officer MD, Casey Cunningham, Vice President of Drug Development Henry Hebel, Vice President of Preclinical and Nonclinical Programs MPH, PhD, Elizabeth Leffel, YEAR FOUNDED 2006 EMAIL [email protected] FAX 512 287 4241 TELEPHONE 512 514 6760 ADDRESS 7000 North MoPac Expressway 2nd Floor TX 78731 Austin, CONTACT PhD Curt Bilby, President and CEO WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u NV TiGenix www.tigenix.com PROFILE COMPANY is a leading European cell therapyTIG) company with a commercial product and an NV (NYSE Euronext: TiGenix advanced clinical stage pipeline of adult stem cell programs. is the first and only approved for cartilage the knee, repair in ChondroCelect®, lead product, The company’s The product has received full national reimbursement in Belgium and the cell-based product in Europe. being commercialized in 5 European countries. Netherlands and is already stem cell programson a validated are based platform adipose-derived stem of allogeneic expanded TiGenix’s and CMC packages, Built on solid pre-clinical and inflammatorycells (eASCs) targeting autoimmune diseases. The company has initiated a Agency. they are being developed in close consultation with the European Medicines has concluded recruitment in disease, in patientsPhase III clinical trial in complex perianal fistulas with Crohn’s and successfully concluded a Phase I trial to investigate the potential of a Phase IIa trial in rheumatoid arthritis, intra-lymphatic administration of eASCs for autoimmune disorders. (the and Sittard-Geleen and has operations in Madrid (Spain), out of Leuven (Belgium), is based TiGenix Netherlands). MANAGEMENT Managing (CEO). Director and Chief Executive Officer Eduardo Bravo, Managing (CBO) Director and Chief Business Officer Gil Beyen BVBA, Chief Financial Officer (CFO) Claudia D’Augusta, Officer (CTO) Technical Chief Wilfried Dalemans, YEAR FOUNDED 2000 EMAIL [email protected] FAX +32 16 397 970 TELEPHONE +32 16 396 060 ADDRESS NV TiGenix 1724 Haasrode Researchpark Romeinse straat 12 bus 2 3001 Leuven Belgium CONTACT Eduardo Bravo (speaker) Managing Director and Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u technologies to-BBB www.tobbb.com FINANCIAL SUMMARY 1M ±€ Seed 2004-2006: ±€4M Series-A 2007: ±€6M Series-B 2011: ±€5M Accum grants/credits: PROFILE COMPANY to-BBB is a clinical stage blood-brain barrier company with a proprietary in the Netherlands technology The company is performing a phase I/II study with lead to safely drug delivery. enhance brain (G-Technology®) which focuses on brain metastases of Breast Cancer and glioblastoma. product 2B3-101, which will be in the ALS, neuropathic pain and to-BBB is also developing 2B3-201 for neuroinflammation in MS, and Alzheimer’s the company is exploring additional product propositions in stroke, Furthermore, clinic in 2013. orphan brain diseases. The company has with pharma/biotech companies. The business model of to-BBB is based on partnerships entered into several research collaborationswith academic and pharma partners on brain drug delivery. €6M and over the years the companyIn 2011 to-BBB completed a series-B round of ± generated substantial The company to be cash positive based on license income after a last equity round expects non-dilutive funding. in 2013. MANAGEMENT Chief Executive Officer MBA, MSc, Weperen, Willem van Chief Scientific Officer/founder: PhD, Pieter Gaillard, Chief Medical Officer Prof., Assoc. PhD, MD, Fredrik Lonnqvist, YEAR FOUNDED 2004 EMAIL [email protected] FAX +31 84 831 3409 TELEPHONE +31 71 332 2252 ADDRESS Niels Bohrweg 11 2333 CA Leiden The Netherlands CONTACT Weperen Willem van Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

1,448 17,859 (20,517) (19,069) (19,118) 2,192 3,100* (19,038) (17,300) (17,300) 31.12.2011* 31.12.2010* Mr. Morgan joined AMT in December 2009 as Chief Financial Officer. He has over ten years experience as CFO with AMT in December 2009 as Chief Financial Officer. joined Morgan Mr. Prior to this period, Therapeutics Ltd. Arrow and Pharma SA, BioAlliance including Phytopharm plc, biotechnology companies, and Equity Capital Markets with Acquisitions, working in Mergers & he gained ten years experience in investment banking, He Therapeutics Ltd. Trino Currently he is Non-executive Chairman of Corporate Finance. Young Close Brothers and Ernst & Accountant in London with PricewaterhouseCoopers qualified as a Chartered Operating result Result for year Cash MANAGEMENT CEO Aldag, Joern CMO Carlos Camozzi, CFO Piers Morgan, R&D VP, Harald Petry, Bus Dev VP, Hans Preusting, Piers Morgan, CFO uniQure www.uniqure.com operating costs Total *Adjusted pro forma PROFILE COMPANY uniQure uniQure is a world leader in the research and early gene based therapies. development of human acute intermittent porphyria, hemophilia B, has a product pipeline of several gene therapies in development: Academic Medical Center, uniQure is located on the premises of the disease and Sanfilippo. Parkinson’s is the world leader for employs a staffwith extensive scientific and industry experience, Amsterdam, University of and has extensive meeting cGMP requirements, scale, products on a commercial AAV-based manufacturing of experience in the regulatory processes for gene therapies. FINANCIAL SUMMARY Amounts in € x 1,000 other income Total YEAR FOUNDED 04.05.2012 EMAIL [email protected] [email protected] [email protected] FAX +31 (0) 20 5667509 Marsha Lemmers +31 (0) 20 5662402 TELEPHONE +31 (0) 20 5667509 Aicha Diba +31 (0) 20 5668014 ADDRESS Meibergdreef 61 Amsterdam 1105 BA The Netherlands CONTACTS Piers Morgan Chief Financial Officer Aicha Diba Affairs Legal Marsha Lemmers Assistant Administrative WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Vexim www.vexim.fr FINANCIAL SUMMARY €1.1m (+93% over 12 months) Half-year 2012 sales: €1.2m Full-year 2011 sales: -€5.1m 2011 net income: PROFILE COMPANY The specialist created is a medical device in FebruaryVexim 2006. (France), Toulouse near Based in Balma, company in the creation has specialised solutions for and marketing of mini-invasive treating spinal pathologies. and Venture, Truffle Capital and Banexi shareholders, Benefitting from the financial support of its longstanding a unique implant capable has designed and developed the SpineJack®, Vexim from OSEO public subsidies, The Company of repairing a deformed correcting the anatomy or fractured vertebra and of the spinal column. distributors in Spain, as well as Germany and Italy, It has its own sales teams in France, currently has 35 staff. 2011 sales amounted to €1.2m and its 2011 The company’s Africa. Argentina and South Turkey, Italy, Portugal, The raising €11m. Alternext in May 2012, was successfully listed on NYSE Vexim gross margin was 58.3%. almost equaling the whole 2011 financial year performance. 1st half 2012 sales achieved €1.1m, company’s MANAGEMENT Chief Executive Officer Vincent Gardès, Chief Commercial Officer Vincent Lefauconnier, YEAR FOUNDED 2006 EMAIL [email protected] FAX +33 5 61 48 95 19 TELEPHONE +33 4 61 48 48 38 ADDRESS Vexim 75 rue Saint Jean 31130 Balma France CONTACT Vincent Lefaiconnier Chief Commercial Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Virogates www.virogates.com PROFILE COMPANY of patients to improve the screening and monitoring A/S is committed setting and healthy in a hospital ViroGates life style relatedindividuals in risk of developing diseases. urokinase (soluble ViroGates an ELISA (enzyme-linked immunosorbent assay) has developed based suPAR has shown to predict mortality and disease in clinical settings, Activator Receptor) test that, Plasminogen and studies havebeen 120.000 patients More than have to date with suPARnostic® been tested progression. Quick ViroGates has recently (2012) launched its suPARnostic peer reviewed articles. reported in more than 80 Triage products provide results in 20 minutes. The Quick on lateral test based flow technology. Triage The ELISA Standard ViroGates product portfoliofully consists of three developed products with CE-IVD approvals. kit marketed for Flex kit marketed for clinical research and the ELISA routine use at central laboratories in test based Triage Quick ViroGates has recently (2012) launched its suPARnostic addition to the ELISA products, Triage product provide results in 20 minutes. The Quick on lateral flow technology. ViroGates has more than 20 ViroGates’ network of distributors. Sales and marketing is carried out through distribution partners worldwide MANAGEMENT Chief Executive Officer Jakob Knudsen, YEAR FOUNDED 2001 EMAIL [email protected] TELEPHONE +45 22 261 355 ADDRESS Blokken 45 3460 Birkerød Denmark CONTACT Jakob Knudsen Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Virometix www.virometix.com PROFILE COMPANY Virometix is a privately held young innovative Swiss Biotech company developing a new class of vaccines, stability and speed, efficacy, which should overcome limitations of current biological of safety, vaccines in terms technologyVirus-Like Nanoparticle (SVLP) platform offers the following Virometix Synthetic manufacturing cost. value propositions: vaccines avoidVirometix SVLP-based the use of life pathogens and the safety concerns associated with Safety. the biological processes used for manufacturing conventional vaccines. a proprietary SVLPs are based on lipopeptide self-assembly process that leads to atomically defined Quality. which increases the lipopeptide monomers per particle, nanoparticles with a constant size and number of and assures lot-to-lot consistency. specificity and quality of the elicited immune response T-cell responses and SVLPs efficiently deliver antigens to antigen presenting cells for optimal B- and . Efficacy induce antibodies that bind with very high affinity to the native target antigen. SVLPs can be prepared extrusion or similar processes. refolding, SVLPs do not require sonication, Convenience. by simply monomers in a buffer dissolving freeze-dried lipopeptide suitable for injection shortly before use. vaccines are in early preclinical Two Virometix develops vaccines for and cancer. infectious diseases Virometix offers collaborative research and licensing partnerships for selected vaccines and development. disease areas. MANAGEMENT CEO and co-founder Arin Ghasparian, CSO and co-founder Robinson, A. John YEAR FOUNDED 2006 EMAIL [email protected] FAX +41 44 63 56833 TELEPHONE +41 44 63 56117 ADDRESS AG Virometix Winterthurerstrasse 190 8057 Zurich Switzerland CONTACT Arin Ghasparian Dr Chief Executive Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Molecular Biologist Certified for Regulatory Affairs & Clinical Trial Management; over 10 years experience in Biotech from Affairs & Clinical Molecular Biologist Certified for Regulatory Expert for acquisition of public grants & funds start-up to licence deal. CSO MD, Peter Petzelbauer, Vienna; over 10 years experience in Biotech & translational research; international of Microvascular Research MedUni Prof. holder of 10 patents scientific network, CFO Ms, Michael Hoffmann, Business Economist; more than 10 years in Biotech management positions; Expert for early stage financing. Science Xiber www.xiberscience.com FINANCIAL SUMMARY € ~ 4 Mio Financial need: 100 k € Shareholder Investment: 570 k € Public grants approved: 1,3 Mio € Public grants pending: 1 Mio € VC–investment: LOI over PROFILE COMPANY of critical Xiber develops new peptide drugs to improve outcome Xiber is a biopharmaceutical start–up company. Xiber will enter peptide drugs preserve organ function & prevent Organ failure. Xiber’s care & transplant patients. – with a total market volume of 630 Transplantation Lung InjuryAcute & Lung market by two niche indications: USD. Mio. A phase I clinical trial will start with forIn 2015 Xiber will complete the preclinical development both indications. the beginning of 2016. supported network by highlyprogramof executives, developmental byteam core qualified Xiber’ driven is small a of academic collaborators partners in a virtual development environment. and contract research partner with an appropriateAfter completion of the phase I trial Xiber aims to Pharma or Biotech company. byThe majority of the shares is owned the founders S. Vienna. Xiber is a spin-off of the Medical University of its shares byThe University holds a non-controlling interest and rewards providing Petzelbauer. Reingruber & P. facility services and management support. infrastructure, cooperation, MANAGEMENT CEO PhD, Sonja Reingruber, YEAR FOUNDED December 2009 EMAIL [email protected] peter.petzelbauer @meduniwien.ac.at TELEPHONE +43 699 170 54086 Prof Dr Peter Petzelbauer (CSO) +43 699 170 54087 ADDRESS Xiber Science GmbH Perlhofgasse 2/1 2372 Giesshuebl Austria CONTACTS Dr Sonja Reingruber Chief Executive Officer (CSO) Prof Dr Peter Petzelbauer Chief Scientific Officer WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.biotop.de +49 30 318 622 11 • Technology transfer science - industry Technology • • Initiation and support of networks • Support for technology-oriented start-ups • Funding support for innovative projects • Providing information on biotechnology • Building and coordination of scientific and interdisciplinary networks • Establishing disciplines contacts between experts from all • Design and organization of events • Public relations work for the biotech region Berlin-Brandenburg

BioTOP Berlin Brandenburg is the central contact and coordinationBioTOP Berlin Brandenburg office biotechnologyfor all issues concerning in the German capitalregion. It is our objective to coordinate all regional activities in biotechnology by networking with all key playersto and initiate in order to turn Berlin-Brandenburg into a globally specific projects cluster. leading life science The services provided by BioTOP include: including a database and scientific work with comprehensive profiles of all companies For more information, please visit our website at www.biotop.de. groups, Kai Bindseil Dr. BioTOP Berlin-Brandenburg 85 Fasanenstr. 10623 Berlin - Germany Tel: Fax + 49 30 318 622 22 BioTOP Berlin-Brandenburg BioTOP Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.citigatedr.co.uk Citigate is the leading international Dewe Rogerson exclusively consultancy specialising in financial and Asia. and America North Europe, corporate communications across the UK, Citigate has a dedicated in the sector experience years combined Pharma & Biotech team with more than 60 journalism and academic finance, corporate and financial PR and investor relations, and a unique mix of skills: benefiting sector expertise and formsThe team provides an integrated part of Citigate Dewe Rogerson, science. and from the cross-fertilisation overall strength of ideas across sectors. from the company’s The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies financial support, transactions core skills in financial calendar work, As well as at all stages in development. design and new media consultancy. the team has extensive experience in branding, PR and media relations, and numerous emerging listed companies in the UK and Europe, Recent clients include global top-five biotechs, and Scandinavia. the Netherlands, Germany, France, businesses in the UK, other public major corporate Pharma & Biotech team has been involved in such as IPOs, transactions Citigate’s haveadvised on a number of IPO transactions across Europe including; We and M&As. and private fundraisings, Santhera €30 million), Algeta (Oslo Stock Exchange - EXplorer (Euronext Paris - €52 million), METabolic Hutchison China (Euronext Brussels - €35 million), ThromboGenics Pharmaceuticals (SWX – CH88.5 million), Inion (LSE - - €63 million), Arpida (SWX Zentiva (LSE and PSE – US $211 million), (AIM - £40 million), MediTech BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million). 30 million), (CSE - € TopoTarget £35 million), Citigate Dewe Rogerson Buildings Wall 3 London Wall London London EC2M 5SY +44 (0)-207-638-9571 Tel: Citigate Dewe Rogerson Citigate Dewe Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.collegehill.com/lifesciences College Hill Life Sciences provides a full serviceCollege Hill Life Sciences communications consultancy focused on science-based life science field we haveWithin the established position a leadership our by working in partnership with sectors. communicationsclients to deliver high quality that build corporatevalue and promote leading edge products, technologies and services). London Sue Charles UK London EC3N 4QN, Royal Mint Court, The Registry, 7866 7900 +44 (0)20 +44 (0)20 7457 2020 F: T: [email protected] Email: Manchester Dr Eileen Paul / Chris Fisher UK CW12 1DN, Congleton, Way, Mountbatten Meadowside, 296501 +44 (0)1260 +44 (0)1260 296500 Fax: Tel: [email protected] Email: Munich Dr Douglas Pretsell Germany 80333 Munich, Augustenstraße 79, (0)89 52 38 80 06 +49 +49 (0)89 57 00 18 06 Fax: Tel: [email protected] Email: San Francisco Erik Clausen USA CA 94105, San Francisco Suite 1100, 201 Spear Street, +1 (415) 230 5385 Tel: [email protected] Email: College Hill Supporting Organisations Supporting Life Sciences WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.lifescienceaustria.at Life Science Austria - LISA - is a program acting as a hub for people from all over the Life Science with its associates Together Austria. in the life science sector in world who are interested first point of contact LISA is the anyonefor with questions about Austrian regions, in the and or funding and sponsoring projects setting up an operation, scientific collaboration, Austria. businesses in human. Austrian regions – ecoplus, all existing life science clusters in the with Working and Cluster, Technology Health Vienna Region, Austria Life Science technology.styria, The - LISA is able to build on their expertise and services. Tirol Life Science Cluster contribute to the success of life science enterprises in aims of LISA and its partners are: assist in the search Austria by helping to introduce scientific discoveries to the market, consultancy and support to ensure healthy and provide general business for funding, commercial development. responsible for is this program running on Wirtschaftsservice GesmbH (aws), Austria (BMWFJ). Youth Family and Federal MinistryAustrian of Economics, behalf of the Austria Wien, 1030 Ungargasse 37, Wirtschaftsservice Gesellschaft mbH, Austria [email protected] +43 (1) 501 75 - 900 • Email: +43 (1) 501 75 - 0 • Fax: Tel.: Life Science Austria Life Science Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.novartis.com +41 61 324 80 01 +41 61 324 11 11 Fax: Fax: Novartis provides healthcare solutions thatNovartis provides healthcare the evolving needs of patients address and Novartis offers portfolio a diversified meet to best Focused solely on healthcare, societies. cost-saving generic pharmaceuticals, eye care products, innovative medicines, these needs: is the only Novartis vaccines and diagnostic preventive tools. consumer health products, company with leading positions in each of these areas. AG Novartis International CH-4002 Basel Switzerland Tel: Novartis Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.swissbiotech.org SwissBiotech – One Nation – One Biotech Cluster SwissBiotech – One BaselArea, the fourSwiss Biotech unites regions leading biotech of Switzerland (BioAlps, The regions have early efforts on combined with Area). and Greater Zurich Ticino Biopolo listings life-science leading position in terms of the SWX Swiss Exchange which holds a and services. Association Represents more Association named Swiss Biotech The National Industry than 150 companies to date and acts as the operational arm for the marketing alliance. in Europe and profiles profile as an economic center Swiss Biotech raises Switzerland’s the biotech industry with its key research institutions and companies. messageSwiss Biotechs’ mission is to spread the as one of the top of Switzerland This will be achieved by presenting a comprehensive biotech locations in the world. finance economics, education, picture of the drivers of biotechnology including research, The bases for success in biotechnology are the critical mass of research and industry. The early integration of industry and institutes and accelerated technology transfer. More well-trained workforce is another critical success factor for rapid economic growth. than 40 technology parks throughout the country support the increasingly important and process. TechTransfer successful Further inquiries: Executive Office SwissBiotech, +41 (0)44 455 56 78 Tel. [email protected] Swiss Biotech Association Swiss Biotech Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.tiberendstrategicadvisors.com 1. To enhance valuation enhance To 1. build visibility forand strategic partnerships alliances To 2. Tiberend Strategic Advisors, Inc. is a corporate communications providing media strategy firm and execution for Inc. Advisors, Strategic Tiberend work with both public and We diagnostics. medical devices and biotech (therapeutics), life science companies – private emerging growth companies. Inc. Advisors, Strategic Tiberend 5th Floor, 35th Street, W. 35 NY 10001-2205 York, New 212.827.0020 Tel: 212.827.0028 Fax Fax: Tiberend Strategic Advisors, Inc. Advisors, Strategic Tiberend Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u www.torreyapartners.com Torreya Partners LLC is a leading boutique advisory Partners LLC is a leading boutique firm that provides strategic advice Torreya and Financings to life science Partnering Acquisitions, Mergers & and assistance with and objective Partners provides the long-term thinking Torreya companies worldwide. take great pride We advice required for create life science companies to lasting value. in handling complex financial and strategic matters of the most sophisticatedfor some Our reputation has been built on private and public life science companies in the world. bring We in deal execution and good outcomes for excellence our clients. quality advice, the caliber of people and quality of relationships found in some of the largest investment service detailed advisory you expect from a boutique banks along with the attentive, firm. Philadelphia and San Francisco. York, has offices located Partners New in Torreya Torreya Partners LLC Partners Torreya Supporting Organisations Supporting WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS www.sachsforum.com • Conference Sponsor – including workshops and social events • Exhibition stands • Distribution of Promotional Material Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging which organises and Associates is a London-based company, Ltd Sachs Associates is dedicated Sachs markets conferences in association with major exchanges and news agencies. only produces a limited number of events each as a result, in conferencing and, to the highest quality standards Technology, European Equities and Associates investment conferences focus on Emerging Markets, Sachs year. Associates is focused on Sachs York and Zurich. New centres such as London, and are held in major financial and the the exchange of ideas and information, participation, the practical benefi ts accruing from conference facilitating of business transactions. Associates may be summarised as follows: participation with Sachs The benefits of conference Multimedia Exposure Associates is uniquely able across extremely to provide its conference sponsors maximum exposure well Sachs is carried out conferences Regular extensive coverage of all the Company’s focused electronic and print media. through video streaming and extensive events coverage through major international financial news agencies, Associates has a number of long established Sachs In addition, Dow Jones and Reuters. including Bloomberg, which allow further effective distribution on relationships with other financial press organisations globally, behalf of its clients. Eminent Speakers Associates is committed to ensuring that its events continue to provide forums the participation with of Sachs its reputationThrough and its long-established the most eminent speakers from the public and private sectors. the Company has attracted the very senior political and economic personalities as speakers local relationships, at its events. Opportunities for forthcoming events Sponsorship and Marketing Associates has developed an extensive knowledge of the key individuals operating within the European Sachs Associates at the This together with a growing reputation forputs Sachs excellence and global biotech industry. forefront of the industry and provides a powerful tool by of your company which to increase the position in this market. profile directly with your potential clients. Sponsorship of any of our events allows you to raise your company’s allowing your organisation to gain the most out All of our sponsorship packages are tailor made to each client, of attending our industry driven events. conferences: at future available opportunities are sponsorship and marketing The following or sponsorship opportunities please call in exhibiting If your company is interested Zoe Harris on +44 203 463 4890. Sachs Associates Organisers WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS London Annual WC1V 7QT 6th Annual 6th Annual 13th 330 High Holborn 1st Floor Holborn Gate Tel: +44 203 463 4890 Tel: Fax: +44 (0)20 7405 4411 Fax: 5th-6th March 2013 • Zurich 5th-6th March 21st-22nd May 2013 • Boston www.sachsforum.com Investment in Drug Development Biotech & Pharma Industry BIOTECH IN EUROPE FORUM BIOTECH PARTNERING & INVESTING in PARTNERING Cancer Bio Partnering Forum Cancer Bio Partnering We look forward to seeing you at: look forward to seeing We 30th September -1st October 2013 • Zurich EUROPEAN LIFE SCIENCE CEO FORUM EUROPEAN LIFE SCIENCE

Promoting Public & Private Sector, Collaboration & Collaboration Sector, Promoting Public & Private M U R O F R O T S E V N I E P O R U E N I H C E T O I B